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Summary 
Vitiligo is an acquired depigmenting disorder characterised by the loss of functional 
melanocytes and of melanin from the cutaneous epidermis. A role for autoimmunity 
in vitiligo pathogenesis is supported by the presence of anti-melanocyte 
autoantibodies and autoreactive T lymphocytes in patients with the disorder. 
Recently, the melanin-concentrating hormone receptor 1 (MCHRI) has been 
identified as an autoantigen in vitiligo. The aim of this study was to characterise the 
properties of MCHR1 autoantibodies. 
The epitopes on MCHR1 that are recognised by autoantibodies in vitiligo patients 
were identified using recombinant receptor in radio-binding assays. Multiple regions 
of MCHR1, including regions between amino acids 1-138 and 139-298, were 
identified as binding sites for MCHR1 autoantibodies. In addition, biopanning of a 
phage-display MCHRI cDNA fragment library with vitiligo patient immunoglobulin 
G (IgG), identified more specifically the target sites of MCHRI autoantibodies. 
A stable Chinese hamster ovary cell line expressing MCHR1 was isolated. The 
cell line clearly showed expression of the receptor by flow cytometry. Stimulation of 
the cell line with melanin-concentrating hormone (MCH) reduced forskolin- 
stimulated cyclic adenosine monophosphate levels and increased the levels of 
intracellular calcium, both indicative of MCHRI expression. 
Functional blocking of MCI-iR1 by receptor autoantibodies was investigated by 
measuring changes in intracellular calcium levels in response to MCH-stimulation of 
MCHRI-expressing cells that had been pre-incubated with vitiligo patient IgG. The 
results revealed that 10/18 (56%) of the vitiligo patient IgGs tested were able to 
block receptor function. In contrast, IgG from healthy controls and from patients 
with other autoimmune disease had no effect upon receptor function. This suggested 
that MCHR1 function blocking autoantibodies are specific to patients with vitiligo 
and are not present in patients with other autoimmune disease. 
The cell line expressing MCHR1 was also used to analyse MCHR1 
autoantibodies for any immunological activities such as complement-fixation and 
antibody-dependent cell-mediated cytotoxicity (ADCC). None of the vitiligo patient 
sera tested appeared to have MCHRI autoantibodies that were able either to fix 
iv 
complement or mediate ADCC. This suggested that there are no such immunological 
activities against MCHR1. 
In conclusion, key findings from this study were that the MCHRI is an important 
autoantigen in vitiligo, with 56% of patients having function-blocking autoantibodies 
against the receptor, and that amino acids 1-138 and 139-298 are major epitopes for 
MCHR1 binding autoantibodies. 
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1 General Introduction 
1.1 Structure and function of the skin 
1.1.1 General skin functions 
The functions of the skin allow man to adapt to a wide variation in environment. The 
skin is a complex organ, comprising approximately one-twelfth of total body mass 
(Millington and Wilkinson 1983), and forming the boundary between the body and 
its external environment. It performs many essential functions that include the 
maintenance of internal homeostasis, protection against chemical and physical 
assault (Millington and Wilkinson 1983) and the prevention of invasion by 
pathogenic micro- and macro-organisms (Reeves and Todd 1996). 
1.1.2 Ultra-structure of the skin 
Human skin is formed of two layers, the epidermis, a cellular, avascular epithelium 
that derives from the embryonic ectoderm, and the dermis, a dense vascularised 
connective tissue arising from the embryonic mesoderm. The ultra-structure of the 
skin is summarised in Figure I. I. The cutaneous epidermis comprises a multi- 
layered epithelium, consisting mostly of keratinocytes. Five epithelial layers are 
described as follows: the basal cell layer (stratum basale), prickle cell layer (stratum 
spinosum), granular cell layer (stratum granulosum), transitional cell layer (stratum 
lucidum) and the dead squamous cell layer (stratum corneum) (Wood and Bladon 
1985). The nomenclature is based on the different morphological appearances of the 
keratinocytes according to their stage in the process of keratinisation. The innermost 
basal layer consists of a single layer of cylindrically shaped cells attached to a 
basement membrane that forms the junction between epidermis and dermis. The 
basal keratinocytes continually proliferate by mitotic division and move outwards 
through the layers undergoing subsequent differentiation, to be shed eventually at the 
exterior. The prickle cells are keratinocytes, so called because their protruding 
desmosomes filled with keratin filaments, are visible as prickles on the cell surface 
under a light microscope. Prickle cells move upwards and, as new cells are formed 
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Figure 1.1 A schematic representation of the ultra-structure of the skin. 
(Adapted from Alberts et al. 1989). 
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beneath them, they gradually change their polyhedral shape to a flatter configuration. 
As they approach the surface they take on their primary function, the production of 
the protein keratin. Above the prickle cell layer are keratinocytes in the penultimate 
stages of keratinisation. They appear granular because of the aggregation of 
keratohyaline. The transitional cells are terminally differentiated keratinocytes 
undergoing loss of their cellular contents. The outermost layer is made up of 
flattened dead keratinocytes termed squames. 
In addition to keratinocytes, the basal epithelial layer contains small numbers of 
other cell types: Merkel cells, Langerhans cells and melanocytes. Merkel cells are 
closely associated with nerve terminals of Schwann cells in the epidermis, often 
lying adjacent to hairs, and are considered to function as sensory receptors or 
transducers (Lacour et al. 1991). Langerhans cells are dendritic cells capable of 
antigen presentation. They function in the immune system by binding antigen 
molecules encountered in the skin and subsequently migrating from the epidermis to 
regional lymph nodes, where they are able to present antigen to T cells (Reeves and 
Todd 1996). Scattered between the basal cells are the pigment producing 
melanocytes that are derived embryologically from the nervous system. Under light 
microscopy they appear as clear cells between the deeply staining basal cells. With 
special staining methods, they can be shown to have dendritic processes with which 
they inject pigment granules into the surrounding keratinocytes. Melanocytes are 
responsible for the production of skin pigmentation and are discussed below. 
1.1.3 The melanocyte 
Melanocytes comprise approximately 5% of the cellular component of the 
interfollicular epidermis. Melanocytes of the skin, uveal tract, inner ear and 
leptomeninges derive from melanoblasts that originate from the embryonic neural 
crest (Rawles 1947). In contrast, the ocular melanocytes of the retinal pigment 
epithelium arise from neural endoderm as it invaginates to form the outer wall of the 
optical cup (Feeny-Burns 1980). The melanoblasts migrate into the developing 
epidermis and eventually settle in the basal epithelial layer during seven weeks of 
early human embryonic gestation period (Holbrook et al. 1989). The control of 
migration and differentiation of embryonic melanoblasts is not fully understood, but 
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the involvement of several genes, including c-kit proto-oncogene, pax gene and stem 
cell factor gene, and transcription factors, especially microphthalmia-associated 
transcription factor (MITF) and SOX10, has been elucidated from mouse mutants 
(Boissy and Nordlund 1995a; Ortonne and Ballotti 2000). 
Melanocytes reside in the basal epithelial layer of the interfollicular epidermis for 
the life of an individual at a density range of 1000-1500 per mm2 (Quevedo et al. 
1987). They have a roughly pyramidal morphology with numerous fine dendritic 
processes that can transfer melanin granules to surrounding keratinocytes. The 
appearance of melanocytes in culture is demonstrated in Figure 1.2. It was thought 
that melanocytes rarely proliferate or die under normal conditions. However, 
melanocytes can be induced to proliferate by stimuli such as ultraviolet (UV) light or 
during an inflammatory process. There is approximately one melanocyte per thirty- 
six keratinocytes in all races and ethnic groups in what is termed the `epidermal 
melanin unit' (Fitzpatrick et al. 1967). Differences in the rate of melanin synthesis 
(Iwata et al. 1990), the type of melanin produced (Quevedo et al. 1974) and the way 
it is distributed within keratinocytes (Szabo et al. 1988), account for the different 
appearances of skin colour between ethnic groups. 
The principal function of melanocytes is the synthesis of the pigment melanin that 
is-primarily deposited in keratinocytes of the interfollicular epidermis. The process 
of melanin synthesis is discussed in Section 1.1.4. Melanin absorbs incident UV 
light and protects the genome of dividing basal keratinocytes and melanocytes 
(Boissy and Nordlund 1995a). Furthermore, melanin effectively absorbs oxygen free 
radicals (Korytowski et al. 1987) and, therefore, might serve to protect the 
metabolically active keratinocytes from oxidative stress (Boissy and Nordlund 
1995a). In addition to their primary function of melanin synthesis, melanocytes can 
express major histocompatibility complex (MHC) class II molecules, cell adhesion 
molecules, and the Fc receptor. Moreover, they are also capable of producing several 
immunomodulatory cytokines (Zachariae et al. 1991) that assist in the maturation of 
antigen presenting cells, such as Langerhans cells, and are involved in the 
recruitment of immune infiltrates into the skin (Swope et al. 1994). Additionally, 
there is evidence to suggest that melanocytes can themselves act as antigen 
presenting cells (Le Poole et al. 1993a; Das et al. 2001). 
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Figure 1.2 Bright field image of cultured melanocytes isolated from the human 
skin (X200 magnification). 
(Provided by Miss C. Balafa and Professor S. MacNeil, Division of Clinical 
Sciences (North), University of Sheffield, UK). 
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1.1.4 Melanogenesis 
1.1.4.1 The melanosome 
In melanocytes, melanin synthesis or melanogenesis occurs in specialised organelles 
called melanosomes. The process of melanogenesis has two parts: the synthesis of 
the melanosome, the specialised organelle that carries the melanin, and the synthesis 
of the enzymes responsible for melanin synthesis. Each process occurs 
independently in the melanocyte in the smooth and rough endoplasmic reticulum, 
respectively, before convergence in the melanosome (Boissy and Nordlund 1995a). 
The melanosome is required to enclose safely the pigmentary pathway, as many of 
the intermediates are highly reactive and potentially toxic to the melanocyte 
(Pawelek et al. 1980; Urabe et al. 1994). 
1.1.4.2 Biochemistry of melanin synthesis 
For many years, the biochemistry of melanin synthesis was considered to be 
relatively simple. The biosynthetic pathways by which melanin is synthesised are 
summarised in Figure 1.3. The initial catalytic enzyme in this process is tyrosinase 
that hydroxylates the amino acid substrate tyrosine to 3,4-dihydroxyphenylalanine 
(DOPA) and then converts DOPA to DOPAquinone. Subsequently, DOPAquinone 
appears to spontaneously progress to leucoDOPAchrome and then to DOPAchrome. 
At this stage a diversion can occur. In the presence of DOPAchrome 
tautomerase/tyrosinase-related protein (TRP)-2 and divalent metal cations, 
DOPAchrome is converted to 5,6-dihydroxyindole-2-carboxylic acid (DHICA), 
which, in turn, is enzymatically oxidised by DHICA oxidase/TRP-1 to indole-5,6- 
quinone-carboxylic acid. Without the catalytic contribution of TRP-2, DOPAchrome 
can spontaneously oxidise to 5,6-dihydroxyindole (DHI) which can then be 
converted to indole-5,6-quinone by the activity of tyrosinase. Again, Pmell7/gplOO 
is involved in the conversion of indole-5,6-quinone and indole-5,6-quinone- 
carboxylic acid to eumelanin which are black and brown polymers (Boissy and 
Nordlund 1995a). 
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Figure 1.3 A diagrammatic overview of the melanin biosynthetic pathway. 
(Adapted from Boissy and Nordlund 1995a; Ortonne and Ballotti 2000) 
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A second group of pigments called phaeomelanins are yellow and red polymers 
and predominantly appear in hair. The synthesis of phaeomelanins is initiated by the 
same mechanism as eumelanins up to the production of DOPAquinone. At this point, 
a high intracellular or intramelanosomal concentration of cysteine or glutathione, 
provided by glutamyl transpeptidase/glutathione reductase, will convert 
DOPAquinone to cysteinyl DOPA and then to phaeomelanin (Mojamdar et al. 1982; 
Jimenez et al. 1986; Jara et al. 1988). This alternative pathway proceeds by largely 
unknown mechanisms to the phaeomelanins that, unlike eumelanins, are 
considerably photolabile and may produce highly cytotoxic and mitogenic free 
radicals on photo-excitation. 
Following melanin synthesis, the melanosome is transported to surrounding 
keratinocytes via the dendritic processes of the melanocyte. The keratinocytes take 
up the melanosome by endocytosis of the dendritic ends (Wolff 1973). 
1.1.4.3 Melanogenic enzymes 
Table 1.1 summarises some key melanosomal proteins and their known functions in 
melanogenesis. Tyrosinase is the rate-limiting enzyme in the melanogenesis pathway 
through its action of the hydroxylation of tyrosine to DOPAquinone (Oetting 2000). 
The presence of tyrosinase activity was first described in mammalian skin by 
Durham (Durham 1904) who also noted an absence of tyrosinase activity in the skin 
of albino animals. The tyrosinase protein is a membrane glycoprotein containing 529 
amino acids, including a signal peptide at the amino end, two copper binding sites 
and a transmembrane region at the carboxy-end (Oetting 2000). The requirement for 
two copper atoms in the catalytic site of tyrosinase is demonstrated by the expression 
of hypopigmentation in the phenotype of Menke's disease, a disorder in which 
copper transport is deficient (Ortonne and Ballotti 2000). The control of tyrosinase 
gene expression, in response to stimuli such as UV light and a-melanocyte- 
stimulating hormone (a-MSH) production, has yet to be fully elucidated, but an 
important regulatory element contained within the tyrosinase promoter has been 
identified and termed the `M' (melanocyte)-Box (Oetting 2000). The 'M'-Box is 
known to bind the family of transcription factors that include MITF (Oetting 2000). 
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Oculocutaneous albinism type (OCA)-1, characterised by a complete lack of melanin 
synthesis in the hair, eyes and skin, is an autosomal recessive disorder caused by 
mutations of the tyrosinase gene (King et al. 1995), of which more than ninety 
patients have been described (Oetting 2000). 
The tyrosinase gene family (Kwon 1993) includes two other structurally 
homologous glycoproteins: TRP-1 and TRP-2. The primary amino acid sequences 
of TRP-1 and TRP-2 are overall approximately 45% identical to that of tyrosinase 
and contain a similar signal sequence and transmembrane domain (Kwon 1993). 
However, both proteins differ significantly from tyrosinase at their carboxyl-end 
(Orlow et al. 1993) and have distinct catalytic activities. Tyrosinase-related protein-2 
acts as a DOPAchrome tautomerase, catalysing the conversion of DOPAchrome to 
DHICA (Aroca et al. 1990). The function of TRP-1 has not been determined in 
human melanogenesis, despite its role being characterised as DHICA oxidase in 
murine melanosomes (Hearing 2000). It is thought to stabilise tyrosinase activity 
(Kobayashi et al. 1994a) and mutations of TRP-1, which affect its ability to do this, 
may lead to OCA-3 (Hearing 2000). 
Pmell7 is a melanosomal matrix glycoprotein (Kobayashi et al. 1994b; Zhou et 
al. 1994) with a limited structural homology to the tyrosinase gene family proteins 
(Kwon 1993). Indeed, Pmel17 complementary DNA (cDNA) was originally isolated 
from a human melanocyte cDNA library using anti-tyrosinase antibodies (Kwon et 
al. 1991). However, the homologous regions are confined to five short regions of 
amino acids only and it is classified within its own gene family (Kwon 1993). 
Mutations at the mouse silver locus, which encodes Pmel17, result in a loss of 
melanocytes in the coat hair and subsequent silvering (Johnson and Jackson 1992). 
Similar mutations in the human Pmel17 gene, D12S53E, have been speculated to 
cause greying of human hair (Ortonne and Ballotti 2000). The Pmel17 protein is 
thought to function as a stablin, more specifically an indole-blocking factor, that 
regulates the deposition of DHI and DHICA into eumelanin (Boissy and Nordlund 
1995a). 
1.1.4.4 Control of melanogenesis 
In addition to UV light exposure, several cytokines and growth factors, including 
tumour necrosis factor-a (TNF-a), endothelin, stem cell factor and basic fibroblast 
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growth factor, are known to mediate melanogenesis (Nordlund 1998). Of particular 
importance in the control of melanogenesis are the melanotrophic peptides a-MSH 
and adrenocorticotrophic hormone (ACTH), which are synthesised in both the 
pituitary gland and locally in the human skin and which competitively bind to the 
melanocortin-1 receptor (MC-1R) on melanocytes (Thody and Graham 1998). Cell- 
signalling pathways, including the cyclic adenosine monophosphate (cyclic AMP)- 
dependent protein kinase pathway and the mitogen-activated protein (MAP) kinase 
pathway, are activated in response to a-MSH binding to MC-IR and ultimately bring 
about an up-regulation of melanogenesis (Ortonne and Ballotti 2000). 
In humans, the mechanism that controls the type of melanin synthesized by 
melanocytes (eumelanin vs phaeomelanin) has not been elucidated. The switch to 
produce eumelanin or phaeomelanin in mouse follicular melanocytes is controlled by 
the extension and the agouti loci (Barsh 1996). The former encodes MC-1R and the 
latter encodes the agouti signal protein (ASP), which acts as a competitive antagonist 
of a-MSH on MC-1R. Activation of MC-1R by a-MSH induces a significant 
increase in the intracellular cyclic AMP content of melanocytes resulting in 
increased eumelanogenesis. Agouti signal protein binds to MC-1R, thereby 
antagonising the effects of a-MSH, including the a-MSH-induced activation of 
adenylate cyclase (Ortonne and Ballotti 2000). It is well established that a-MSH 
increases the synthesis of eumelanin in human melanocytes. A human homologue 
for the mouse agouti gene has been cloned and its product functions in a similar 
manner to the mouse ASP both in vivo and in vitro. However, its physiological 
function in humans remains to be elucidated. 
1.2 Vitiligo 
1.2.1 Definition 
Vitiligo is an acquired depigmentary disorder characterised by the loss of functional 
melanocytes and of melanin from the cutaneous epidermis. Additionally, the 
disorder may affect melanocytes in the hair bulb, mucous membranes, inner ear and 
eye (Biswas et at 2003). Clinically, the disorder is typified by pigment loss from the 
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skin in circumscribed maculae that have a tendency to enlarge peripherally with 
disease progression. 
1.2.2 Prevalence 
In approximately 50% of cases vitiligo presents before the age of 20 years 
(Majumder et al. 1993). The prevalence of the disease in the world ranges from 
0.38% (Howitz et al. 1977) to 1.13% (Mehta et al. 1973) with a consensus 
prevalence of around 1% (Lerner 1971). The incidence of the disease in both sexes is 
equal. There is no preponderance of vitiligo in a particular racial skin type, although 
the disease is more visually apparent in darker skin. 
1.2.3 Inheritance and genetics 
A genetic involvement in vitiligo is supported by observations on familial 
aggregation of the disorder in over 20% of vitiligo patients (Ortonne et al. 1983; 
Majumder et al. 1993). In addition, concordance in monozygotic twins has been 
reported (Mohr 1951; Siemens 1953; Mayenburg et al. 1976; Alkhateeb et al. 2002) 
but the exact frequency of concordance has not been determined and the reporting of 
isolated cases is subject to ascertainment bias. Genetic studies of familial cases of 
vitiligo conclude that the disorder is most likely due to the action of genes at 
multiple loci (Majumder et al. 1993; Kim et al. 1998; Acros et al. 1999) and is not 
transmitted by a simple Mendelian mechanism. However, some authors propose that 
an autosomal dominant gene with variable expression and incomplete penetrance 
may be responsible (Mosher et al. 1979; Lorincz 1985). In the Smyth line chicken 
(Smyth 1989), an animal model of vitiligo, the disorder results from a genetically 
inherited defect that is expressed in the melanocytes and which appears to be 
transmitted to offspring as an autosomal recessive trait. Similarly, depigmentation in 
the mouse model C57BL/6J Ler-vit/vit results from a genetic mutation that is 
inherited as an autosomal recessive trait (Lerner et al. 1986). The mutation in the 
vit/vit mouse occurs at the microphthalmia locus that encodes MITF, and, therefore, 
interest arose in the human homologue as a susceptibility gene for vitiligo. However, 
linkage studies have proven negative (Tripathi et al. 1999) with respect to this locus. 
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1.2.3.1 Immune response related genes 
Since vitiligo may have an immune involvement (Sections 1.3.6 and 1.5), candidate 
genes include those that have a regulating role in the immune system. In particular, 
the genes of the MHC have been associated with the presence of autoimmune 
disorders (Larsen and Alper 2004). The study of MHC genes has revealed 
associations of vitiligo with certain human leukocyte antigen (HLA) specificities, 
but there is no consistent association with MHC class I or class II alleles (Table 1.2) 
and the reported relative risks have been modest. Several autoimmune disorders are 
associated with homozygous or heterozygous deficiencies of the MHC class III 
molecules complement (C) components C4 and C2 (Kahl and Atkinson 1988) and an 
increased frequency of heterozygous C4 and C2 deficiency has been found in 
patients with vitiligo (Venneker et al. 1992). 
The cytotoxic T lymphocyte antigen-4 (CTLA-4) gene encodes aT cell receptor 
that is involved in the regulation of T cell activation (Walunas et al. 1994). Several 
polymorphisms of the CTLA-4 gene are associated with autoimmune disorders such 
as Graves' disease (Kotsa et al. 1997), autoimmune hypothyroidism (Kotsa et al. 
1997), Addison's disease (Kemp et al. 1998a) and type 1 diabetes mellitus (Ide et al. 
2004). With respect to vitiligo, the 106 base pair allele of the CTLA-4 microsatellite 
polymorphism has been associated with vitiligo in patients who have at least one 
autoimmune disease in addition to their cutaneous depigmentation (Kemp et al. 
1999b). 
The autoimmune regulator (AIRS) gene encodes aT cell-specific protein that 
contains motifs indicative of a transcription factor (Heino et al. 2001; Myhre et al. 
2001) and mutations in AIRE result in autoimmune polyendocrine syndrome type 1 
(APS1), a disorder with which vitiligo can be associated (The Finnish-German 
APECED consortium 1997; Nagamine et al. 1997). However, it is unlikely that 
AIRE gene is related to the onset of vitiligo that develops independently of APS1. 
Analysis of 552 vitiligo patients and their families, with respect to polymorphic 
markers in a panel of genes encoding proteins involved in the immune response, has 
also been undertaken (McCormack et al. 2001). The genes analysed included: low 
molecular weight protein (LMP)-2 and LMP-7; transporters involved in antigen- 
processing (TAP)-1 and TAP-2; the proteosome multi-catalytic endopeptidase 
13 
Table 1.2 Major histocompatibility complex antigen associations with vitiligo. 
I Origin of population Number of patients Associated specificity Reference 
in study 
Slovakia 67 A2, Dw7 Buc et at 1996 
Italy 87 A30, B27, Cw6, DQw3 Finco et at 1991 
Holland 42 DR4, C4BQO Venneker et al. 1992 
Holland 50 DRB4, DQB I Zamani et at 2001 
Holland Not given Cw7, DR06 Venneker et at 1993 
Kuwait 40 B21, Cw6, DR53 Al-Fouzan et at 1995 
Oman 50 Bw6, DR7 Venkataram et at 1995 
Hungary 88 DRI, DR3 Poloy et at 1991 
USA (African) 24 DR4, DQw3 Dunston and Haider 1990 
USA (Caucasian) 48 DR4 Foley et at 1983 
USA 6 HLA-DR Le Poole et al. 2003 
Italy (Northern) 86 A3 Lorini et al. 1992 
Italy (Northern) 93 A30, Cw6, DQw3 Orecchia et al. 1992 
Morocco (Jewish) 18 B13 Metzker et al. 1980 
Yemen 16 Bw35 Metzker et al. 1980 
Germany (Northern) 102 A2, B13, Bw60 Schallreuter et al. 1993 
Germany 34 DRB 1, DQB 1 Buc et al. 1998 
Colombia 56 families D6S265, D6S276, D6S273 Arcos-Burgos et al. 2002 
Turkey 41 DRB 1 *03, DRB 1 *04, DRB 1 *07 Tastan et al. 2004 
China (Hans) 187 HLA-A*2501, HLA-A*30, Zhang et al. 2004 
HLA-B*13, HLA-B*27 
HLA-Cw*0602 
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complex-like 1; CD4; CD59; membrane cofactor protein; interleukin (IL)-1 ; IL-I 
receptor-a; TNF-a; intercellular adhesion molecule-1 (ICAM-1); co-stimulatory 
lymphocyte activation ligands CD28 and CTLA-4. Only polymorphic markers for 
LMP/TAP and CD28/CTLA-4 appeared to be positively associated with vitiligo 
susceptibility. 
A recent genome wide linkage scan of 102 white multiplex families with vitiligo 
from the USA and the UK mapped a new autoimmune susceptibility 1 (AIS1) gene, a 
locus on chromosome 1 that apparently confers susceptibility to generalized vitiligo 
(Alkhateeb et al. 2002; Fain et al. 2003; Spritz et al. 2004). In addition, Spritz et al. 
reported two more loci AIS2 and AIS3 on chromosomes 7 and 8, respectively, that 
confer susceptibility to vitiligo (Spritz et al. 2004). A European-American pedigree 
study detected a susceptibility gene SLEVI on chromosome 17 in families with 
vitiligo-related systemic lupus erythematosus (Nath et al. 2001). Subsequently, 
Spritz et al. confirmed the presence of SLEV1 on chromosome 17 in the genome 
scan of 102 vitiligo families from the UK and the USA (Spritz et al. 2004). 
1.2.3.2 Genes related to metabolism 
An association of vitiligo with mutations in the gene encoding guanosine 
triphosphate-cyclohydrolase 1 (GTP-CH. 1) has been reported (de la Fuente- 
Fernandez 1997). Sequencing of the GTP-CH 1 gene showed missense mutations in 
vitiligo families. This enzyme catalyses the initial step in 5,6,7,8- tetrahydrobiopterin 
synthesis (BH4). from guanosine triphosphate. The BH4 is an essential cofactor for 
phenylalanine and tyrosine synthesis that are involved in the production of melanin 
(Schallreuter et al. 1994a). Patients with active vitiligo have abnormalities in BH4 
and GTP-CH 1 activity compared to controls (Schallreuter et al. 1994c). 
Both case-control and family-based genetic studies of a T/C single nucleotide 
polymorphism in exon 9 of the catalase (CAT) gene demonstrated that T/C 
heterozygotes of the CAT gene are more frequent among vitiligo patients than 
controls and that the C allele is transmitted more frequently to patients than controls 
(Casp et al. 2002). The CAT gene encodes catalase that is responsible for the 
conversion of hydrogen peroxide (H202) to water (H20) and oxygen (02). A 
reduction of this enzyme and the concomitant accumulation of excess H202 have 
15 
been observed in the entire epidermis of vitiligo patients (Schallreuter et al. 1991; 
Schallreuter et al. 1999). An accumulation of H202 can directly oxidise BH4 to 6- 
biopterin that is toxic to melanocytes (Schallreuter et al. 1999). 
It has been demonstrated that the G/A polymorphism at codon 158 of the 
catechol-O-methyltransferase (COMI) gene leads to low activity of COMT and 
results in the development of acrofacial vitiligo (Tursen et al. 2002). Catechol-O- 
methyltransferase catalyses the O-methylation of biologically active or toxic 
catechols, that are produced at the nerve endings, and plays a major role in the 
metabolism of drugs and neurotransmitters. It has been suggested that the low 
activity of COMT might lead to an increase in O-quinones that are highly toxic to 
melanocytes (Pavel et al. 1983; Tursen et al. 2002). 
Recently, it has been found that I/D polymorphism at intron 16 of angiotensin 
converting enzyme (ACE) gene has a strong association with the development of 
vitiligo in Korean patients (Jin et al. 2004). The ACE gene encodes angiotensin 
converting enzyme which is capable of degrading neuropeptides released from 
sensory nerves in response to chemical stimuli and mechanical injury (Scholzen et 
al. 2003). In addition, it also plays an important role in the physiology of the 
vasculature, blood pressure and inflammation. The I/D polymorphism of ACE gene 
is also associated with other autoimmune diseases (Papadopoulos et al. 2000). 
1.2.3.3 Other genes 
By comparing the different gene expression levels of non-lesional melanocytes from 
vitiligo patients and control melanocytes, a novel candidate gene `VITI' has been 
found which is associated with vitiligo (Le Poole et al. 2001). The VITI-encoded 
protein contains an amino acid sequence that is identical to a putative zinc-finger 
motif, found in N-recognin, which is involved in the degradation of cellular proteins 
(Kwon et al. 1998). The authors, therefore, suggest that the VITI-encoded protein 
might be involved in protein degradation and reduced VIT1 expression, as found in 
vitiligo patient melanocytes, might help to explain protein accumulation leading to 
dilated endoplasmic reticulum profiles, a hallmark of vitiligo pigment cells (Le 
Poole et al. 2001). 
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A high frequency of the A allele of G/A polymorphism in codon 274 of MC-IR 
gene and the G allele of G/A polymorphism in codon 8818 of ASP gene has been 
found in vitiligo patients compared to controls but the study could not able to find 
any statistically significant association of these polymorphisms with vitiligo (Na et 
al. 2003). 
A study involving 552 vitiligo patients and their families, examined polymorphic 
markers in a panel of twenty-four candidate genes that might confer susceptibility to 
vitiligo (McCormack et al. 2001). The genes analysed in this study included those 
encoding tyrosinase, TRP-1, TRP-2, tyrosine hydroxylase, phenylalanine 
hydroxylase, GTP-CH 1, the transcription factor nuclear factor 1, and two genes 
involved in melanocyte embryogenesis, kit and pax3. No association was found 
between any of these genes involved in melanocyte function and an increased risk of 
vitiligo. 
1.2.4 Pathology 
Affected skin shows a loss of melanin and a decrease in the number of melanocytes 
in the epidermis when compared to normal skin (Figures 1.4 a and b). Electron 
microscopic analysis and immunohistochemical studies of vitiligo lesions using a 
variety of monoclonal and polyclonal antibodies confirm the degeneration of 
melanocytes and also the presence of abnormal keratinocytes (Moellmann et al. 
1982; Le Poole et al. 1993b). In peri-lesional areas, abnormal pigment cells are seen 
that are fragmented, grossly enlarged or show the appearance of vacuoles (Le Poole 
et al. 1993b). In addition, in the peri-lesional regions of inflammatory vitiligo, a 
lymphocytic infiltrate can be identified in the -basal layer of the epidermis in 
proximity to the melanocytes (Bleehan, 1979). It has also been reported that the 
epidermis of vitiligo lesions has reduced thioredoxin reductase activity (Schallreuter 
et al. 1987), defective calcium uptake (Schallreuter and Pittelkow 1988), low 
catalase activity (Schallreuter et al. 1991) and high expression of ß-adrenoreceptors 
(Schalireuter et al. 1992). 
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Figure 1.4 (a) Melanocytes in normal cutaneous epidermis. Photomicrograph 
showing a whole mount of a sheet of epidermis from normal 
skin, spread upon a slide and viewed from the underside. The epidermis 
was separated from the dermis by the generation of a suction blister. 
The epidermal sheet was then incubated with DOPA that selectively stains 
melanocytes brown (X300). 
(b) Melanocytes in the cutaneous epidermis of a vitiligo patient. 
Photomicrograph of a whole mount of a sheet of epidermis from an 
area of vitiligo skin, spread upon a slide and viewed from the 
underside. The epidermis was separated from the dermis by the 
generation of a suction blister. The epidermal sheet was then 
incubated with DOPA that selectively stains melanocytes brown (X300). 
Melanocytes are observed at a much lower density in the vitiligo skin than in the 
normal skin. 
(Provided by Professor D. J. Gawkrodger, Royal Hallamshire Hospital, Sheffield, 
UK). 
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1.2.5 Clinical features 
Vitiligo can be classified by the extent and distribution of cutaneous depigmentation. 
There are five main disease categories: generalised or symmetrical, segmental, focal, 
acrofacial and universal (Kovacs 1998). Generalised or symmetrical type vitiligo is 
the most common presentation with a bilateral, symmetrical depigmentation of the 
face (especially peri-orificial areas), neck, torso and the extensor surfaces or bony 
-prominences of the hands, wrist and legs. Segmental vitiligo has a dermatomal, 
asymmetrical distribution of depigmentation, usually with one or more macules in 
one area of the body. This type of vitiligo often begins in childhood, is rarely 
associated with autoimmune disorders and has stable results after autologous 
grafting. In contrast, symmetrical vitiligo has a later age of onset, is frequently 
associated with autoimmunity and has unstable results with autologous grafting. 
These contrasts have lead to the speculation that symmetrical and segmental vitiligo 
represent two quite separate disease manifestations (Kovacs 1998; Taieb 2000). 
Focal type vitiligo is localised and non-dermatomal in distribution, whereas 
acrofacial vitiligo is characterised by depigmentation of the distal fingers and facial 
orifices only, the latter being in a circumferential pattern. Finally, patients with 
universal vitiligo exhibit a loss of pigment over the entire body surface, a type of 
vitiligo that occurs rarely. The two most common clinical presentations are 
segmental and symmetrical vitiligo and these are shown in Figures 1.5 a. and b, 
respectively. 
Trichrome, inflammatory, and occupational vitiligo represent unusual forms of 
the disease. Trichrome vitiligo involves macules in which there are areas of both 
complete and partial loss of pigment, forming a pattern of varying hues between the 
affected and non-affected skin (Fitzpatrick 1964; Gawkrodger 1998). Uniquely, 
areas of normally pigmented skin adjacent to an area of vitiligo may become 
hyperpigmented (Gawkrodger . 1998). Inflammatory vitiligo is characterised by 
actively spreading lesions that are inflamed, presenting a raised erythematosus peri- 
lesional border (Grab and Wise 1948; Le Poole et al. 1996). Chemically induced 
occupational vitiligo can occur in workers exposed to compounds such as catechols, 
phenols, hydroquinone and monobenzene. The depigmentation is usually confined to 
the parts of the body exposed to the chemical, e. g. the hands and forearms, but can 
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Figure 1.5 (a) Segmental vitiligo affecting one side of the neck. 
(Provided by Professor A. P. Weetman, Division of Clinical Sciences 
(North), University of Sheffield, UK). 
(b) Symmetrical vitiligo on the dorsal aspects of the hands. 
(Provided by Professor D. J. Gawkrodger, Royal Hallamshire 
Hospital, Sheffield, UK). 
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arise in areas distant from the original point of contact, suggestive of systemic 
exposure through percutaneous adsorption, inhalation or ingestion. Some of the 
compounds shown to cause depigmentation in occupational vitiligo are now 
specifically used in depigmenting therapies in idiopathic vitiligo. 
In addition to the disease categories described by the distribution of vitiliginous 
skin, a three-grade pathological staging system corresponding to depletion of the 
melanocytes has been proposed by Gauthier (Gauthier 1994). In this classification 
scheme, grade I vitiligo exhibits only a partial depletion in epidermal melanocytes 
and results in the possibility of repigmentation, without a follicular pattern, after 
phototherapy treatment. Grade II vitiligo has complete depletion of the epidermal 
melanocytes and corresponds to a follicular pattern of repigmentation, in which 
melanocytes have migrated from the follicular reservoir to replace the absent 
epidermal melanocytes, after phototherapy treatment. Grade III vitiligo is 
characterised by a total depletion of both epidermal and follicular melanocytes and 
patients at this stage do not respond to medical therapy. More recently, a vitiligo 
disease activity score has been proposed which measures disease activity in relation 
to time, as assessed by the patient (Njoo et al. 1999). 
Although vitiligo may be considered a relatively minor disorder, the 
psychological effects can be considerable, particularly in those with racially darkly 
pigmented skin in whom the appearance of the lesions is more marked. Detrimental 
feelings of stress, embarrassment or self-consciousness when in contact with 
strangers, perception of discrimination and low self-esteem are common, especially 
in patients with visible lesions (Porter et al. 1986; Porter et al. 1990; Kent and 
A1'Abadie 1996). 
1.2.6 Associated disorders 
Vitiligo is frequently associated with other autoimmune disorders including 
autoimmune thyroid disease, type 1 diabetes mellitus, alopecia areata, pernicious 
anaemia, Addison's disease, autoimmune polyendocrine syndromes and other 
disease conditions and rare syndromes (Table 1.3). Patients with vitiligo are more 
likely to suffer from an autoimmune condition than those in the general population. 
Autoimmune thyroiditis, for example, has a prevalence of up to 30% in vitiligo 
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Table 1.3 Association of vitiligo with autoimmune and other disorders. 
Disorder 
Thyroid disease 
Type 1 diabetes mellitus 
Addison's disease 
Systemic lupus erythematosus 
Alopecia areata 
Myasthenia gravis 
Pernicious anaemia 
Rheumatoid arthritis 
Sarcoidosis 
Chronic active hepatitis 
Vogt-Koyanagi-Harada syndrome 
Autoimmune polyendocrine syndromes 
Psoriasis 
Lichen planus 
Reference 
Grimes et al. 1983; Shong and Kim 
1991; Schallreuter et al. 1994b; Hegedus 
et al. 1994; Barnadas et al. 2000; Dervis 
et al. 2004; Kurtev and Dourmishev 
2004 
Gould et al. 1985 
Mulligan and Sowers 1985 
Mihailova et al. 1999 
Grimes et al. 1983; Sharma et al. 1996 
Tan 1974 
Howitz and Schwartz 1971; Abraham et 
al. 1993; Barnadas et al. 2000 
Abraham et al. 1993 
Barnadas et al. 2000; Terunuma et al. 
2000 
Sacher et al. 1990 
Okada et al. 1996; Tsuruta et al. 2001 
Ahonen et at. 1990 
Dhar and Malakar 1998; Hwang et al. 
1998; Sandhu et al. 2004 
Anstey and Marks 1993; Rubisz- 
Brzezinska et al. 1996 
(Adapted from Ongenae et at 2003) 
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patients (Cunliffe et al. 1968), a figure that is significantly higher than that of 1% as 
reported in the general population (Turnbridge et al. 1977). Autoimmune gastritis, 
pernicious anaemia, alopecia areata and type 1 diabetes mellitus are also found more 
commonly in vitiligo patients compared with normal subjects with frequencies of 
15%, 5.3%, 16% and 7.2%, respectively (Cunliffe et al. 1968; Turnbridge et al. 
1977; Zauli et al. 1986). In addition, circulating organ-specific autoantibodies, 
particularly to the thyroid, adrenal glands and gastric parietal cells, are commonly 
detected in the sera of vitiligo patients (Brostoff et al. 1969; Betterle et al. 1976; 
Mandry et al. 1996). 
Halo naevi, areas of depigmentation seen surrounding a melanocytic naevus or 
`mole', may be associated with vitiligo and sometimes pre-date the onset of the 
disorder (Lerner 1971). Premature greying of the hair (canities) may also be found in 
patients with vitiligo (Nordlund et al. 1981). Vitiligo can affect all active 
melanocytes, including those of the retinal pigment epithelium and uveal tract of the 
eye and the scala vestibuli of the inner ear, which may lead to ocular abnormalities 
such as iris, conjunctival and chorioretinal depigmentation and uveitis (Albert et al. 
1979; Cowan et al. 1986) or auditory problems including hearing impairment in the 
2-8 kHz range (Thurmon et al. 1976; Tosti et al. 1986; Tosti et al. 1987). The 
combination of vitiligo with uveitis, auditory anomalies, neurological involvement 
and canities is known as the Vogt-Koyanagi-Harada (VKH) syndrome (Barnes 
1988). It has been proposed that VKH syndrome may represent a systemic 
manifestation of vitiligo, since the neurological involvement may also result from 
melanocyte destruction in the leptomeninges of the brain (Kovacs 1998). 
1.2.7 Treatment 
Since the aetiology of vitiligo is not yet understood, there are no effective treatments 
available to correct the basic defects that lead to the destruction of melanocytes. 
Current therapies can be categorised as medical or surgical and these are summarised 
in Table 1.4. Medical therapies include topical steroids and phototherapy and 
surgical treatments include various forms of melanocyte grafts and tattooing. On- 
going psychological support is also important, particularly for patients who have 
suffered serious psychological affects or social stigma as a result of the disease. 
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Table 1.4 Therapies for vitiligo. 
Treatment Reference 
I. MEDICAL TREATMENTS 
Cosmetic modalities Kovacs 1998 
Corticosteroids (topical or systemic) Boissy and Nordlund 1995b; 
Gawkrodger 1998; Kovacs 1998; 
Parsad et al. 2004 
Calcineurin antagonists Hartmann et aL 2004 
Tacrolimus (topical immunomodulator) Grimes et al. 2002; Tanghetti 2003; 
Lepe et al. 2003; Castanedo- 
Cazares et al. 2003; Grimes et al. 
2004 
Psoralen (topical or systemic) and ultraviolet A (PUVA) Boissy and Nordlund 1995b; 
Gawkrodger 1998; Kovacs 1998 
Khellin (topical or systemic) with ultraviolet A or natural Gawkrodger 1998 
sunlight 
Phenylalanine (topical or systemic) with ultraviolet A Kovacs 1998 
Topical pseudocatalase with ultraviolet B Gawkrodger 1998 
Oral antioxidants (e. g. vitamin E acetate; selenio-methionine) Gawkrodger 1998 
5-Fluorouracil (topical) Kovacs 1998 
Depigmentation with monobenzyl ether of hydroquinone Kovacs 1998 
II. SURGICAL TREATMENTS 
Epidermal grafting Boissy and Nordlund 1995b; 
Kovacs 1998 
Punch grafting Agarwa12004 
Autologous minigrafts Boissy and Nordlund 1995b; 
Kovacs 1998 
Transplantation of cultured epidermis Boissy and Nordlund 1995b; 
Kovacs 1998 
Transplantation of non-cultured melanocytes Boissy and Nordlund 1995b; 
Kovacs 1998 
Tattooing Boissy and Nordlund 1995b 
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Steroids, both systemic and topical, have been used extensively to treat vitiligo by 
inducing repigmentation in affected areas of skin. However, since treatment might 
need to be continued for many months, systemic steroids are not usually appropriate 
because of their numerous side effects. Topically applied steroids avoid systemic 
toxicity (Boissy and Nordlund 1995b) and can be useful in children under the age of 
10 years or for those patients with limited depigmentation. 
Psoralen in combination with exposure to UV-A light (PUVA) in the 320-400 nm 
spectra is the most common treatment for vitiligo (Boissy and Nordlund 1995b). The 
molecular mechanism involved in PUVA-induced repigmentation has confirmed that 
the re-colonising melanocytes are derived from pigment cells reservoirs in hair 
follicles (Cui et al. 1991). In addition, it has been proposed that PUVA treatment 
may stimulate the production of melanocyte growth factors and may deplete vitiligo- 
associated antigen expression on melanocytes thus blocking the binding of specific 
autoantibodies (Kao and Yu 1992). Furthermore, it has been shown that PUVA 
therapy depletes epidermal Langerhans cells in vivo which may reduce 
immunological responses against pigment cells in vitiligo skin (Kao and Yu 1992). 
The observation that the cutaneous epidermis in vitiligo lesions has low levels of 
catalase activity and defective catecholamine metabolism, led to the development of 
pseudocatalase (Schallreuter et al. 1995). Vitiligo patients treated with a 
pseudocatalase cream, that also received UV-B and a topical calcium preparation, 
were reported to show complete repigmentation of the face and dorsa of the hands in 
90% of cases (Schallreuter et al. 1995). 
If topical steroids or PUVA treatments fail to induce repigmention, surgical 
alternatives exist. However, because of the time consuming nature of surgical 
therapies, these procedures are most often limited to segmental or localised vitiligo, 
although they can be successful in generalised vitiligo (Kovacs 1998). Surgical 
modalities are only considered in the case of inactive and non-progressive disease. 
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1.3 Theories of vitiligo aetiology 
The aetiology of vitiligo is unknown and it is possible that there may be more than 
one mechanism involved in the cause of the disorder. Various theories have been put 
forward to explain the destruction of melanocytes in vitiligo and the main hypotheses 
are: - 
i. Autoimmune effects that destroy melanocytes 
ii. Neurochemical-mediated effects on melanocytes 
iii. Self-destruction of melanocytes due to an intrinsic melanocyte defect 
In addition to the above separate theories, a convergence theory states that 
psychological stress, the accumulation of toxic compounds, infection, autoimmunity, 
an inherent genetic predisposition (Section 1.2.3), mechanical stress injury and 
impaired melanocyte migration and/or proliferation can all contribute to vitiligo 
pathogenesis in varying proportions (Le Poole et al. 1993c; Taieb 2000). 
1.3.1 Psychological stress 
Many vitiligo patients report that their vitiligo lesions first appeared or expanded 
under conditions of extreme stress (Lerner 1959; Papadopoulos et al. 1999). Stress 
induces an increase in the production of catecholamines, the possible influences of 
which on the destruction of melanocytes are described in Table 1.5. 
1.3.2 Physical stress (Koebner's phenomenon) 
Vitiligo maculae may appear at the site of mechanical stress or friction injury to the 
skin (Taieb 2000). Gauthier demonstrated that the distribution of vitiligo lesions 
commonly correlates to areas of the body subjected to the most mechanical stresses 
(Gauthier 1996). It has been reported. that there is some correlation between the 
activity of non-segmental vitiligo and the presence of experimentally-induced 
Koebner's phenomenon (Njoo et al. 1999). 
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1.3.3 Infections 
It is possible that infections can result in melanocyte destruction by triggering an 
immune response leading to vitiligo in some patients. The melanocyte may be 
destroyed as a result of harbouring an infectious agent or because it exposes antigens 
similar to a micro-organism to immune surveillance (Le Poole et aL 1993c). 
Vitiligo-like hypopigmentation has been reported in some infectious diseases such as 
leprosy (Shegan 1971), candidiasis (Howanitz et al. 1981) and acquired 
immunodeficiency syndrome (Ivker et al. 1994). Cytomegalovirus DNA was found 
in skin biopsies in 11 out of 29 patients with vitiligo, with particular prominence in 
biopsy specimens of active lesions (Grimes et al. 1996), and has, therefore, been 
suggested as a trigger for vitiligo. 
1.3.4 Neuronal hypothesis 
Neurochemical-mediated effects on melanocytes would explain the often 
symmetrical distribution of vitiligo lesions or the dermatomal pattern of segmental- 
type vitiligo (Lerner 1959). Indeed, immunohistochemical studies of lesional and 
perilesional vitiligo skin have demonstrated abnormalities in the levels of skin 
neuropeptides. It has been reported that 5 of 10 patients with symmetrical type 
vitiligo had increased levels of neuropeptide Y in the margins of vitiligo lesions and 
those with active disease also had elevated neuropeptide Y within lesional skin 
(Al'Abadie et al. 1994). In addition, the number of nerve fibres immunoreactive to 
nerve growth factor (NGF) and calcitonin gene-related peptides has been shown to 
be increased in vitiligo lesions compared to the uninvolved and control skin (Liu et 
al. 1996). The secretion of both NGF and calcitonin gene-related peptide is thought 
to influence normal melanocyte function (Yaar et al. 1991; Hara et al. 1995) and 
could be implicated in vitiligo pathogenesis (Liu et al. 1996). Electron microscopy 
studies have also demonstrated regenerative and degenerative changes in dermal 
nerves in lesional and perilesional skin of vitiligo patients (Al'Abadie et al. 1995). 
Furthermore, melanocytes originate from the neural crest and, in many cases of 
vitiligo, perilesional melanocytes appear progressing more neural in their behaviour, 
both in an increasingly dendritic morphology and in ability to synthesise adrenalin 
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(Iyengar and Misra 1988; Iyengar 1989). A reduced activity of acetylcholinesterase 
has been reported in vitiliginous skin compared to normal skin (Iyengar 1989), and 
this is due to high concentrations of H202 in the skin of vitiligo patients (Schallreuter 
et al. 2004). Investigations into the levels of neurotransmitters in vitiligo patients are 
summarised in Table 1.5. 
Several clinical observations provide further evidence for an association of the 
nervous system with vitiligo. It has been noted that vitiligo spares denervated skin, 
for example, below the level of neurological damage in certain patients with severe 
spinal cord injury (Lerner 1959). Spontaneous repigmentation of lesions occurs 
occasionally in vitiligo patients whose nervous system has been compromised by 
diabetic neuropathy. In contrast, vitiligo-like hypopigmented macules are sometimes 
produced in inflammatory diseases affecting the peripheral nervous system such as 
leprosy, and in neurodysplasias such as neurofibromatosis and tuberous sclerosis. 
Additional indirect evidence is provided by the requirement for innervation for skin 
transplants to repigment an area. While vitiligo patients do not complain of sensory 
abnormalities in lesional skin, autonomic dysfunction has been reported, including: 
increased skin surface temperature and an increased sweating response in vitiliginous 
areas, when compared to normal skin, and an abnormal sympathetic skin response 
quantified by electrical measurement of sympathetic nerve activity (Chanco-Turner 
and Lerner 1965; Dutta and Mandal 1982; Merello et al. 1993). However, this could 
be associated with the absence of Merkel cells from the basal layer of vitiligo lesions 
(Bose and Ortonne 1994) that are thought to interact with nerve endings (Lacour et 
al. 1991). 
13.5 The melanocyte defect/self-destruction hypothesis 
It has been hypothesised that intrinsic melanocyte defects such as the accumulation 
of toxic intermediate products of melanin synthesis (Pawelek et al. 1980; Moellmann 
et al. 1982), the breakdown of free radical defence (Nordlund and Lerner 1982), an 
increase of serum nitric oxide levels (Rocha and Guillo 2001; Yildirim et al. 2003) 
and the build-up of excess H202 (Schallreuter et al. 1991; Schallreuter et al. 1994c, 
Schallreuter et al. 2004) might result in the self-destruction of melanocytes in 
vitiligo. The theory is also supported by the clinical observation that certain chemical 
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compounds can produce a pattern of depigmentation indistinguishable from 
idiopathic vitiligo, e. g. mercaptoamines (Bleehan 1979) and phenolic agents (Le 
Poole et al. 1999; Boissy and Manga 2004). The suggestion that vitiligo melanocytes 
show an increased sensitivity to oxidative stress (Schallreuter 1999; Jimbow et al. 
2001) has also led to the use of the antioxidant pseudocatalase in the treatment of 
vitiligo (Section 1.2.7). The proposed involvement of some of the biochemicals 
thought to contribute to vitiligo pathogenesis through melanocyte autocytotoxicity is 
summarised in Table 1.5. 
1.3.6 The autoimmune theory 
The concept of autoimmunity and the development of autoimmune disease are 
discussed in Section 1.4. Here, the evidence for autoimmunity as a pathogenic 
mechanism for the development of vitiligo is outlined. Initially, a role for 
autoimmunity was suggested due to the frequent clinical association of vitiligo with 
diseases of an autoimmune origin (Table 1.3) and by the presence of organ-specific 
autoantibodies in vitiligo patients (Table 1.6). Subsequently, autoantibodies that 
target pigment cell antigens and are capable of causing damage to the melanocyte 
have been identified in vitiligo patient sera (Naughton et al. 1983a; Naughton et al. 
1983b; Norris et al. 1988b; Cui et al. 1992; Gilhar et al. 1995). Autoreactive T 
lymphocytes targeting melanocyte-specific proteins have also been identified both 
circulating in the blood and at the margins of advancing lesions of vitiligo patients 
(Ogg et al. 1998; van den Wijngaard et al. 2000; Lang et al. 2001). These aberrant 
cellular and humoral responses in vitiligo are described in further detail in Section 
1.5. 
The association of vitiligo with certain HLA specificities and other immune 
response genes (Section 1.2.3.1) adds credence to an autoimmune hypothesis. All 
autoimmune endocrinopathies are associated with particular alleles of the MHC class 
II HLA-DR (Dahlberg et al. 1981; Platz et al. 1981; Maclaren and Riley 1986). 
Although studies of association of MHC specificities with vitiligo have shown 
variability, several studies have reported a iignificant association of HLA-DR with 
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Table 1.6 The frequency of organ-specific autoantibodies in vitiligo patients. 
Autoantibody reactivity Number of 
patients 
in study 
Percentage with 
antibody 
reactivity 
Reference 
Gastric parietal cells 65 17 Zauli et at 1986 
Gastric parietal cells 80 21 Brostoff 1969 
Gastric parietal cells 96 13.7 Betterle et at 1976 
Gastric parietal cells 20 30 Mandry et at 1996 
Thyroid cytoplasm 80 28 Brostoff 1969 
Thyroid microsomes/peroxidase 96 20 Betterle et at 1976 
Thyroid microsomes/peroxidase 20 50 Mandry et at 1996 
Thyroglobulin 80 9 Brostoff 1969 
Thyroglobulin 20 40 Mandry et at 1996 
Adrenal cortex 80 4 Brostoff 1969 
Pancreatic islet cells 96 7.2 Betterle et at 1976 
(Adapted from Kemp et al. 2001 c) 
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vitiligo patients in different ethnic populations (Foley et al. 1983; Dunston and 
Haider 1990; Poloy et al. 1991; Venneker et al. 1992; Venkataram et al. 1995; 
Zamani et al. 2001; Tastan et al. 2004). 
The therapeutic response of some vitiligo patients to PUVA (Boissy and 
Nordlund 1995b), topical corticosteroids (Kovacs 1998; Parsad et al. 2004) and 
topical cytotoxic drugs such as fluorouracil (Tsuji and Hamada 1983) is believed to 
result from immunosuppression of the local immune reactions responsible for 
damaging melanocytes. Approximately 50% of vitiligo patients will note a 
significant return of pigment in those lesions that retain melanocytes after the 
application of topical steroids (Boissy and Nordlund 1995b). 
Despite the persuasive evidence detailed above for an autoimmune aetiology, 
exactly how aberrant immunological reactivities (Section 1.5) might contribute to 
vitiligo development remains open to speculation. It is currently unknown whether 
abnormal immune responses are the primary cause of the disease or if they arise as a 
secondary phenomenon resulting from damage to melanocytes via other mechanisms 
and, in turn, exacerbates the condition. It is also possible that different pathogenic 
mechanisms account for the different clinical subtypes of vitiligo (Section 1.2.5). 
For example, associated autoimmunity is rare in patients with segmental vitiligo and, 
therefore, immune mechanisms might play a lesser role than in symmetrical vitiligo 
that is often associated with autoimmune disorders. Several animal models of vitiligo 
also support the autoimmune theory of vitiligo development and these are discussed 
below. 
1.3.6.1 Animal models 
There are several spontaneous animal models of vitiligo (Boissy and Lamoreux 
1988) but how the acquired depigmentation relates to that of the human disease 
remains to be established. The well-documented Smyth line chickens (Smyth 1989), 
express a genetically inherited form of vitiligo-like depigmentation resulting from 
the loss of melanocytes in feather and ocular tissues. In this avian model, vitiligo 
begins with an inherent melanocyte defect that is followed by an autoimmune 
response involving both humoral and cellular reactions that eliminate abnormal 
pigment cells (Lamont and Smyth 1981; Boyle et al. 1987; Pardue et al. 1987). 
Autoantibodies to chicken melanocytes have been detected in the sera of 100% of 
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Smyth line chickens but not in the sera of normally pigmented birds (Austin et al. 
1992). These antibodies were found to be present both before and during the 
presentation of vitiligo (Searle et al. 1991). In addition, an increase of T cells is seen 
in the feather pulp and in the circulation of Smyth chicks prior to the onset and 
during development of vitiligo-like depigmentation (Erf et al. 1995; Erf and Smyth 
1996). Recently, it has been demonstrated that enhanced apoptosis in the feathers of 
Smyth line chickens is at least one pathogenic mechanism involved in the death of 
melanocytes and this appears to be induced by infiltrating cytotoxic T cells (Wang 
and Erf 2004). Depigmentation is reduced by cyclosporine A, a selective inhibitor of 
inflammatory T cells, and by performing neonatal bursectomy that causes B cell 
deficiency (Lamont and Smyth 1981). The vitiligo-like disorder of Smyth chickens 
is accompanied by autoimmune hypothyroidism and an avian equivalent of alopecia 
areata (Smyth 1989). 
Autoantibodies targeting pigment cell surface antigens have also been identified 
in several other animal models of vitiligo, including Arabian horses, Siamese cats 
and Tervuren dogs (Naughton et al. 1986a) as well as in the Sinclair pig, an animal 
model for regressive melanoma with vitiligo-like hypopigmentation (Cui et al. 
1995a). These antibodies recognise a similar pattern of melanocyte antigens in 
immunoprecipitation experiments as antibodies in vitiligo patients (Naughton et al. 
1986a), indicating, that similar immunological responses may occur in both animals 
and humans. 
1.3.7 The convergence theory 
The convergence theory (Figure 1.6) proposes that all of the previously described 
mechanisms can contribute to the development of vitiligo (Le Poole et al. 1993c; 
Taieb 2000). Moreover, the different causal factors can act independently or 
synergistically to bring about the local destruction of melanocytes and are 
differentially involved in separate vitiligo patients (Le Poole et al. 1993c). 
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1.4 Autoimmunity and autoimmune disease 
Normally, individuals do not form potentially destructive autoantibodies and 
autoreactive T cells to their own tissues, but only to foreign antigens (Janeway 
1992). This is because the body has developed a tolerance to self-antigens that is 
maintained by a complex network of T and B lymphocytes and their regulatory 
products. However, the intrinsic variability of the regulatory mechanisms governing 
the immune repertoire can allow for the development of autoreactive immune cells 
and any subsequent failure of the regulatory networks that maintain self-tolerance 
can result in the transition from autoreactivity to autoimmune disease (Avrameas 
1991; Viglietta et al. 2004). 
1.4.1 Self-tolerance 
The processes leading to the discrimination between self and non-self by T cells 
include: central tolerance induced in the thymus, peripheral tolerance and active 
suppression. T cells are predominantly subject to clonal deletion in the thymus 
(Nossal 1989; Schwartz 1989; Kroemer and Martinez 1992) where the recognition of 
the complex of self-peptide with self-MHC antigen during development results in the 
elimination by apoptosis of the majority of potentially self-reactive T cells. This 
thymic negative selection of T cells occurs primarily by the interaction with MHC 
molecules/self-peptides on macrophages and dendritic cells (Speiser et al. 1989), 
although the thymic epithelium may also cause tolerance (Salaun et al. 1990). T cells 
can be subject to positive selection in the thymus. This involves the selection of T 
lymphocytes with moderate but not high affinity for self-MHC antigens (von 
Boehmer and Kisielow 1990) and this selection procedure ensures that circulating T 
cells have some affinity for self-MHC molecules and can thus recognise foreign 
antigens when appropriate. In addition to the aforementioned mechanisms of T cell 
regulation, T cells are also controlled in the thymus by clonal anergy. In this case, 
the interaction of a specific T cell with an antigen results in the production of a state 
of non-responsiveness or anergy in which T cells do not proliferate or produce 
cytokines and thus do not trigger an immune response (Rammensee et al. 1989). 
Clearly, the combination of mechanisms so far described cannot guarantee there will 
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be complete discrimination between self and non-self and prevent the development 
and release of potentially autoreactive T cells into the peripheral circulation. Two 
additional levels of extrathymic control are known to deal with autoreactive T 
lymphocytes that escape central tolerance, namely, peripheral tolerance and active 
suppression. 
Peripheral tolerance has been largely explored through the use of transgenic mice 
and it has been shown that the expression of recombinant antigen in different cells 
and tissues can lead to anergy or deactivation in the corresponding specific T cells 
(Markmann et at 1988). This effect appears to be due to the presentation of antigen 
by non-professional antigen presenting cells and the concomitant absence of 
secondary signalling molecules necessary for the generation of an immune response. 
Finally, studies have demonstrated a role for specific T cell subsets in the 
suppression of autoreactive T cells. Developments in the technology of cell cloning 
have led to the isolation of several T cell clones with suppressor function. Antigen- 
specific CD8+ suppressor T cell clones have been established from patients with 
leprosy and these are able to inhibit T cell proliferative responses to mycobacterial 
antigen (Modlin et at 1987). Recently, it has been shown that the depletion of T cell 
populations can give rise to autoimmune thyroid disease in human patients and this 
may be due to T helper lymphocyte type-1 (Thl)/ T helper lymphocyte type-2 (Th2) 
switching (Coles et at 1999). 
There is compelling evidence that immune responsiveness is also controlled by a 
sub-population of other regulatory T cells that are enriched in a naturally activated 
subset of CD4+ T cells, which constitutively express CD25. The thymus is the 
primary source of this regulatory CD4+CD25+ T cell subset, which participates in the 
active suppression of potentially autoreactive T cells in the periphery (Sakaguchi et 
at 1995). Regulatory CD4+CD25+ T cells are naturally anergic in vitro and they 
inhibit the proliferation of co-cultured conventional CD4+CD25' T cells in a contact- 
dependent manner and have been shown in a variety of experimental systems to 
provide protection from T cell-mediated autoimmune disorders (Shevach 2002). 
A decrease in the number of circulating CD4+CD25+ T cells has been reported in 
type-1 diabetes mellitus (Kukreja et at 2002) and the loss of functional activity for 
circulating CD4+CD25+ T cells (Viglietta et at 2004) has been shown in multiple 
sclerosis. In contrast, the CD4+CD25+ T subset was shown to be enriched with 
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functionally active regulatory T cells in the inflamed joints of patients with 
rheumatoid arthritis (Cao et al. 2003). In myasthenia gravis patients, although a 
normal number of CD4+CD25+ T cells was found, a severe functional defect in their 
regulatory activity together with a decreased expression of the transcription factor 
Foxp3, which is essential for T cell regulatory function (Balandina et aL 2005), was 
apparent. 
Similar tolerising mechanisms of clonal deletion and anergy have been described 
for autoreactive B cells (Goodnow et al. 1989). However, in contrast to T cells, 
antigen concentration is critical for the induction of B cell tolerance as low amounts 
may fail to tolerise B cells. In some transgenic animal models, it has been shown that 
autoreactive B cells can escape the tolerisation process and this may occur in tissues 
where the corresponding antigen is not present or is sequestered (Murakami et al. 
1992). 
Despite the safety mechanisms, self-tolerance can breakdown and several triggers 
have been shown to cause this. 
1.4.2 Mechanisms of breakdown in self-tolerance 
A breakdown in self-tolerance can be triggered by defects in the immune network 
that strictly monitors the recognition of self-antigens by immune cells (Ring and 
Lakkis 1999). This can include: the failure to delete autoreactive lymphocytes or to 
render them anergic in the thymus, the failure of the mechanism of peripheral 
tolerance to again render autoreactive immune cells anergic and the failure of active 
suppression of autoreactive T cells in the peripheral circulation (Ring and Lakkis 
1999). Self-reactive B lymphocytes may also be stimulated by polyclonal activators 
such as lipopolysaccharides with the subsequent formation of antibodies to self 
components (Tsubata 2000). Overall, the breakdown of the immune network can 
occur at several levels resulting in the presence of autoreactive lymphocytes. 
Self-tolerance of non-exposed (cryptic) antigens means that potentially 
autoreactive T cells are not subjected to the normal deletion response. Self-tolerance 
to these antigens continues as far as they remain immunologically hidden, 
sequestered in a tissue compartment devoid of immune cells. Exposure of these 
antigens through tissue damage could trigger an autoimmune response. Examples of 
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this include the immune response against lens protein after eye trauma (Goldschmidt 
et al. 1982) and Dressler's syndrome after myocardial infarction, due to ischemic 
tissue damage (Bartels et al. 1994). 
An attractive concept explaining the initiation of autoimmunity is the existence of 
cross-reactive antigens or molecular mimicry (Wucherpfenning 2001). If a 
pathogenic antigen resembles a host self-antigen, then tolerance of self may be 
broken. A classical example is rheumatic fever, where antibodies to a streptococcal 
protein cross-react with cardiac muscle myosin leading to carditis (Williams et al. 
1985). However, there is no firm evidence that such a mechanism plays a role in the 
aetiology of organ-specific autoimmune diseases. 
An event that could lead to a breakdown in self-tolerance is viral infection. Since 
viruses can cause the display of viral antigens on the surface of cell, viral antigenic 
expression could act to directly induce autoimmune reactivity (Lernmark 2001). 
Viruses can also elicit autoimmune diseases by the polyclonal activation of 
lymphocytes, the release of subcellular organelles after viral lysis of the cell, by 
antigenic mimicry and by the functional impairment of regulatory immune cells such 
as T-helper lymphocytes. Viral infections prior to disease have been associated with 
systemic lupus erythematosus (SLE), multiple sclerosis and type 1 diabetes mellitus 
(Lernmark 2001). 
Once self-tolerance has broken down, the resulting production of autoreactive T 
cells and autoantibodies can cause an array of autoimmune diseases. 
1.4.3 Autoimmune disease 
Autoimmune diseases are generally classified into those affecting a single organ or 
tissue, the organ-specific, and those affecting more than one organ, the non-organ 
specific or systemic (Roitt and Delves 2001). In organ-specific diseases, the tissue 
destruction occurs is restricted to the specific antigens localised in that organ. 
Examples of this type of autoimmune diseases are Graves' disease, type 1 diabetes 
mellitus, multiple sclerosis, pernicious anaemia and myasthenia gravis (Roitt and 
Delves 2001). In contrast, systemic autoimmune diseases can affect many regions of 
the body and circulating immune complexes are often deposited in several different 
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organ regions. Examples of systemic autoimmune diseases are rheumatoid disease 
and SLE (Roitt and Delves 2001). 
In autoimmune disease, damage to tissue results from autoreactive T cells and 
autoantibodies. With respect to cellular autoimmune responses, the recognition of 
self-antigens as immunostimulatory can lead to the initiation and expansion of T 
lymphocyte subsets (Lang et al. 2003). Populations of phagocytic cells and cytotoxic 
T cells are then drawn to the antigenic site and proceed to destroy cells displaying 
the specific self-antigen. An example of this type of immune mechanism is 
autoimmune thyroiditis where an accumulation of cytotoxic T cells can be found in 
thyroid lesions (Martin et al. 1990). As the present study concerns humoral immune 
reactivity in vitiligo, the role of autoantibodies in autoimmune disease is considered 
in more detail in the next section. 
1.4.4 Autoantibodies 
In autoimmune disease, autoantibodies may be the actual pathogenic agents of the 
disease or arise as a secondary consequence due to tissue damage. They can be 
directed against cell surface molecules such as hormone receptors, extracellular 
targets such as circulating soluble antigens and intracellular components such as 
DNA (Naparstek and Poltz 1993). With respect to intracellular antigens, there is 
evidence that autoantibodies can penetrate living cells and can interact with their 
target altering function or even causing apoptosis (Reichlin 1995). To establish that 
an autoantibody is pathogenic, it should fulfil certain criteria (Rose and Bona 1993): 
i) The autoantibody should be capable of causing the lesions attributed to it in 
an experimental system or by transplacental transfer in man, and suitable 
immunisation that leads to the production of similar autoantibodies in 
animals should lead to a similar disease process. 
ii) Autoantibody level and disease activity should, in general, correlate. 
iii) Removal of autoantibody should ameliorate the disease process. 
iv) The antibody has to be found in all patients with the relevant disease in a 
significantly higher frequency or titre than in normal. 
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In pemphigus, anti-epidermal antibodies correlate with disease activity and the 
removal of these antibodies by plasmapheresis leads to clinical improvement 
(Grando et al. 1990). In addition, the injection of pemphigus foliaceus 
autoantibodies into neonatal balb/c mice reproduced the human form of the disease 
in the animals (Rock et al. 1990). Similarly, in myasthenia gravis, autoantibodies to 
the acetylcholine receptor also fulfil the main criteria for the pathogenicity of disease 
(Eymard et al. 1991). 
There are a variety of ways in which autoantibodies can cause tissue damage in 
autoimmune disease including: damage by complement fixation, detrimental effects 
on normal cellular function, the formation of immune complexes that initiate a 
destructive inflammatory response and antibody-dependent cell-mediated 
cytotoxicity (ADCC). These are discussed below with examples of the resulting 
autoimmune disorders. 
1.4.4.1 Effects on cellular functions 
In autoimmune thyroid disease, antibodies against thyroid-stimulating hormone 
receptor (TSHR) play a role in causing the different manifestations of the disease 
(Weetman and McGregor 1994). Autoantibodies in Graves' disease are directed 
against the TSHR and mimic the action of thyroid-stimulating hormone (TSH). 
Since their production is not subject to the feedback control of the thyroid hormone 
whose synthesis they stimulate, the thyroid gland overproduces thyroid hormones 
and enlarges under the tropic stimulus delivered through the receptor. The antibodies 
associate strongly with the disease. In autoimmune hypothyroidism, certain TSHR 
autoantibodies may cause blockage of TSH function leading to hypothyroidism. 
Similarly, blocking autoantibodies in autoimmune hypoglycaemia are directed 
against the insulin receptor and mimic the actions of insulin (Taylor et al. 1989). In 
myasthenia gravis, autoantibodies are produced to acetylcholine receptors located at 
the neuromuscular junction. These antibodies interfere with proper 
neurotransmission and diminish the contractility of the muscle cells (Fabien et al. 
2001). 
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1.4.4.2 Complement activation 
The complement system (Figure 1.7) comprises a complex group of proteins whose 
activation leads to the production of biologically active molecules with several 
discrete functions (Whaley and Schwaeble 1997). Activation of complement may 
occur by two pathways, the classical and the alternative, both of which lead to 
splitting of the C3 and C5 components and the formation of a membrane attack 
complex (MAC) capable of producing cell lysis. The classical pathway is usually 
activated by immune complexes of antigen and antibody of the IgM, IgG1, IgG2, or 
IgG3 isotypes. Immunoglobulin bound to antigen as an immune complex undergoes 
conformational changes that expose a Cl q binding region in the CH2 domain of the 
Fc portion of the antibody and thus stimulates classical pathway activation. The 
initial components of the alternative pathway are factors B, D and P. These factors 
are activated by substances like endotoxin and IgA and feed into MAC formation 
through C3, as does the classical pathway. 
Autoantibodies directed at self-antigens located on the cell surface may bind to 
the recognised antigen and activate the complement system resulting in cytolysis. 
This occurs in autoimmune haemolytic anaemia where IgG autoantibodies bind to 
certain blood group antigens on erythrocytes causing haemolysis (Silverstein 1989). 
In antiphospholipid syndrome, autoantibodies that react with lipid-binding proteins 
on the surface of endothelial cells trigger complement activation and subsequent 
thrombosis (Munakata et al. 2000). 
1.4.4.3 Antibody-dependent cell-mediated cytotoxicity 
Unlike cell killing by cytotoxic T lymphocytes or natural killer (NK) cells, ADCC 
depends on the presence of specific and high-affinity antibodies directed to the 
surface of target cells. The mechanism responsible for this type of killing is the 
capture of such antibodies on the surface of certain cell types including: NK' cells, 
neutrophils, eosinophils and macrophages, through receptors that bind the Fc portion 
of the antibody thus leaving the antigen-binding site of the antibody molecule ready 
to interact with membrane antigens (Yokoyama 1999). Binding of such antibodies to 
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Figure 1.7 An overview of the complement pathway. Initiation of the classical 
pathway requires the presence of antibodies, either IgG or IgM, bound to cell surface 
antigen. The serum protein C1 binds to antibody that, in turn, activates C4 and C2 
leading to the deposition of C3. Following the activation of C5, C6, C7, C8 and C9, 
the membrane attack complex (MAC) is formed. The alternative pathway is initiated 
by non-immune activators such as lipopolysaccharides and is characterised by a two- 
phase system in which six proteins participate. Initiation is the first phase with 
particle-bound C3b acting like the Cl recognition complex of the classical pathway. 
The second phase is called amplification that involves bound C3b, Factors B, D, P 
and that finally leads to the formation of MAC. At the end of both pathways MAC, 
mediates lysis of the target cell. 
(Adapted from Prodinger et al. 1999) 
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the target cell signals to the cell bearing the Fc receptor to initiate cell killing. In the 
case of NK cells and eosinophils, this involves perforin but in the case of 
macrophages and neutrophils killing results entirely from secretion of granzymes and 
TNF-a (Yokoyama 1999). 
Examples of autoimmune disorders in which ADCC can play a pathogenic role 
include autoimmune thyroid disease. Autoantibodies mediating ADCC have been 
found in patients with Hashimoto's thyroiditis but not in those with Graves' disease 
(Bogner et al. 1984). In the same study, a strong association between anti-thyroid 
peroxidase antibody titres and cell lysis was evident (Bogner et al. 1984). Antibodies 
mediating ADCC can also be associated with primary myxoedema (Bogner et al. 
1995; Metcalfe et al. 1997). 
1.4.4.4 Formation of immune complexes 
Autoantibodies produced against soluble self-antigens and extracellular molecules 
can form immune complexes that lead to the activation of the complement cascade. 
The subsequent formation of the complement components C3 and C5 (Figure 1.7) 
results in the release of histamine and an increase in phagocytic activity, 
respectively, causing an inflammatory response that is destructive to tissues at the 
site of immune-complex formation. This is the usual series of events that occurs in 
SLE with anti-DNA/DNA complex formation. In autoimmune thyroid disease, 
autoantibodies to thyroid peroxidase are able to fix complement resulting in tissue 
damage. The deposition of the early components of complement has been identified 
in the thyroid of patients with Hashimoto's thyroiditis (Weetman and McGregor 
1994) and the terminal complement complexes have been found around thyroid 
follicles and in elevated circulating levels in both Hashimoto's thyroiditis and 
Graves' disease patients (Weetman et al. 1989a). In epidermolysis bullosa acquisita, 
an autoimmune skin disease characterised by autoantibodies to type VII collagen, 
complement activation by autoantibody-antigen complexes occurs at the basement 
membrane zone of the skin resulting in inflammatory subepidermal blistering 
(Mooney et al. 1992). 
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1.5 The immune responses in vitiligo 
The possible mechanisms by which both cellular and humoral immune reactivities in 
vitiligo may arise and contribute to its pathogenesis are summarised in Figure 1.8. 
1.5.1 Cellular immunity 
1.5.1.1 T lymphocytes 
Autoimmune diseases are often associated with an expansion of CD4+ T 
lymphocytes (Stites 1994). However, with respect to vitiligo, inconsistent data 
regarding abnormalities in circulating T cells have been reported. An increase in the 
number of CD4+ T lymphocytes as well as an elevated CD4+/CD8+ ratio were 
detected in patients with stable vitiligo and in their first-degree relatives (Soubiran et 
al. 1985; D'Amelio et al. 1990; Al-Fouzan et al. 1995). In addition, a higher 
proportion of activated peripheral T cells, as determined by the expression of HLA- 
DR, has also been found in vitiligo patients compared to healthy individuals (Abdel- 
Naser et al. 1992). In contrast, a decrease in the CD4+ T lymphocytes and reduced 
CD4+/CD8+ ratio has been observed in vitiligo patients (Grimes et al. 1986; Haider 
et al. 1986). These contradictory results may arise from differences in the techniques 
used to evaluate T-cell subpopulations, as well as from differences in the vitiligo 
patients studied e. g. clinical type, disease activity. The studies conclude that 
circulating T-cell subpopulations have rarely been found to be normal in vitiligo 
patients. 
Of more functional relevance, a recent study has demonstrated the presence of 
circulating MelanA-specific cytotoxic T lymphocytes, expressing a skin-homing 
receptor cutaneous lymphocyte-associated antigen (CLA), in a significant number of 
patients with vitiligo (Ogg et al. 1998). These results were confirmed in a subsequent 
study, in which the presence of MelanA-specific cytotoxic T cells expressing CLA 
was also found to be significantly greater in the peripheral blood of vitiligo patients 
with active, progressive disease (Palermo et al. 2001; Lang et al. 2001). These 
studies have also demonstrated the presence of CD8+ cytotoxic cells that react with 
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peptides from tyrosinase (Ogg et al. 1998; Lang et al. 2001) and Pmel17 (Lang et al. 
2001). 
A dermal and epidermal, inflammatory infiltrate consisting of CD3+, CD4+ and 
CD8+ T cells and macrophages, closely associated with areas of melanocyte 
depletion, has been observed in vitiligo patients (Al Badri et al. 1993b). The 
infiltrate is most prominent at the margins of vitiligo lesions and contains a 
significant number of activated T cells, as measured by expression of MHC class II 
antigen HLA-DR and CLA antigen (Al Badri et al. 1993b). There is also evidence of 
expression of the IL-2 receptor (IL-2R) and the interferon y (IFN-y) receptor by the 
lymphocytic infiltrate (Abdel-Naser et al. 1994). In rare cases of inflammatory 
vitiligo, similar observations with regard to perilesional, epidermis-infiltrating T 
cells have been made (Le Poole et al. 1996). A recent study isolated MelanA- 
specific CD8+ T cells expressing CLA antigen from vitiligo skin biopsies, 
demonstrating the presence of a cytotoxic response to a melanocyte-specific antigen 
within vitiligo lesions (van den Wijngaard et al. 2000). However, the absolute 
numbers of infiltrating cells in lesional and perilesional skin are small when 
compared with other inflammatory skin disorders (van den Wijngaard et al. 2000) 
and it remains to be seen whether the infiltrate arises as a result of the disease 
process as opposed to being the cause of vitiligo. 
1.5.1.2 Cytokines 
Cytokines mediate many functions of cellular immunity and a number of studies 
have analysed the levels of various cytokines in patients with vitiligo (Table 1.7). 
Studies have demonstrated that the level of soluble IL-2R in patients with vitiligo is 
significantly increased compared with that of controls, indicating an activation of T 
lymphocytes may be involved in the disease pathogenesis (Caixia et al. 1999; Yeo et 
al. 1999). A recent study also demonstrated that serum IL-2R concentration in 
vitiligo patients depends on the activity and intensity of the disease process 
(Franczuk et al. 2004). The levels of production of IL-6 and IL-8 by peripheral 
mononuclear cells are also elevated in vitiligo patients, both of which can act to 
recruit lymphocytes to the site of an immune response (Yu et al. 1997). In contrast, 
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the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
TNF-a by peripheral mononuclear cells in active vitiligo was found to be reduced 
compared with healthy controls (Yu et al. 1997). The expression of cytokines by 
lymphocytes from the margins of vitiligo lesions has yet to be fully characterised but 
initial data suggest that cytokines which promote inflammation and cytotoxicity, that 
is, those of the T helper lymphocyte type-1 subset, particularly IFN-y and TNF-a, are 
predominantly expressed (Das et al. 2001). 
1.5.1.3 Adhesion molecules 
Adhesion molecules, which allow cell-cell attachments, are required for lymphocyte 
migration and infiltration through the epidermis and also for interaction with antigen 
presenting cells. Several studies have shown expression of ICAM-1 by keratinocytes 
and melanocytes in areas of vitiligo (Norris 1990; Al Badri et al. 1993a; van den 
Wijngaard et al. 2000). The expression of ICAM-1 by melanocytes at the edge of 
vitiligo lesions was found to be increased by six-fold, and was present in nineteen of 
twenty biopsies from perilesional skin, compared to six of seven biopsies from non- 
lesional skin and five of eight samples from control skin (Al Badri et al. 1993a). 
Immunohistochemistry of serial sections of vitiligo skin biopsies has shown that the 
epidermal expression of ICAM-1 coincides with the expression of HLA-DR (van 
den Wijngaard et al. 2000). Similar abnormal expression of HLA-DR and ICAM-1 
are shown by the pancreatic islet cells in type 1 diabetes mellitus (Cambell and 
Harrison 1990) and by the thyroid follicular cells in autoimmune thyroid disease 
(Hanafusa et al. 1983; Weetman et al. 1989b; Zheng et al. 1990). 
Vascular expression of E-selectin, the adhesion molecule responsible for capture 
of leucocytes from the circulation to initiate migration to the site of a local immune 
response, appears neither to be upregulated nor more widely dispersed in post- 
capillary venules in vitiligo, when compared to control skin (van den Wijngaard et 
al. 2000). However, immunohistochemical analysis demonstrated that where there is 
expression of E-selectin in perilesional skin, it is co-localised with T cell infiltration 
(van den Wijngaard et al. 2000). The expression of E-selectin is dependent on 
cytokines, particularly TNF-a (Pilewski et al. 1995). 
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1.5.1.4 Langerhans cells 
The role of Langerhans cells (LC), which act as antigen-presenting cells to primed T 
lymphocytes, in vitiligo is unclear (Facchetti et al. 1984). The density of LC in 
vitiligo has been reported as normal (Claudy and Rouchouse 1984) or increased 
(Riley 1967), relative to that of the non-lesional skin and skin from control subjects. 
An increase in the numbers of LC might contribute to the immunological responses 
to melanocytes in vitiligo. Patients with repigmenting lesions in response to PUVA 
or Fluocinonide treatment show a decrease in epidermal LC further supporting a role 
for these cells in the disease (Kao and Yu 1990). 
1.5.1.5 Natural killer cells 
It has been shown that the number of NK cells present in affected vitiligo skin is no 
different from that present in the skin of control subjects (Abdel-Naser et al. 1992; 
Hann et al. 1993b). Although previous studies have implicated an involvement of 
these cells in the destruction of melanocytes in vitiligo (Haider et al. 1986; 
Mozzanica et al. 1989), a recent study found no significant differences between the 
level of activity of NK cells from vitiligo patients and control subjects, against both 
normal and malignant melanocytes (Durham-Pierre et al. 1995). 
1.5.2 Humoral Immunity 
1.5.2.1 Organ-specific autoantibodies 
In addition to the frequent association of vitiligo with autoimmune disorders, 
previously described (Section 1.2.6 and Table 1.3), a variety of organ-specific 
autoantibodies are commonly detected in the sera of vitiligo patients (Table 1.6). 
1.5.2.2 Anti-melanocyte antibodies 
Significantly, antibodies to melanocytes are present in the circulation of most 
patients with the vitiligo (Naughton et al. 1983a). In one study, 12 out of 12 of 
vitiligo patients but none of control subjects were found to have anti-pigment cell 
antibodies in their sera (Naughton et al. 1983b). In addition, a correlation has been 
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described between the incidence and level of melanocyte antibodies and disease 
activity in vitiligo: 8/10 patients with active vitiligo, 0/14 with inactive disease and 
0/19 controls were found to have circulating anti-pigment cell antibodies (Harning et 
al. 1991). Furthermore, the presence of these antibodies is related to the extent of 
disease: they were detected in 50% of patients with minimal vitiligo, less than 2% of 
skin area involved, compared to 93% of patients with greater depigmentation 
covering 5-10% of their skin (Naughton et al. 1986b). Furthermore, the level of 
melanocyte antibodies appears to decrease in vitiligo patients who respond to PUVA 
therapy or following systemic steroid treatment, suggesting that the disease activity 
is somehow related to the incidence of these antibodies (Park et al. 1996). 
Generally, vitiligo antibodies belong to the IgG class (Harning et al. 1991) with 
subclasses IgGI, IgG2 and IgG3 represented (Xie et al. 1991). Deposits of IgG have 
been observed in the basal membrane zone and in the keratinocytes of vitiligo 
lesions (Yu et al. 1993; Uda et al. 1984) and fluorescence staining for IgG-binding 
to cultured normal melanocytes and keratinocytes is more prominent in IgG samples 
from patients with active and extensive vitiligo (Yu et al. 1993). However, other 
investigators have reported that IgA anti-pigment cell membrane antibody levels also 
correlate well with vitiligo activity (Aronson and Hashimoto 1987). 
The pathogenic role of antimelanocyte antibodies in vitiligo still remains unclear. 
However, the capacity of anti-melanocyte antibodies to injure pigment cells has been 
demonstrated experimentally: vitiligo antibodies are able to destroy melanocytes in 
vitro by complement-mediated cytotoxicity and ADCC (Norris et al. 1988b) and in 
vivo following passive immunisation of nude mice grafted with human skin (Gilhar 
et al. 1995). Furthermore, it has been shown that the purified IgG fraction of vitiligo 
sera has a destructive effect on melanoma cells both in vivo and in vitro (Fishman 
1993). More recently, a reduced expression of the membrane regulators of 
complement activation in both lesional and perilesional keratinocytes and 
melanocytes has been reported, possibly indicating an increased vulnerability of 
these cells to autologous complement attack (van den Wijngaard et al. 2002). The 
selective destruction of melanocytes in vitiligo may result from antibody reactivity 
directed to the antigens preferentially expressed on pigment cells (Cui et al. 1992). 
Alternatively, an antibody response against antigens expressed on a variety of cell 
types may selectively destroy melanocytes because they have been shown to be 
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intrinsically more sensitive to immune-mediated injury than, for example, 
keratinocytes or fibroblasts (Norris et al. 1988a). 
Vitiligo antibodies were initially identified in immunoprecipitation experiments 
with melanocyte protein extracts and vitiligo patient sera. The antibodies were most 
commonly directed against pigment cell antigens with molecular weights of 35,40- 
45,75,90 and 150 kDa, which are located on the surface of the cell (Cui et al. 1992; 
Cui et al. 1995b). Although the proteins have not been specifically identified, some 
(40-45,75 and 150 kDa) are expressed both on pigment cells and in other tissues, 
while others (35 and 90 kDa) are preferentially expressed on pigment cells (Cui et al. 
1992). Immunoblotting studies have revealed antibody reactivity in vitiligo patient 
sera to melanocyte proteins of 45,65,68,90,110 and 165 kDa (Park et al. 1996; 
Hann et al. 1996; Rocha et al. 2000). Again, however, the identity of these antigens 
has not been determined. 
In addition, antibodies to the melanocyte-specific proteins tyrosinase (Song et al. 
1994b; Baharav et al. 1996; Kemp et al. 1997a; Okamoto et al. 1998), TRP-1 (Kemp 
et al. 1998b), TRP-2 (Kemp et al. 1997b; Okamoto et al. 1998) and Pmel17 (Kemp 
et al. 1998c) have been detected in the sera of patients with vitiligo. In a recent 
study, antibodies to transcription factors SOX9 and SOX10 were identified in 
vitiligo patients with polyendocrine syndrome type 1 (Hedstrand et al. 2001). In 
addition, the melanin-concentrating hormone receptor 1 (MCHRI) has been 
identified as an autoantigen in 16.5% of vitiligo patients (Kemp et al. 2002) and this 
is discussed further in Section 1.6. Although all these proteins may be considered 
cytoplasmic autoantigens a de novo mechanism may exist whereby antibodies 
recognise autoantigens directly via cell surface or cytoplasmic penetration (Okamoto 
et al. 1998). For example, antibodies have been shown to be taken up by non- 
haemopoietic cells and react with nuclear antigens in vivo (Isenberg et al. 1997). 
Alternatively, antigens may be released if the melanocyte is damaged by another 
mechanism such as cytotoxic T cell lysis. A summary of the autoantigens implicated 
in vitiligo is given in Table 1.8. 
The stimulus for the production of anti-melanocyte antibodies has not been 
identified and it is unknown whether vitiligo autoantibodies initiate the development 
of the disease. It is possible that cross-reacting antigens expressed either on other cell 
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Table 1.8 Identified target autoantigens for vitiligo antibodies. 
Autoantigen Detection method 
Percentage 
reactivity 
in patients 
Reference 
Tyrosinase Immunoblotting with recombinant human tyrosinase 61 Song et at 1994b 
Tyrosinase ELISA with mushroom tyrosinase 38.8 Baharav et al. 1996 
Tyrosinase Immunoprecipitation dopa essay/ELISA with human 0 Xie et al. 1999 
tyrosinase 
Tyrosinase Radiobinding assay with recombinant human 10.9 Kemp et at 1997a 
tyrosinase 
TRP-2 ELISA with recombinant human TRP-2 67 Okamoto et al. 1998 
TRP-2 Radiobinding assay with recombinant human TRP-2 5.9 Kemp et al. 1997b 
TRP-I Radiobinding assay with recombinant human TRP-1 5.7 Kemp et al. 1998b 
PmeI17 Radiobinding assay with recombinant human Pmell7 5.9 Kemp et al. 1998c 
MelanA/MARTI Radiobinding assay with recombinant 0 Waterman et al. 
MelanA/MARTI 2002 
MCHRI Radiobinding assay with recombinant MCI-IR1 16.4 Kemp et al. 2002 
SOX9 Immunoprecipitation of recombinant human SOX9 47 Hedstrand et al. 
2001 
SOX10 Immunoprecipitation of recombinant human SOX10 63 Hedstrand et al. 
2001 
40-45 kDa Immunoprecipitation of human melanocytes 72 Cui et at 1995b 
75 kDa Immunoprecipitation of human melanocytes 76 Cui et at 1995b 
90 kDa Immunoprecipitation of human melanocytes 45 Cui et al. 1995b 
65 kDa Immunoprecipitation of human melanocytes 44 Park et at 1996 
35 kDa Immunoprecipitation of human melanocytes 4 Cui et al. 1992 
150 kDa Immunoprecipitation of human melanocytes 4 Cui et al. 1992 
110 kDa Immunoblotting of melanocytes membrane extract 31 Hann et at 1996 
165 kDa Immunoblotting of human melanoma cells 11 Rocha et at 2000 
90 kDa Immunoblotting of human melanoma cells 26 Rocha et al 2000 
68 kDa Immunoblotting of human melanoma cells 37 Rocha et at 2000 
(Adapted from Kemp et al. 2001 c and Ongenae et al. 2003) 
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types or on infecting micro-organisms may elicit their production. For example, 
common antigens have been identified in mycobacteria and malignant melanocytes 
(Bystryn 1997). Alternatively, vitiligo antibodies might result from a secondary 
immune response to melanocyte antigens following damage to pigment cells by 
other mechanisms, and these antibodies might further exacerbate the condition. It is 
presently unknown if humoral immune responses actually damage melanocytes in 
vivo and it is still possible that they play no direct part in vitiligo aetiology. 
Nonetheless, these antibodies serve as relevant markers to identify potential 
autoantigens, even if the disease is T cell mediated. 
1.5.2.3 Other antibody reactivities 
Aside from organ-specific antibodies (Table 1.6), anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have been detected in 
vitiligo patients (Yu et al. 1993) and specific IgA reactivity against human melanoma 
cells in patients with active vitiligo has been reported (Aronson and Hashimoto 
1987). An increased incidence of anti-nuclear, anti-microsomal, and anti-smooth 
muscle cell antibodies has also been observed in the sera of vitiligo patients (Hann et 
al. 1993a). A significant number of vitiligo patients also have antibodies against 
compounds containing the benzene ring structure (Wojdani et al. 1992; Vojdani and 
Grimes 1996). These were investigated for immune reactivity because compounds 
containing the benzene ring, including catechols, phenols, hydroquinone and mono- 
benzene, can induce cutaneous depigmentation (Section 1.2.5). Although the nature 
of the action of the anti-benzene ring antibodies is not proven, it has been suggested 
that exposure to compounds containing this structure may induce aberrant 
immunological responses in some individuals with vitiligo (Wojdani et al. 1992; 
Vojdani and Grimes 1996). As with melanocyte antibodies, although to a greater 
degree, it is presently unclear how these antibodies relate temporally and 
pathogenically to the lesions in vitiligo. 
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1.6 Melanin-concentrating hormone and melanin-concentrating 
hormone receptor 1 
1.6.1 Melanin-concentrating hormone 
Melanin-concentrating hormone (MCH) is a cyclic polypeptide that was first isolated 
from the pituitary of salmon fish. In teleost fish, MCH circulates and lightens skin 
colour by stimulating melanosome aggregation within the melanophores (Kawauchi 
et al. 1983). In fish, MCH consists of seventeen amino acids with a cysteine-cysteine 
disulfide bond, whereas in mammals, it consists of nineteen amino acids and, 
although it has high homology to salmon MCH, the N-terminus is extended by two 
additional amino acids, Asp' and Phe2 (Pissios and Maratos-Flier 2003). Among 
mammals, MCH is highly conserved in all species and, indeed, rat MCH is identical 
to human MCH. Melanin-concentrating hormone is produced from pro-MCH that 
encodes neuropeptide E-I and neuropeptide G-E, in addition to MCH (Mahon et al. 
1989). The human MCH gene was assigned to chromosome 12 (Pedeutour et al. 
1994). 
In contrast to the salmon MCH gene that is intronless (Takayama et al. 1989), the 
mammalian gene has two introns and three exons (Nahon 1994). In lower 
invertebrates, MCH acts to regulate skin colour by antagonising the melanin- 
dispersing actions of a-MSH (Baker 1988; Baker 1993). In addition, it has been 
found that MCH evokes an increase in proliferation of the erythrophoroma cell line, 
GEM-81, a skin tumour cell line developed from teleost fish (Isoldi et al. 2004). The 
physiological roles of MCH in mammals have yet to be fully elucidated but since it 
is highly expressed in the regulatory centres of the brain, particularly the 
hypothalamus, and throughout the central and peripheral nervous systems, it is 
thought to act as a neuromodulator or neurotransmitter mediating a broad range of 
behavioural responses (Skofitsch et al. 1985; Bittencourt et al. 1992; Mouri et al. 
1993; Knigge et al. 1996). Most functional studies of MCH have concentrated on its 
influence on feeding (Qu et al. 1996), a role which is highlighted by the lean 
phenotype created by knocking-out the function of MCH in mice (Segal-Lieberman 
et al. 2003) and by the obese phenotype of mice engineered to over-express MCH 
(Ludwig et al. 2001). Furthermore, a recent study reported the expression of prepro- 
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MCH by human immune cells such as peripheral blood mononuclear cells, 
thymocytes and splenocytes (Verlaet et al. 2002). 
So far, very little is known about the actions of MCH on the regulation of 
pigmentation in higher vertebrates including humans. Recently, it has been 
demonstrated that human skin expresses MCH and the hormone inhibits a-MSH- 
induced melanogenesis in cultured human melanocytes (Hoogduijn et al. 2001; 
Hoogduijn et al. 2002). Some of the characterised physiological functions of MCH, 
with reference to the antagonistic effects of MCH on a-MSH, are shown in Table 
1.9. 
Several studies have identified a somatostatin-like receptor SLC-1 (Kolakowski et 
al. 1996) as the receptor for MCH, which has been renamed as the melanin- 
concentrating hormone receptor 1 (MCHRI) (Bachner et al. 1999; Chambers et al. 
1999; Saito et al. 1999; Shimomura et al. 1999) and this is discussed in the Section 
1.6.2. 
1.6.2 The melanin-concentrating hormone receptor 1 
1.6.2.1 Expression of MCHR1 
The gene encoding MCHRI has been localized to chromosome 22 and contains two 
exons (Kolakowski et al. 1996). The receptor is widely and strongly expressed in the 
brain, major sites of expression being the cerebral cortex, hippocampus, 
hypothalamus, cerebellum and the olfactory organs (Kolakowski et al. 1996; 
Bachner et al. 1999; Chambers et al. 1999; Saito et al. 1999; Hervieu et al. 2000; 
Kokkotou et al. 2001). Moderate expression has also been noted in the eye, skeletal 
muscle and tongue of the rat, although the function of the receptor at these locations 
is unknown (Saito et al. 1999; Saito et al. 2000). In addition, MCHR1 is expressed in 
human skin, (Hoogduijn et al. 2002), melanocytes (Hoogduijn et al. 2001; 
Hoogduijn et al. 2002), keratinocytes (Burgaud et al. 1997), melanoma cell lines 
(Hoogduijn et al. 2001; Hoogduijn et al. 2002), mouse melanoma cell lines (Drozdz 
et al. 1995; Hoogduijn et al. 2001; Hoogduijn et al. 2002), human immune cells such 
as peripheral blood mononuclear cells, thymocytes and splenocytes (Verlaet et al. 
2002). 
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Table 1.9 Physiological functions influenced by MCH and a-MSH. 
Location Ligand Receptor Function Reference 
Fish melanophore Salmon a-MSH Not characterised Pigment dispersion. Kawauchi et 
al. 1983. 
Salmon MCH Not characterised Pigment aggregation. 
Human Human a-MSH MC-1R 
melanocyte 
Human MCH MCHRI 
Mouse melanoma Rat a-MSH MC-IR 
cells 
Rat MCH 7 
Mammalian brain Rat a-MSH MC-4R' 
Rat MCH MCHRI 
Increases Hoogduijn et 
intracellular calcium, al. 2001. 
Melanogenesis. 
Decreases a-MSH Hoogduijn et 
stimulated a1.2002. 
intracellular calcium. 
Partially inhibits a- 
MSH induced 
melanogenesis. 
Melanogenesis. Ludwig et al. 
1998. 
No apparent effect on 
melanogenesis. 
Inhibits feeding. Ludwig et al. 
1998. 
Increases feeding. 
The large brackets indicate a functionally antagonistic relationship between MCH 
and a-MSH. 
1 MC-4R, melanocortin 4 receptor. 
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1.6.2.2 Structure and function of MCHR1 
The melanin-concentrating hormone receptor 1 is aG protein-coupled receptor 
(GPCR; Bachner et al. 1999; Chambers et al. 1999; Saito et al. 1999; Shimomura et 
al. 1999) that specifically binds MCH. The GPCRs are classified in a superfamily of 
membrane proteins, with a distinguishing arrangement of seven transmembrane 
(TM) domains, encompassing hundreds of receptors for a diverse range of chemical 
messengers including hormones and neurotransmitters (Iismaa and Shine 1992; 
Eckard and Beck-Sickinger 2000). The GPCRs share a common core domain 
consisting of seven TM helices connected by three intracellular and three 
extracellular loops, with the N- and C-terminal domains protruding, respectively, on 
the extracellular and intracellular sides of the membrane. The MCHR1 is 402 amino 
acids long, with all the hallmark features of aG protein-coupled receptor, including 
seven TM helices, an Asp-Arg-Phe motif at the end of the third intracellular loop and 
three potential glycosylation sites at the N-terminus. The receptor shows the highest 
degree of homology (35%) to the somatostatin receptor family. Comparison of the 
human and the rodent receptors shows a high degree of conservation between species 
with 98% identity between rat and mouse and 91% identity between rat and human 
(Schlumberger et al. 2002). 
Mutational analysis of several GPCRs has revealed that the extracellular regions 
and the TM domains contribute to the formation of the ligand-binding site, whereas 
the intracellular loops interact with G proteins, as well as with other regulatory 
proteins (Bockaert and Pin 1999; Gether 2000). Biochemical analyses have 
identified two amino acid residues important for rat MCH binding to the receptor: 
Asp123 in the transmembrane domain (Macdonald et at 2000) and Asn23 in the 
extracellular amino-terminal region (Saito et al. 2003). Glycosylation is a common 
posttranslational feature of . the 
GPCRs superfamily. It has been shown that 
glycosylation of the receptor may be involved in a variety of biological activities. 
These activities include maintenance of receptor stability, folding, trafficking of the 
receptor to the cell surface, ligand binding and signal transduction. In human 
MCHR1, N-linked glycosylation of Asn23 is necessary for expression of the receptor 
on the cell surface, signal transduction and ligand binding (Saito et al. 2003). 
Binding of agonist to GPCRs results in the activation of one or more class of G 
proteins that regulate numerous signal transduction pathways (Hawes et al. 2000). 
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G proteins are heterotrimeric proteins composed of a-, ß- and y- subunits and are 
categorised by the signalling characteristics of the Ga-subunit. Over 20 distinct Ga- 
subunits are grouped into four classes, G,, G; /Go, Gq and G12. G$ proteins stimulate 
adenylate cyclase, activate cyclic guanosine monophosphate phosphodiesterase and 
regulate potassium and calcium channels. Gq proteins activate phospholipase C 
(PLC), leading to increased production of inositol 1,4,5- triphosphate (IP3) and 
diacyl glycerol (DAG) and consequently the activation of protein kinase C (PKC) 
(Hawes et al. 2000). G12 proteins regulate sodium/potassium exchange (Hawes et al. 
2000). 
It has been demonstrated that binding of MCH to cells expressing MCHR1 
inhibits forskolin-stimulated cyclic AMP production, increases intracellular calcium 
and IP3, and activates MAP kinase (Figure 1.9; Chambers et al. 1999; Lembo et al. 
1999; Saito et al. 1999; Shimomura et al. 1999; Hawes et al. 2000; Verlaet et al. 
2002). Studies have been carried out to determine with which G protein class 
MCHR1 interacts. Pre-treatment of Chinese hamster ovary cells (CHO-K1) 
expressing MCHR1 with pertussis toxin (PTX), which blocks G, /Go protein activity, 
reverses the MCH-provoked inhibition of cyclic AMP production and indicates that 
MCHR1 couples to G; /Go proteins to mediate the inhibition of adenylate cyclase 
(Figure 1.9; Hawes et al. 2000). Melanin-concentrating hormone also stimulates 
increased IP3 production and increased levels of intracellular calcium that are 
attenuated, but not abolished, by PTX pre-treatment in CHO-MCHRI cells. These 
results suggest that multiple G protein types (a PTX-sensitive G; /Go-type and a PTX- 
insensitive Gq-type) are responsible for coupling the MCH receptor to increases in 
IP3 production and intracellular calcium (Hawes et al. 2000). 
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Figure 1.9 A model of the intracellular signalling pathways coupled to MCHR1. 
The MCHR1 couples to multiple G proteins, including Gi, Go and Gq. G; activation 
results in a decrease in adenylate cyclase activity and reduced cyclic AMP 
production. The ßy-subunit of G; mediates a portion of MCH-stimulated MAP kinase 
activation. In addition, G; is responsible for mediating a component of MCH- 
stimulated IP3 production and increases intracellular calcium levels. Go mediates a 
portion of MCH-stimulated MAP kinase activation and might also mediate increases 
intracellular calcium levels. Gq mediates one component of MCH-stimulated IP3 
production and increases intracellular calcium levels. Pertussis toxin inhibits G; and 
Go activity. [Ca2+];, intracellular calcium. 
(Adapted from Hawes et al. 2000) 
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1.6.2.3 The melanin-concentrating hormone receptor as an autoantigen in 
vitiligo 
Using IgG from vitiligo patients in biopanning experiments with a melanocyte 
cDNA phage-display library, MCHR1 was identified as a novel autoantigen 
recognised by autoantibodies in vitiligo (Kemp et al. 2002). Antibodies against the 
receptor were demonstrated in 9/55 (16.4%) of the vitiligo patient sera tested in 
radiobinding assays and were at a significantly increased frequency compared with a 
control population (p=0.025). Among sera from healthy controls and from patients 
with other autoimmune disease, SLE, none exhibited immunoreactivity to MCHR1, 
indicating a high degree of disease specificity for antibodies against the receptor. 
Although the frequency of MCHRI antibodies appears low, it is possible that some 
receptor antibodies were not detected in the radiobinding assay since recombinant in 
vitro translated MCHR1 was used as the radioactive ligand. Indeed, the incidence of 
MCHRI antibodies may be increased if native receptor was employed in an assay to 
detect MCHRI antibodies that recognise conformational epitopes. 
As discussed (Section 1.6.1), the effect of MCH on pigmentation has not been 
fully elucidated in mammalian systems. Initial studies have shown that the 
stimulation of cultured human melanocytes with MCH reduces the a-MSH-induced 
increase in cyclic AMP production via binding to MCHRI (Hoogduijn et al. 2002). 
Furthermore, the melanogenic actions of a-MSH were inhibited by the interaction of 
MCH with its receptor (Hoogduijn et al. 2002). In conclusion, the authors proposed 
that the MCH/MCHRI signalling system might have a role, along with the 
melanocortins, in regulating the physiological reactivities of melanocytes, including 
melanin synthesis. As MCHR1 is expressed on the cell surface, it could be accessible 
to autoantibodies that might adversely affect the functioning of the receptor, leading 
to the disruption of normal melanocyte behaviour. Interestingly, IgG from MCHRI 
antibody-positive vitiligo patients inhibited the binding of 125I-MCH to membranes 
of CHO-K1 cells expressing the receptor (Kemp et al. 2002). However, the effects of 
MCHRI antibodies on the functioning of the receptor and on normal melanocyte 
physiology as well as their possible relationship to the aetiology of vitiligo have yet 
to be established. 
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1.7 Aims of this study 
Although both aberrant cellular and humoral immune responses have been reported 
in vitiligo patients (Section 1.5), the exact contribution of these to the pathogenesis 
of the disorder have yet to be fully elucidated. However, characterising the 
autoimmune response in vitiligo has several potential clinical implications and 
applications. It is possible that analysing the abnormal immune response in vitiligo 
might lead to the development of more effective treatments, as well as to a greater 
understanding of the action of current immunosuppressive treatments, such as 
PUVA, which are effective in some cases of vitiligo. If autoimmune responses could 
be identified routinely, more appropriate treatments could be applied to individual 
patients. It might also be possible to establish whether particular clinical subtypes of 
vitiligo do indeed have separate disease aetiologies. 
Part of the elucidation of the autoimmune response in vitiligo is the identification 
and characterisation of melanocyte autoantigens that are recognised by 
autoantibodies and/or autoreactive T cells in vitiligo patients. In the long term, this 
might be of use in the diagnosis of the disorder and in the development of markers 
for disease activity and progression. With respect to this, the aim of this study was to 
characterise autoantibodies to MCHR1, an autoantigen in vitiligo. The specific aims 
were: 
1) To identify B cell epitopes on the MCHRI using recombinant protein and 
phage-display technology. 
2) To isolate a stable Chinese hamster ovary (CHO-KI) cell line expressing 
MCHRI. 
3) To examine the effects of MCHR1 autoantibodies on the functioning of the 
receptor by using fluorimetry to measure changes in intracellular calcium 
levels in response to MCH-stimulation in a CHO-Ki cell line expressing 
MCHRI. 
4) To investigate complement fixation activity and ADCC with respect to 
MCHR1 autoantibodies. 
64 
2 General Materials and Methods 
2.1 Patient sera 
Sera from patients with vitiligo and other autoimmune diseases were collected from 
dermatology and endocrinology clinics at the Royal Hallamshire Hospital, Sheffield, 
UK, and the Northern General Hospital, Sheffield, UK, respectively, between 
1990-2004. Patient details are given in Table 2.1. Control sera were also obtained 
from healthy laboratory volunteers with no personal or family history of vitiligo or 
of autoimmune disorders their details are given in the relevant chapters. The details 
of other patient groups are also summarised in the relevant chapters. Serum was 
separated from whole blood samples (10-20 ml) by centrifugation in a Sorval® 
RT6000-D centrifuge at 2800 revolutions per minute (rpm) for 20 minutes. Sera 
were kept frozen at -20°C until use. All work was approved by the Ethics Committee 
of the Northern General Hospital NHS Trust, Sheffield, UK and all subjects gave 
informed consent. 
2.2 Chemicals 
The majority of chemicals were purchased from either Sigma (Poole, UK) or BDH 
(Poole, UK), and were of either molecular biology grade or `AnaiR' grade, 
respectively. The source of some chemicals is indicated in the text where 
appropriate. 
2.3 Media 
The media used in this study are given below. All media were sterilised either by 
autoclaving or by filtration using Millipore GS disposable filters (Millipore Corp., 
Bedford, MA, USA). 
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2.3.1 Luria Bertani medium and agar 
Luria Bertani (LB) medium was prepared in double distilled water and contained: 
1% (w/v) Bacto-tryptone (Sigma); 0.5% (w/v) yeast extract (Sigma); 0.5% (w/v) 
NaCl. Luria Bertani agar was made by adding 1.5% (w/v) Bacto-agar (Sigma) to LB 
medium. After sterilisation, the agar was left to cool to 40-45°C before the addition 
of appropriate antibiotics. The agar was then poured into 90-mm petri-dishes, 
allowed to set and the plates stored at 4°C until required. 
2.4 Antibiotics 
Antibiotics (Sigma) were prepared as 100x concentrated stocks in double-distilled 
water, sterilised by filtration with a Millex® Filter Unit (Millipore Corp. ) and used in 
medium at either the final concentration shown below or as stated in the text. 
Tetracycline was dissolved in 50% (v/v) ethanol/H20. The stocks were stored 
at -20°C. 
Final concentration 
in medium (tg/ml): 
Ampicillin (Sodium salt) 100 
Kanamycin (Monosulfate) 12 
Tetracycline (Hydrochloride) 10 
2.5 Bacterial strains 
The bacterial strains used in this study were derivatives of Escherichia coli K-12 and 
were strains JM109 (Promega, Southampton, UK; Yanisch-Perron et al. 1985) and 
XL-1 Blue (Tetracycline resistant; Stratagene, La Jolla, CA, USA; Bullock et al. 
1987). Derivatives of strains carrying various plasmids were constructed by 
transformation (Section 2.14) and are defined in the text. 
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2.6 Plasmids 
The plasmids used in this study are listed in Table 2.2. They were kept at -20°C in 
sterile TE buffer (10 mM Tris-HCI; 1 mM ethylenediaminetetraacetic acid (EDTA); 
pH 8.0). Maps of the plasmid vectors used in DNA cloning experiments are given in 
the relevant chapters. 
2.7 Growth and maintenance of bacterial strains 
When first obtained, strains were checked for the presence of relevant antibiotic 
markers by streaking onto selective LB agar. All E. coli strains were routinely grown 
from single colonies on LB agar plates in LB medium, with the appropriate 
antibiotics, at 37°C in a rotary incubator shaking at 200 rpm. 
For storage, bacterial strains were streaked onto LB agar plates, containing 
appropriate antibiotics, and incubated overnight at 37°C and then placed at 4°C for 
up to one month. Additionally, 10 ml bacterial cultures were grown overnight at 
37°C and then mixed with an equal volume of 50% (v/v) sterile glycerol/H20 for 
long-term storage at -20°C. 
2.8 Small-scale plasmid preparations 
The WizardTM Minipreps DNA Purification System (Promega) was used to purify 
plasmid DNA from a 5-10 ml overnight culture of a required bacterial strain, 
according to the manufacturer's protocol. Briefly, single colonies of the desired 
bacterial strain were isolated by streaking out 20 µl of frozen bacterial stock onto LB 
agar containing the appropriate antibiotic. A single colony from a selective plate was 
then used toa inoculate 10 ml of LB containing the relevant antibiotic. This culture 
was shaken in a rotary incubator at 200 rpm at 37°C overnight. A bacterial cell pellet 
was obtained by centrifugation at 10,000 g for 10 minutes. The pellet was 
resuspended in 300 µl of WizardTM resuspension solution (50 mM Tris-HCI, pH 7.5; 
10 mM EDTA; 100 µg/ml RNase A), and the cells were lysed by addition of 300 µl 
of WizardTM cell lysis solution (0.2 M NaOH; 1% (w/v) sodium dodecyl sulphate 
(SDS)) and then neutralised by addition of 300 µl of WizardTM neutralisation buffer 
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Table 2.2 Plasmids used in this study. 
Plasmid Characteristics Source Reference 
pcDNA3 with a 1.3 kb Dr. E. H. Kemp, Kemp et al. 2002 
EcoRI Xbal insert of Division of 
pcMCHRI MCHR1 cDNA. Contains Clinical Sciences 
promoters for T7 and SP6 (North), 
polymerases flanking a University of 
diverse multiple cloning Sheffield, 
site. (Amp R)1. Sheffield, UK 
Multicopy 5.4 kb Invitrogen Akrigg et al. 1985 
expression vector. (Paisley, UK) Boshart et al. 
pcDNA3 Contains promoters for T7 1985 
and SP6 polymerases 
flanking a diverse multiple 
cloning site. (Amp'). 
Multicopy 4.0 kb Prof. C. F. Barbas, Barbas et al. 1991 
expression vector with The Scripps 
pComb3 EcoRV insert of MCHR1 Research Institute, 
cDNA fragments. (Amp'). La Jolla, CA, USA 
AmpR, ampicillin resistance. 
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(1.32 M potassium acetate). The resulting solution was mixed gently and centrifuged 
at 10,000 g for 10 minutes at room temperature. The clear lysate was then mixed 
with 1 ml of WizardTM resin and loaded on to a WizardTM minicolumn via a2 ml 
syringe, followed by washing with 2 ml of WizardTM column wash solution (80 mM 
potassium acetate; 8.3 mM Tris-HCI, pH 7.5; 40 µM EDTA; 55% (v/v) ethanol). 
The WizardTM minicolumn was centrifuged at 10,000 g for 2 minutes to remove 
excess column wash solution prior to DNA elution. Fifty microlitres of TE buffer, 
heated to 65°C, was subsequently added to the column, left for 1 minute and then 
centrifuged at 10,000 g for 30 seconds. The concentration of the DNA was 
determined by spectrophotometry at 260 nm. 
2.9 Large-scale plasmid preparations 
A large-scale overnight culture of a bacterial strain carrying the desired plasmid was 
prepared by inoculation of 0.5-1 L of LB, containing relevant antibiotics, followed 
by incubation of the culture with shaking at 37°C. The culture was then centrifuged 
at 5000 g (Sorval® RC-3B) for 30 minutes and plasmid extracted from the cell pellet 
using a Qiagen Plasmid DNA Maxiprep Kit (Qiagen Ltd., Crawley, UK) as per the 
kit instructions. The bacterial cell pellet was first resuspended in 10 ml of buffer P1 
(50 mM Tris-HCI, pH 8.0; 10 mM EDTA; 100 µg/ml RNase A). An equal volume of 
buffer P2 (0.2 M NaOH; 1% (w/v) SDS) was added to the resuspended cells and 
mixed by gentle inversion, followed by incubation at room temperature for 
5 minutes. The tube was then mixed gently again after the addition of 10 ml of buffer 
P3 (1.32 M potassium acetate, pH 5.5) and incubated on ice for 20 minutes. The 
mixture was subsequently centrifuged at 20,000 g for 30 minutes at 4°C resulting in 
a clear supernatant. A Qiagen column was equilibrated by adding buffer QBT 
(750 mM NaCl; 50 mM 3-[N-morpholino] propanesulphonic acid (MOPS), pH 7.0; 
15% (v/v) isopropanol; 0.15% (v/v) Triton X100) and was allowed to empty by 
gravity flow. Clear supernatant was then loaded onto the column and left to flow 
through, followed by washing of the column twice with 30 ml of QC buffer 
(1 M NaCl; 50 mM MOPS, pH 7.0; 15% (v/v) isopropanol). Plasmid DNA was 
subsequently eluted with 15 ml of buffer QF (1.25 M NaCl; 50 mM Tris-HCI, 
pH 8.5; 15% (v/v) isopropanol) and precipitated by the addition of 10.5 ml of 
isopropanol and centrifugation at 15,000 g for 30 minutes at 4°C. The resulting DNA 
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pellet was washed with 70% (v/v) ethanol, centrifuged at 15,000 g for 10 minutes at 
4°C and finally resuspended in 300 gl of TE buffer that had been pre-heated to 65°C. 
The concentration of the DNA was ascertained by spectrophotometry at 260 nm. 
2.10 Restriction enzyme digestion 
All restriction endonucleases and restriction endonuclease reaction buffers were 
supplied by Promega. Restriction enzyme digests of plasmid and polymerase chain 
reaction (PCR) amplified products were carried out in a volume not normally 
exceeding 25 µl, containing 10 U of enzyme(s) and 0.1 volumes of an appropriate 
lOx concentration restriction buffer. Each reaction proceeded for 2 hours at 37°C. 
A typical reaction comprised: 
1 µl 1 µg/µl DNA 
16 µl sterile distilled H2O 
2 µl 1 Ox reaction buffer 
1 µl 10 U/µl restriction endonuclease 
2.11 Agarose gel electrophoresis 
Agarose gels, 0.8-1% (w/v), were prepared by boiling molecular biology grade 
agarose (Sigma) in TAE electrophoresis buffer (40 mM Tris-base; 0.1% (v/v) glacial 
acetic acid; 100 mM EDTA, pH 8.0) for 1-2 minutes in a microwave oven. One 
microlitre of ethidium bromide (10 mg/ml) was added for every 50 ml of the gel 
solution. The molten agarose was cooled and poured into the casting deck of a 
dedicated gel electrophoresis apparatus. After it had set, the combs were removed, 
and the electrophoresis tank was filled with TAE as a running buffer. A loading dye 
(6x concentration contained: 0.25% (w/v) bromophenol blue; 40% (w/v) sucrose) 
was added to the DNA, acquiring approximately 1/6' of the volume to be loaded, 
and this was then pipetted into the gel slots. A `marker' lane was always included 
which either contained HindIII-restricted bacteriophage ?. DNA (Promega) or 
100 base pair DNA ladder (Promega), with which to size the DNA products after 
they had migrated through the gel. The gels were run at 100 volts (V) and 
subsequently viewed using an UV transilluminator. 
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2.12 Preparation of DNA fragments from agarose gels 
When electrophoresis was performed to purify a particular DNA fragment, either 
from a PCR or a restriction digest, the DNA fragment of interest was recovered from 
the gel using a WizardTM PCR Prep DNA Purification Kit (Promega). Briefly, the 
area of the gel containing the relevant piece of DNA was excised using a clean 
scalpel and placed in a 1.5 ml eppendorf tube. One millilitre of purification resin was 
used to dissolve the gel slice and the resulting mixture was applied via a2 ml syringe 
to a WizardTM minicolumn followed by washing with 2 ml of 80% (v/v) isopropanol. 
The WizardTM minicolumn was centrifuged at 10,000 g for 2 minutes, to remove 
excess isopropanol, prior to DNA elution with 30 µl of sterile TE buffer, which had 
been pre-heated to 65°C. 
2.13 DNA ligations 
Ligation of vector and DNA fragments was performed using T4 DNA ligase 
(Promega). An estimation of the concentration of each vector and insert was 
performed by agarose gel electrophoresis next to base pairs (bp) markers of a known 
concentration. Approximately 200 ng of vector DNA were mixed together with 
insert (the amount of which to be added was calculated using a molar ratio, vector: 
insert, of between 1 and 3), and sterile H2O added to a final volume of 18 µl in a 
clean 0.5 ml eppendorf tube. The mixture was heated to 65°C and gradually cooled 
to 16°C in a thermal cycler block, to allow DNA to anneal slowly, before addition of 
1 µl of T4 DNA ligase enzyme (Promega) and 2 µl of lOx ligase buffer (300 mM 
Tris-HCI, pH 7.8; 100 mM MgC12; 100 mM dithiothreitol (DTT); 10 mM ATP; 
Promega). The reaction was subsequently incubated at 16°C overnight. 
2.14 Bacterial transformation 
2.14.1 Transformation of chemically-competent bacterial cells 
When required, a 100-µl aliquot of competent E. cola JM109 (Promega) cells was 
thawed. The appropriate DNA sample, usually 0.5-1 jig, was gently mixed with the 
cells and this was incubated on ice for 10 minutes. The cells were then heat shocked 
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at exactly 42°C for 45 seconds and returned to ice. After 2 minutes, the cells were 
transferred to a culture tube containing 990 µl of chilled SOC medium (Invitrogen, 
Paisley, UK) which comprises: 2% (w/v) tryptone; 0.5% (w/v) yeast extract; 10 mM 
NaCl; 2.5 mM KCI; 10 mM MgCl2; 10 mM MgSO4; 20 mM glucose. The culture 
tube was placed in a shaking incubator at 37°C and grown for 1 hour, to allow 
expression of the antibiotic resistance genes carried by the transforming plasmid 
DNA. A 100-µl aliquot of undiluted transformed cells, and of 1: 10 and 1: 100 
dilutions, were then spread onto LB agar plates containing the appropriate antibiotic, 
and incubated at 37°C overnight. A proportion of the colony forming units were then 
picked with a sterile pipette tip and streaked on to fresh LB agar plates for growth 
overnight at 37°C. 
2.14.2 Transformation of electrocompetent bacterial cells 
A 50-µ1 aliquot of electrocompetent E. coif XL-1 Blue cells (Stratagene) were 
thawed on ice and then added to a pre-chilled 0.1 cm cuvette (Invitrogen). The 
appropriate DNA sample, usually 0.5-1 µg, was added, mixed by pipetting, and the 
cuvette placed into an E. coli Pulser electroporator (Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK) and a charge of 1800 V applied. The cuvette was removed 
from the electroporator and the cells resupended in 500 µl of super optimal catabolite 
(SOC) medium and then incubated with shaking at 37°C for 1 hour. A 100-µl aliquot 
of undiluted transformed cells, and of 1: 10 and 1: 100 dilutions, were spread onto LB 
agar plates containing appropriate antibiotics, and incubated at 37°C overnight. A 
proportion of the colony forming units were then picked with a sterile pipette tip and 
streaked on to fresh LB agar plates for growth overnight at 37°C. 
2.15 Polymerase chain reaction amplification 
Preceding the PCR amplification, oligonucleotide primers were appropriately 
designed to amplify the relevant DNA fragment (details are given where appropriate 
in the text). Reactions were carried out in 50-µ1 volumes comprising, unless 
indicated, 50 ng of template DNA, 0.3 mM of each required (forward and reverse) 
primer, 1U of ExpandTm High Fidelity Taq polymerase (Roche Diagnostics Ltd., 
Lewes, UK), 0.1 mM deoxynucleotides (Promega), in buffer containing: 1.5 mM 
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MgCl2; 10 mM Tris-HCI (pH 8.3); 0.01% gelatin; 50 mM KCI; 0.1% Tween 20; 
0.1 % Nonidet P-40 (Roche Diagnostics Ltd. ). Each reaction was overlaid with a drop 
of mineral oil to prevent evaporation during heating and was subject to PCR 
amplification in a DNA Thermal Cycler (Perkin-Elmer/Cetus, Norwalk, CT, USA) 
using the conditions stated in the text. 
2.16 Direct purification of PCR products 
Polymerase chain reaction amplification products were directly extracted from the 
PCR constituents using a WizardTM PCR Prep DNA Purification Kit (Promega). 
Briefly, one or more PCR reactions assuming a volume of no more than 300 µl, were 
mixed with 100 µl of WizardTM direct purification buffer (50 mm KCI; 10 mM Tris- 
HCI, pH 8.8; 1.5 mM MgC12; 0.1% (v/v) Triton X100). One millilitre of WizardTM 
PCR Prep DNA Purification resin was added and the mixture vortexed briefly three 
times during a period of 1 minute. The mixture was then applied to a WizardTM 
minicolumn, which was treated as previously described in Section 2.12. 
2.17 DNA sequencing 
2.17.1 Manual DNA sequencing 
Sequencing of plasmid DNA was performed using a T7 Sequenase® Version 2.0 
DNA Sequencing Kit (Amersham Pharmacia Biotech, Little Chalfont, UK) by the 
dideoxy-chain termination method (Sanger et al. 1977) using the appropriate 
oligonucleotide primer and [a- 5S]dATP (NEN Life Science Products, Hounslow, 
UK), as outlined below. 
One-to-three micrograms of plasmid DNA in a volume of 10 111 of TE were 
denatured by incubation at 37°C with 1 p. 1 of 2 mM EDTA (pH 8.0) and I µl of 2M 
NaOH for 30 minutes. One microlitre of 3M sodium acetate (pH 5.2) and 50 gl of 
100% ethanol were added and the DNA was precipitated at -20°C for 1-2 hours. A 
pellet was collected by centrifugation at 12,000 g for 15 minutes and was air-dried, 
before being resuspended in 10 µl of diluted sequencing primer mixture containing 
7 µl sterile distilled H2O, 2 µl of T7 Sequenase® reaction buffer and 1-5 pmoles of 
the relevant primer (details are given where appropriate in text). The reaction was 
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then heated to 65°C for 2 minutes, to allow annealing of the primer with its target 
sequence, prior to slow cooling to 0°C. 
Two-point-five microlitres of each of four termination mixes (ddGTP, ddATP, 
ddTTP, ddCTP) were aliquoted into separate tubes and heated to 37°C. Termination 
mixes contained: 80 µM of each dNTP; 8 pM of the relevant ddNTP. To the 
annealed DNA, 1 µl DTT, 2 µl of diluted labelling mix (5x concentration contained: 
7.5 µM dGTP; 7.5 µM dTTP; 7.5 pM dCTP; diluted to lx with sterile H20), 1 µl 
[a- 5S]dATP (1250 Ci/mmol; 12.5 mCi/ml; NEN Life Science Products) and 2 Al 
diluted T7 Sequenase® polymerase (diluted 1: 8 with enzyme dilution buffer) were 
added. This was incubated at room temperature for 2 minutes before 3.5 µl was 
removed from the reaction into each of the four tubes containing dideoxynucleotides. 
These were then incubated at 37°C for five minutes after which 4 µl of stop solution 
were added. The tubes were subsequently heated at 85°C to denature the DNA and 
then applied to sequencing gels for electrophoresis as described in the Section 2.18. 
2.17.2 Automated DNA sequencing 
Automated DNA sequencing was carried out by the genomic facility of the Division 
of Genomic Medicine at the University of Sheffield, Sheffield, UK and also at the 
Department of Biological Sciences at University of Durham, Durham, UK. 
Sequencing reactions were performed using the ABI PRISM BigDyeTM 
Terminators Version 3.0 Cycle Sequencing Kit (Applied Biosystems, Foster City, 
CA, USA). Generally, 1-2 µg of the DNA samples (plasmid, phagemid or PCR 
product) and 3.2 pmoles of the relevant primers were sent to the automated DNA 
sequencing facility. The facility performed cycle sequencing reactions using 
fluorescent dye terminators, ran the gel, acquired the data, and provided the sequence 
as chromatogram and text files. DNA sequence homology searches against the 
GenBank database were performed using the BLAST service of the National Centre 
for Biotechnology Information (Bethesda, MD, USA). 
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2.18 Sequence gels and autoradiography 
The sequencing reaction products were resolved on 6% (w/v) polyacrylamide gels 
containing: 7 mM urea; 89 mM Tris-base; 2 mM EDTA (pH 8.0); 89 mM boric acid; 
0.03% (w/v) ammonium persulphate; 0.07% (v/v) of N, N, N, N'- 
tetramethylethylenediamine (TEMED). A standard non-gradient sequencing gel 
apparatus, (Bio-Rad Laboratories Ltd. ), was used in the set up. The gel running 
buffer contained: 89 mM Tris-base; 2 mM EDTA (pH 8.0); 89 mM boric acid. The 
gel and buffer were warmed to 50°C prior to electrophoresis by running at 2000 V 
for one hour. Gel slots were flushed with buffer to remove any urea and 
unpolymerised acrylamide. DNA sequence reactions were then loaded. Gels were 
run at a voltage of approximately 1800 V for 2 to 4 hours at 50°C depending on the 
length of the sequence to be studied. After the reactions had run to the desired extent, 
the current was turned off, apparatus dismantled and the gel fixed in 12% (v/v) 
methanol, 10% (v/v) glacial acetic acid. The gel was then transferred to a sheet of 
3MM blotting paper (Whatman International Ltd., Maidstone, UK) and dried on a 
Bio-Rad Gel Dryer 583 (Bio-Rad Laboratories Ltd. ) at 80°C for 2 hours. 
The dried gel was subjected to autoradiography by exposure to Fuji RX X-ray 
film (Genetic Research Instrumentation Ltd., Dunmow, UK) in a HypercassetteTM 
(Amersham Pharmacia Biotech) at room temperature for 24 hours. The film was 
subsequently developed using Photosol CD 18 X-ray developer (Photosol Ltd., 
Basildon, UK) for 3 minutes, rinsed in water and then fixed for 3 minutes in 
Photosol CF40 fixer (Photosol Ltd. ). 
2.19 SDS-PAGE and autoradiography 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
protein samples was performed in 12.5% (w/v), or 15% (w/v) SDS-polyacrylamide 
resolving gels. The exact constitution of gels and associated buffers is shown in 
Table 2.3. The percentage acrylamide of the gel varied according to the size of the 
protein products to be electrophoresed. The gels were created using a Bio-Rad 
Protean II apparatus (Bio-Rad Laboratories Ltd. ). 
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Table 2.3 Constitution of SDS-PAGE gels. 
Resolving gel: 
Constituent Final concentration in gel 
Buffer A: 
Tris-base 
SDS 
0.4 M 
0.1% (w/v) 
Acrylamide: bisacrylamide (37.5: 1) 
(Bio-Rad Laboratories Ltd. ) 
12.5% (w/v) or 15 % (w/v) 
Ammonium persulphate 0.04% (w/v) 
TEMED 0.0004% (v/v) 
Stacking gel: 
Constituent Final concentration in gel 
Buffer B: 
Tris-base 
SDS 
0.125 M 
0.1% (w/v) 
Acrylamide: bisacrylamide (37.5: 1) 4% (w/v) 
Ammonium persulphate 0.05% (w/v) 
TEMED 0.075% (v/v) 
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Briefly, two glass plates (12 cm2 and 12 x 16 cm) and 1 mm spacers were 
assembled using the dedicated equipment according to the manufacturer's 
instructions. The resolving gel solution was poured into the space between the plates, 
(to a level approximately 5 cm from the top of the smaller plate), and overlaid with 
1 ml isopropyl alcohol. After the gel mixture had polymerised the isopropyl alcohol 
was poured off, and a comb was inserted before the solution for the stacking gel was 
poured in on top. Subsequently, the comb was removed and the full apparatus 
assembled. Laemmlli buffer (250 mM Tris-base; 0.1% (w/v) SDS, 0.2 M glycine) 
was poured into the tank until the bottom of the plates was covered and the top 
reservoir was full. 
Prior to loading, samples to be analysed were mixed with 2x SDS sample buffer 
(4% (w/v) SDS; 20% (v/v) glycerol; 0.002% (w/v) bromophenol blue; 2% (v/v) 
2-mercaptoethanol; 25% (v/v) buffer B as detailed in Table 2.3) and heated at 85°C 
for 5 minutes. Protein molecular weight standards (Bio-Rad Laboratories Ltd. ) used 
were: bovine serum albumin, 77 kilodaltons (kDa); ovalbumin, 50 kDa; carbonic 
anhydrase, 35 kDa; soybean trypsin inhibitor, 29 kDa; lysozyme, 21 kDa. Gels were 
run at a current of 35 milli-amperes (mA) for 3-5 hours or until the visible dye-front 
had reached the bottom of the plates. The apparatus was subsequently dismantled 
and the gel transferred to a plastic tray and covered with Coomassie® Blue stain 
containing: 0.05% (w/v) Coomassie® Brilliant Blue (Bio-Rad Laboratories Ltd. ); 
10% (v/v) glacial acetic acid; 25% (v/v) isopropanol. This was placed on a rocking 
platform. After a minimum of 30 minutes staining, the gel was destained by repeated 
fresh additions of a solution containing: 10% (v/v) glacial acetic acid; 25% (v/v) 
isopropanol. The destain was discarded and the gel was soaked for a further 
30 minutes in Amplify fluorographic reagent (Amersham Pharmacia Biotech), before 
being dried for 2 hours at 60°C onto 3MM Whatman paper. Gels were exposed to 
Fuji RX X-ray film at -70°C for the required time (usually overnight) and, then 
developed as in Section 2.18. 
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2.20 Chinese hamster ovary (CHO-K1) cell culture 
All cell culture media and reagents were purchased from Invitrogen, unless 
otherwise stated. Chinese hamster ovary (CHO-K1) cells were obtained from the 
European Collection of Animal Cell Cultures (Salisbury, UK). CHO-K1 cells were 
routinely grown in culture media containing Nutrient Mixture F-12 (Ham) 
supplemented with 10% foetal bovine serum (FBS; Bio West Ltd., Ringmer, UK), 
2 mM L-glutamine, 100 U/ml pencillin G (sodium salt), 100 µg/ml streptomycin 
sulphate and 1.25 µg/m1 fungizone (amphotericin) in T75 tissue culture flasks (Nalge 
Nunc International, Rochester, NY, USA) in a 5% CO2 incubator at 37°C. 
Transfected CHO-K1 cell lines were cultured in media containing 1 mg/ml geneticin 
sulphate (G-418; Invitrogen). 
Cells were passaged when 80-90% confluent, usually every 2-3 days. At each 
time of passage, the CHO-K1 cells were washed once with phosphate-buffered saline 
(PBS; 0.01 M phosphate buffer; 0.0027 M KCI; 0.137 M NaCl; pH 7.4; Oxoid, 
Basingstoke, UK) and then incubated in a solution containing 0.05% trypsin and 
0.53 mM EDTA at 37°C in a 5% C02 incubator for 5 minutes. After incubation, the 
cells were resuspended in a culture media and centrifuged at 1000 g for 5 minutes. 
The cell pellet was resuspended in culture media and the cells plated at a 1: 10 
dilution in T75 tissue culture flasks. 
For long-term maintenance of CHO-K1 cells, cells were frozen and stored in 
liquid nitrogen. Cells were grown to 80-90% confluence and then the cells washed 
once with PBS and incubated with trypsin/EDTA at 37°C for 5 minutes in a 5% CO2 
incubator. The cells were then centrifuged in culture media at 1000 g for 5 minutes 
and the pellet resuspended in 1 ml of freezing mixture containing FBS and dimethyl 
sulfoxide (Fisher Scientific UK Ltd., Loughborough, UK) at a ratio of 9: 1. The cells 
were then transferred to cryogen vials (Nalge Nunc International) and stored- 
at -80°C for 24 hours. The cells were then transferred to liquid nitrogen until 
required. 
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3B Cell Epitope Mapping of the Melanin-Concentrating 
Hormone Receptor 1 Using Recombinant Protein 
3.1 Introduction 
3.1.1 Antibody-antigen interaction 
In order for binding to take place between an antibody and its antigen, there must be 
complementarity between surface structures on the antigen and the combining site of 
the antibody. The precise region of the antibody's combining site which contacts 
with antigen is called the paratope and the part of the antigen recognised by the 
paratope is termed the epitope. Antigens are highly diverse in size and in primary 
sequence, as well as in their secondary structure. Consequently, antigenic epitopes 
are extremely varied and are usually classified as either'continuous or discontinuous. 
An epitope that constitutes part of a linear amino acid sequence on a polypeptide 
chain is known as a continuous or linear epitope. An epitope that is formed by two 
stretches of the primary sequence that are distant from each other but are brought 
together in the folded molecule's secondary or tertiary structure is known as a 
discontinuous or conformational epitope (Westwood and Hay 2001). The size of a 
linear epitope can range in length from 5-6 amino acids (Roitt and Delves 2001) up 
to 15-22 amino acids (von Mikecz et al. 1995). Conformational epitopes can consist 
of approximately discontinuous 16 amino acid side-chains (Roitt and Delves 2001). 
For binding of an antibody to an antigen to occur, the specific epitope must be 
exposed on the surface of the antigen (Roitt and Delves 2001). There are a number of 
criteria that might, therefore, determine which areas of an antigen can act as antibody 
binding sites including: 
1. The mobility of the region of the protein. X-ray crystallography and nuclear 
magnetic resonance techniques may indicate surface amino acid residues with 
higher mobility that are more likely to act as an epitope than areas on the 
molecule where there are rigid structures such as a-helices and ß-sheets 
(Westwood and Hay 2001). 
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2. The nature of the primary sequence, in the case of protein antigens. For 
example, where there is the potential to form a loop or a turn, e. g., in the 
presence of proline residues, amino acid residues can be exposed for 
antibody binding (Westwood and Hay 2001). 
3. The hydrophilicity of the protein sequence. Generally, the hydrophobic 
stretches of sequence will reside in the interior of the molecule, with the 
hydrophilic stretches found on the surface. Therefore, highly hydrophilic 
sequences are likely to be on the surface of a molecular fold and thus be 
putative epitopes (Westwood and Hay 2001). 
Epitope mapping is the identification and localisation of the specific regions of 
protein molecules that are recognised by the immune system (Roitt and Delves 
2001). It is possible to predict areas of probable antigenicity on a particular protein 
(Parker et al. 1986). However, in order to determine the exact location of epitopes on 
an antigen, experimental epitope mapping techniques need to be applied. 
3.1.2 Methods of B cell epitope mapping 
Several epitope mapping strategies for the identification of autoepitopes have been 
used (Table 3.1). The most precise available method of defining the area of an 
antigen making contact with an antibody is X-ray crystallography of the antigen- 
antibody complex. This technique has the advantage of allowing the study of the 
three-dimensional structures and even can provide information about conformational 
epitopes. However, it is costly and requires sufficiently large quantities of a pure 
monoclonal antibody and its antigen to produce crystal. If the primary amino acid 
sequence of the antigen is known, there are two main approaches to B cell epitope 
mapping. The first method relies on molecular manipulation at the cDNA level using 
techniques such as polymerase chain reaction amplification, site-directed 
mutagenesis, and restriction with DNA exonucleases and endonucleases. 
Substitutions and/or deletions are created in the amino acid sequence followed by 
comparative analysis of the immunoreactivity of these recombinant proteins either 
by immunoblotting, immunoprecipitation or enzyme-linked immunosorbent assay 
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Table 3.1 A summary of techniques for mapping linear and conformational B 
cell epitopes. 
Technique 
X-RAY CRYSTALLOGRAPHY' 
PHAGE-DISPLAY= 
i) Random-peptide library 
Suitable for which type/s of Reference 
epitope 
Conformational and linear 
Williams et al. 2001 
ii) Single chain Fv3 fragment (scFv) library 
SYNTHETIC PEPTIDES4 
i) Peptide synthesiser 
(Generates peptides >10 amino acid 
residues) 
Conformational and linear 
Amit et al. 1986 
Mostly linear Petterson 1992 
ii) `PEPSCAN'5 
(Peptides <_ 10 amino acid residues) 
PEPTIDE FRAGMENTS6 Mostly linear 
Derived enzymatically from the whole 
protein 
RECOMBINANT PROTEIN? Mostly linear 
Subcloning and expressions of cDNA 
encoding peptide fragments generated by: 
i) Naturally occurring restriction sites 
ii) Exonuclease digestion 
iii) Polymerase chain reaction (PCR) 
amplification 
iv) Site-directed mutagenesis 
Sumar 2001 
Petterson 1992 
Petterson 1992 
Petterson 1992 
Petterson 1992 
Petterson 1992 
Perdue 2001 
'Allows direct analysis of the 3-dimensional structure of an antigen-antibody complex. 
2Epitope regions are determined by affinity selection screening with either (i) antibody, or (ii) antigen. 
'Fv, variable region of the fragment withantigen binding (Fab) of an immunoglobulin. 
'Can be used in a number of different assay systems including enzyme-linked immunosorbent assay (ELISA) and 
immunoprecipitation using monoclonal antibody (mAb) or polyclonal sera. 
5'PEPSCAN' involves the synthesis of short overlapping peptide sequences on to solid supports (polystyrene 
pins) which are then used in a modified ELISA. 
'Can be used in a number of different assay systems including ELISA and immunoprecipitation using mAb or 
polyclonal sera. 
7Can be used in a number of different assay systems including immunoblotting, ELISA, immunoprecipitation and 
radioimmunoassays (RIA) using mAb or polyclonal sera. 
'A variety of expression vectors/systems may be used. Vectors may fuse a tag to the protein for purification, or 
allow the incorporation of a radiolabelled amino acid into the recombinant protein for RIA. 
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(ELISA) (Petterson 1992). Examples of studies in which B cell epitopes have been 
identified in several autoimmune diseases using recombinant proteins are given in 
Table 3.2. The second technique begins at the peptide level and involves the analysis 
of antibody reactivity to either synthetic peptides or enzymatically digested protein 
fragments (Petterson 1992). By using synthetic peptides the entire sequence of the 
antigen can be represented by sets of consecutive or overlapping peptides that are 
then assayed for antigenicity. However, both these methods can only accurately 
detect linear epitopes and short sequences that may constitute part of a 
conformational epitope. More recently, the use of phage-display technology has 
allowed the identification of conformational peptide epitopes (Williams et al. 2001), 
and this will be discussed further in Chapter Four. 
3.1.3 The role of B cell epitope mapping in autoimmunity 
Mapping of B cell epitopes on autoantigens can provide understanding of the 
association of an autoantigen with a particular autoimmune pathogenesis. For 
example, epitopes may reside in functional domains of autoantigenic proteins. 
Indeed, autoantibodies in myasthenia gravis, directed against the acetylcholine 
receptor, are known to bind to an epitope in the acetylcholine-binding site which can 
directly inhibit the receptor function (Hoedemaekers et a!. 1997). Similarly, the 
autoantigenic epitopes in SLE have been found to reside in highly conserved regions 
of proteins and can thus inhibit functions of both structural proteins and enzymes 
(Casiano and Tan 1996). For example, antinuclear antibodies targeting tRNA 
synthetase and DNA polymerase delta auxiliary protein have been shown to 
functionally inhibit the aminoacylation of tRNA and DNA replication and repair, 
respectively, in in vitro studies (Tan et a!. 1994). 
Epitope mapping can also provide an insight into the initiation of the autoimmune 
process. Autoimmunity may be triggered by an initial infection with a pathogenic 
organism (Wucherpfenning 2001). One of the mechanisms by which this might 
induce immune disease is the phenomenon of molecular mimicry in which a 
microbial peptide has sufficient structural similarity with a self-peptide to evoke a 
cross-reactive autoimmune response. For example, an epitope on the bacterium 
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Table 3.2 Examples of previous studies employing recombinant proteins to 
map B cell epitopes in autoimmune disease. 
Study 
Burch et at 1993 
Antigen Disease Techniques 
Thyroid stimulating 
hormone-receptor 
Graves' disease 
Peterson and Krohn 1994 Steroid 17a-hydroxylase Autoimmune 
Addison's disease 
Wedlock et al. 1993 Steroid 21-hydroxylase Autoimmune 
Addison's disease 
Song et al. 1994a Steroid 21-hydroxylase Autoimmune 
Addison's disease 
Volpato et aL 1998 Steroid 21-hydroxylase Autoimmune 
Addison's disease 
Nikoshkov et al. 1999 
von Mikecz et aL 1995 
I Syren et al. 1996 
Daw et al. 1996 
Lin et al. 1999 
Kemp et al. 2001 a 
Steroid 21-hydroxylase Autoimmune 
Addison's disease 
Ribosomal protein L7 Systemic lupus 
erythematosus and 
mixed connective 
tissue disease 
Glutamate decarboxylase Type 1 diabetes 
mellitus 
Glutamate decarboxylase Type I diabetes 
mellitus 
`BP 180' Bullous 
(collagen XVII) pemphigoid 
Sodium iodide symporter Autoimmune 
thyroid disease 
Subcloning of cDNA amplif- 
ied by PCR. Expressed in 
bacteria. Immunoprecipit- 
ation (IP) experiments with 
patient sera. 
Subcloning of endonucl- 
ease restricted cDNA fragments 
and exonuclea- 
se digestion. Expressed in 
bacteria and immunoblot- 
ted with patient sera 
Subcloning of endonucl- 
ease restricted cDNA fragments. 
Expressed in bacteria and 
immunoblot- 
ted with patient sera 
Subcloning ofcDNA amphf- 
ied by PCR Expressed in 
bacteria and immunoblot- 
ted with patient sera 
Subcloning of endonucl- 
ease restricted cDNA fragments. 
Site-directed mutagenesis. 
Expressed in bacteria. IP 
experiments with patient sera. 
Site-directed mutagenesis. 
Expressed in bacteria. IP 
experiments with patient sera. 
Also expressed in mammalian 
cells and immunoblotted with 
patient sera 
Subcloning of cDNA amplif- 
ied by PCR. Expressed in 
bacteria and immunoblot 
-ted with patient aera. Also IP 
experiments with patient sera. 
Subcloning ofendonucl- 
ease restricted cDNA fragments 
and cDNA ampl- 
ified by PCR. Expressed in 
bacteria. IP experiments with 
patient monoclonal antibodies 
(mAbs} Also expressed in 
mammalian cells and 
immunoblotted with mAbs. 
Subcloning of endonucl- 
ease restricted cDNA fragments 
and cDNA ampl- 
ified by PCR. Expressed in 
bacteria. IP experim- 
ents with patient sera. 
Subcloning of cDNA amplif- 
ied by PCR Expressed in 
bacteria and immunoblot- 
ted with patient sera 
Subcloning of cDNA amplif- 
ied by PCR Expressed in 
bacteria. IP experim- 
ents with patient sera. 
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Yersinia entericolitica has homology with the extracellular domain of human 
thyroid-stimulating hormone receptor and could therefore cross-react with 
autoantibodies in Graves' disease (Tomer and Davies 1993). There is also evidence 
that similarities between epitopes on the parasite Trypanosoma cruzi and the cardiac 
muscle protein myosin may cause the aberrant immune response in Chagas' disease 
(Roitt and Delves 2001). The inflammation that results from a viral or bacterial 
infection can lead to local activation of antigen-presenting cells resulting in 
enhanced processing and presentation of self-antigens present at that tissue. 
As well as providing insights into the mechanisms of autoimmune pathogenesis, 
the molecular characterisation of B cell epitopes may also allow new and more 
specific assays for autoimmune diseases to be established (Lernmark 2001). For 
example, if the epitope of a pathogenic autoantibody can be precisely defined, 
recombinant proteins containing only the significant epitope region could be used to 
measure titres of pathogenic autoantibodies within the heterogeneous antibody 
population of a patient's serum (Ishii et al. 1997). A further application of epitope 
mapping lies in the development of specific-active immunotherapies: the ability to 
determine a single relevant antigenic site within a target protein is the basis for the 
development of synthetic vaccines for the prevention of and protection against 
disease (Atabani 2001). There is a need for vaccines to be epitope specific to 
eliminate the possibility of cross-reactivity with self-protein or related antigens and 
also to make the production of the synthetic peptides economical. 
3.1.4 Aim 
The aim of this part of the study was to identify B cell epitopes on the MCHR1, a 
protein previously reported as an autoantigen in some vitiligo patients (Kemp et al. 
2002). Deletion derivatives of MCHRI cDNA were constructed by PCR 
amplification and then translated in vitro with the concomitant incorporation of 
[35S]-methionine into the protein products. The [35S]-labelled MCHR1 derivatives 
were subsequently used in radio-binding assays to investigate the reactivity of sera 
from vitiligo patients to the receptor. This method of epitope mapping has been 
successfully used to identify antibody-binding sites on the vitiligo autoantigens 
tyrosinase (Kemp et al. 1999a) and Pmel17 (Kemp et al. 2001b). 
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3.2 Materials and Methods 
3.2.1 Patients and controls 
Sera from nine vitiligo patients (V1-V9; Table 2.1), that were previously shown to 
contain MCHR1 antibodies (Kemp et al. 2002), were analysed in these experiments. 
In addition, sera from ten vitiligo patients (V10-V19; Table 2.1), - that were 
previously shown not to contain MCHR1 antibodies (Kemp et al. 2002), were 
analysed. Sera from twenty healthy individuals (9 male, 11 female; mean age: 32 
years with range 24-48 years) with no history of either vitiligo or autoimmune 
disorders were used as controls. 
3.2.2 Generation of MCHR1 cDNA deletion constructs by PCR amplification 
Full-length MCHR1 cDNA in pcDNA3 (Figure 3.1; Invitrogen) and referred to as 
pcMCHR1 is as detailed previously (Kemp et al. 2002). Fragments of MCHRI 
cDNA, including base pairs 1-414,1-534,1-654,1-774,1-894,1-1014 and 1-1134, 
415-894,895-1206, where the A residue of the initiating ATG codon is assigned as 
base pair number 1 (Kolakowski et al. 1996), were generated from pcMCHRI by 
PCR amplification using the oligonucleotide primers (Life Technologies, Paisley, 
UK) listed in Table 3.3. Restriction sites for EcoRI and XbaI were incorporated into 
the 5'and 3' primers, respectively, in order to allow subcloning of the PCR products 
into pcDNA3 and the subsequent expression of the MCHRI cDNA fragments from 
the T7 promoter present in the vector. 
Samples of plasmid DNA containing MCHRI cDNA (50 ng) were subjected to 
30 cycles of PCR amplification in a DNA Thermal Cycler using the following 
conditions: denaturation at 94°C for 1 minute; annealing at 55°C for 1 minute; 
extension at 72°C for 2 minutes; 72°C for 10 minutes to terminate the reaction. The 
composition of each 50-µ1 PCR reaction was as previously described (Section 2.15). 
86 
= __> 
cExpöx= ocýca ". 
=YMmWWMZ 
Ndel 
Nrui 
Bglfl 
Smal 
pcDNA3 Pvul 
jTth111l 
5.4 kb 
" There is an ATG upstream 8ý16wwý % 
of the Xba I site. Bsml 
Figure 3.1 A map of the pcDNA3 vector detailing restriction sites. MCHR1 
cDNA fragments generated by PCR amplification were cloned into the EcoRI-XbaI 
sites of pcDNA3 so that expression of the cDNA fragments is controlled by the T7 
promoter. 
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Table 3.3 Oligonucleotide primers used to generate MCHR1 cDNA fragments 
by PCR amplification. 
Base pairs' Primer sequences2 
Forward 5'-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-414 Reverse 5'-AATCTAGACGCCTATCAATCTACTACCGAGAG-3' 
Forward 5'-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-534 Reverse 5'-AATCTAGACGCCTATCAGGTGAACTGACTATT-3' 
Forward 5'-TTGAAT7CGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-654 Reverse 5'-AATCTAGACGCCTATCAGGCCCACAGGAGGCA-3' 
Forward 5"-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-774 Reverse 5'-AATCTAGACGCCTATCAGGTGAACCAGTAGAG-3' 
Forward 5'-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-894 Reverse 5'-AATCTAGACGCCTATCACAGCCGGATGCTGCG-3' 
Forward 5'-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-1014 Reverse 5'-AATCTAGACGCCTATCAAAAGGTGAGGGTCGG-3' 
Forward 5'-TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG-3' 
1-1134 Reverse 5'-AATCTAGACGCCTATCATGCAGGCTTCACCGA-3' 
Forward 5'-TTGAATTCGCCGCCATGCTCCTCTTTCTCCTG-3' 
415-894 
Reverse 5'-AATCTAGACGCCTATCACAGCCGGATGCTGCG-3' 
Forward 5'-TTGAATTCGCCGCCATGCGGACAAAGAGGGTG-3' 
895-1206 Reverse 5'-AATCTAGACGCCTATCAGGTG CCTTTGCTTC-3' 
1 The numbers correspond to base pairs of MCHRI cDNA included in the construct 
with the A residue of the initiating ATG codon assigned as base pair number 1. 
2 The EcoRI and Xbal restriction sites are underlined. The translation initiation codon 
and the translation termination codons in the forward and reverse primers, 
respectively, are shown in bold-type face. 
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The PCR products were purified using a Wizard PCR Preps DNA Purification 
System (Promega) from 0.8% (w/v) agarose gels as detailed in Section 2.12. Each 
PCR product was restricted with EcoRI and Xbal and then re-purified from a 0.8% 
(w/v) agarose gel. The PCR products were ligated into pcDNA3, previously 
restricted with EcoRI and XbaI, as described in Section 2.13. The ligation reactions 
were used to transform E. coli JM109 as in Section 2.14.1. Plasmid DNA was 
purified from individual transformants using a The WizardTM Minipreps DNA 
Purification System (Section 2.8), digested with EcoRI and Xbal and analysed by gel 
electrophoresis in 0.8% (w/v) agarose. Appropriate recombinant plasmids were 
sequenced (Section 2.17.1) using T7 and SP6 primers (Promega) by the dideoxy 
termination methods according to a Sequence Version 2.0 DNA Sequencing Kit 
(Amersham Pharmacia Biotech) with [a 35S] dideoxy adenosine triphosphate (NEN 
Life Science Products), to verify that no sequence errors had been introduced. The 
plasmids created are summarised in Table 3.4. 
3.2.3 In vitro coupled transcription and translation 
The plasmid constructs (Table 3.4) were used in a TnT® T7 Coupled Reticulocyte 
Lysate System (Promega) to produce and label MCHR1 and its deletion derivatives 
with [35S]methionine in vitro. Each MCHR1 cDNA fragment was inserted into 
pcDNA3 in the correct orientation to allow expression from the T7 promoter, and 
each template contained appropriate start and stop codons to ensure accurate 
translation. The TnT® Coupled Reticulocyte Lysate System is `cell-free' and 
contains purified reticulocyte lysate with ribosomes, tRNA, and all the initiation, 
elongation and termination factors necessary for protein synthesis. It contains little 
endogenous RNA that would produce unwanted background protein. 
A standard reaction mixture of 50 µl contained: rabbit reticulocyte lysate, 25 µl; 
TnT® T7 RNA polymerase, 1 µl; TnT® reaction buffer, 2 µl; amino acids minus 
methionine, 1 µl; RNasin® RNase Inhibitor (Promega), 40 U; plasmid template, 2µg; 
[35S]methionine (1000 Ci/mmol; 10 mci/ml; Amersham Pharmacia Biotech), 4 µl. 
The reaction was incubated for 120 minutes at 30°C and then stored at -20°C until 
required. 
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Table 3.4 Deletion derivatives used in determining the antigenic domains on 
MCHR1 that are recognised by autoantibodies from patients with 
vitiligo. 
MCHR1 construct 
Amino acids 
encoded' (base pairs)2 
Predicted 
molecular weight 
of expressed 
protein (kDa)3 
Estimated 
molecular weight 
of expressed 
protein (kDa)4 
pcMCHR15 1-402 (1-1206) 44 45 
pMCHR1-378 1-378 (1-1134) 42 39 
pMCHR1-338 1-338 (1-1014) 37 34 
pMCHR1-298 1-298 (1-894) 33 30 
pMCHRI-258 1-258 (1-774) 28 27 
pMCHR1-218 1-218 (1-654) 24 23 
pMCHR1-178 1-178 (1-534) 20 21 
pMCHR1-138 1-138 (1-414) 15 19 
pMCHR1-139 139-298 (415-894) 18 20 
pMCHRI-299 299-402 (895-1206) 11 10 
'Numbers correspond to the amino acid residues of MCHR1 with the initiating 
methionine as residue number 1. 
2 Numbers correspond to base pair of MCHR1 cDNA with the A residue of the 
initiating ATG codon assigned as base pair number 1. 
3 Predicted from the amino acid sequence of the protein. 
4Estimated from the mobility of the protein in SDS-polyacrylamide gels. 
5 Encodes full-length MCHRI. 
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Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of in 
vitro translated products was performed in either 12.5% (w/v) or 15% (w/v) 
polyacrylamide resolving gels as described in Section 2.19. An aliquot of each of the 
in vitro translation reaction mixtures was added to SDS sample buffer (Section 2.19) 
and boiled for 2 minutes before electrophoresis. Prior to drying under vacuum, gels 
were stained, destained and soaked in Amplify fluorographic reagent (Section 2.19). 
Autoradiography was carried out at -70°C. 
3.2.4 Radio-binding assays 
Vitiligo and control sera were tested for binding to [35S]-MCHR1 and its labelled 
deletion derivatives in radio-binding assays as follows. For each assay, an aliquot of 
in vitro translation reaction mixture (equivalent to 50,000-100,000 counts per minute 
(cpm) of trichloroacetic acid (TCA)-precipitable material) was suspended in 50 µl of 
immunoprecipitation buffer containing: 20 mM Tris-HC1 pH 8.0; 150 mM NaCl; 1% 
(v/v) Triton X-100; 10 gg/ml aprotinin (Bayer, Newbury, UK). Serum was then 
added to a final dilution of 1: 50. After overnight incubation with shaking at 4°C, 50 
µl of protein G Sepharose 4 Fast Flow beads (Amersham Pharmacia Biotech), 
prepared according to the manufacturer's protocol, were added and incubation 
continued for 1 hour at 4°C. The protein G Sepharose-antibody complexes were then 
collected by centrifugation and washed six times for 15 minutes in 
immunoprecipitation buffer at 4°C. Immunoprecipitated radioactivity was evaluated 
in a LKB 1217 Rackbeta liquid scintillation analyser (Wallac UK, Milton Keynes, 
UK). All samples were analysed in duplicate and the mean cpm immunoprecipitated 
were determined. 
The binding reactivity of each patient and control sera to full-length MCHR1 and 
each deletion derivative was expressed as an antibody index calculated as: cpm 
immunoprecipitated by tested serum divided by mean cpm immunoprecipitated by 
20 healthy control sera. Each serum was analysed in two experiments and the mean 
antibody index was calculated from these. The upper level of normal for each assay 
with a different ligand was calculated using the mean antibody index +3 standard 
deviations (SD) of 20 control sera. Patient sera with an antibody index greater than 
the upper level of normal were regarded as positive for binding to the radio-labelled 
ligand used in the assay. 
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For analysis of immunoprecipitated proteins by SDS-PAGE and autoradiography, 
the protein G Sepharose-antibody complexes were resuspended in 50 µl of SDS 
sample buffer, boiled and the supernatant recovered for electrophoresis in SDS- 
polyacrylamide gels that were processed as described in Section 2.19. 
3.2.5 Computer analysis 
Computer analysis predictions of B cell epitopes were carried out as previously 
described (Parker et al. 1986). Since antigenic regions are those recognised by 
antibodies, it is most likely that these sites are accessible on the surface of a protein 
and are, therefore, probably hydrophilic in nature. Indeed, alogorithms for 
hydrophilicity and accessibility have been used to predict antigenicity (Parker et al. 
1986). DNA sequence homology searches against the GenBank database were 
performed using the BLAST service of the National Centre for Biotechnology 
Information (Bethesda, MD, USA). 
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3.3 Results 
3.3.1 In vitro translation of MCHR1 cDNA and its deletion derivatives 
For identification of autoepitopes on MCHR1, PCR amplification was used to 
generate MCHR1 cDNA fragments of varying lengths that were restricted with 
EcoRI and Xbal and then cloned into pcDNA3 (Figures 3.2a and b). DNA 
sequencing of the fragments was carried out to verify that no sequence errors had 
been introduced. All the constructs used in the study are listed in Table 3.4. Products 
generated from in vitro translation of MCHR1 cDNA and its deletion derivatives 
were evaluated by SDS-PAGE in a 12.5% (w/v) SDS-polyacrylamide gel and 
subsequent autoradiography (Figure 3.3). Major bands representing the intact and 
modified [35S]-labelled MCHRI proteins were found in each case (Table 3.4). The 
deletion derivative encoded by pMCHRI-299 was detected on a 15% (w/v) SDS- 
polyacrylamide gel (data not shown). 
3.3.2 Radio-binding assays of MCHR1 deletion derivatives with sera from 
vitiligo patients and controls 
Sera from nine MCHRI antibody-positive vitiligo patients, 10 MCHR1 antibody- 
negative vitiligo patients and 20 healthy controls were tested for their ability to 
immunoprecipitate [35S]-labelled MCHR1 and its radio-labelled deletion derivatives. 
The results of the reactivity of the vitiligo sera with the MCHRI deletion derivatives 
are summarised in Tables 3.5 and 3.6. The reactivity of each serum with each [35S]- 
labelled ligand was expressed as an antibody index. For each assay, the mean 
antibody index +3 SD of 20 control sera was used to calculate the upper level of 
normal. Any patient serum that had an antibody index greater than the upper level of 
normal was regarded as positive for binding to the labelled MCHR1 ligand used in 
the assay. 
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23J 30 bp 
9,416 bp -ý 
6,557 bp -* 
4361 bp -ý 
2,322 bp 
_ilý 
2.027 bp -º 
5o4 hp --pl. 
f-- pcDNA3 
Figure 3.2a Agarose gel electrophoresis of MCHR1 cDNA deletion constructs. 
Plasmid DNA was restricted with Xbal and EcoRl and the DNA fragments generated 
were analysed by electrophoresis in a 0.8% (w/v) agarose gel as described in Section 
2.1 1. The above gel shows Hind III -restricted bacteriophage k DNA (lane 1); 
pcMCHRI (lane 2); pMCHRI-378 (lane 3); pMCHRI-338 (lane 4); pMCHRI-298 
(lane 5); pMCHRI-258 (lane 6); pMCHRI-218 (lane 7). 
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I2-4567 
A-- pcDNA3 
f-- 1.500 hp 
- 500 bp 
Figure 3.2b Agarose gel electrophoresis of MCHRI cDNA deletion constructs. 
Plasmid DNA was restricted with Xbal and EcoRl and the DNA fragments generated 
were analysed by electrophoresis in a 0.8% (w/v) agarose gel as described in Section 
2.11. The above gel shows: pMCHR I -178 (lane 1); pMCHR I -139 (lane 2). 
pMCHRI-138 (lane 3); pMCHRI-299 (lane 4); 100 base pair ladder (lane 5). 
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2345 
kDa 
Figure 3.3 SDS-PAGE and autoradiography of products arising from in vitro 
translation of MCHRI cDNA and its deletion derivatives. MCHRI cDNA and its 
deletion derivatives were translated in vitro in a TnT"-" T7 Coupled Reticulocyte 
Lysate System and the radio-labelled products analysed by electrophoresis in a 
12.5% (w/v) SDS-polyacrylamide gel followed by autoradiography as described in 
Section 2.19. Deletion derivatives of MCHRI in vitro translated from: pMCHR 1- 
138 (lane 1); pMCHRl-139 (lane 2). pMCHRI-l78 (lane 3); pMCHRI-218 (lane 
4): pMCHRI-258 (lane 5); pMCHRI-298 (lane 6); pMCHRI-338 (lane 7); 
pMCHRI-378 (lane 8); pcMCHRI (lane 9). Protein molecular weight markers are 
shown on the right-hand side of the gel. 
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On this basis, none of the healthy individuals was positive for antibodies to any of 
the MCHRI deletion derivatives used in the assay. In addition, none of the MCHRI 
antibody-negative vitiligo patient sera reacted with any of the radio-labelled MCI-IRI 
deletion derivatives tested (Table 3.5). Of the nine MCHRI antibody-positive 
vitiligo (V) patient sera analysed. all were positive in the radio-binding assay when 
full-length MCHRI positive was used as the radio-labelled antigen (Table 3.6). 
Seven of the nine (78%) sera (VI, V2. V3, V4, V7, V8, V9) were positive for 
binding to radio-labelled ligands containing amino acids 1-378,1-338,1-298,1-258, 
1-218.1-178 and 1-138 (Table 3.6). Five of nine (56%) sera (VI, V3, V4, V5, V6) 
were found to react with a MCHRI deletion derivative comprising amino acids 139- 
298 (Table 3.6). Using a cDNA construct encoding the C-terminal domain of the 
receptor (amino acids 299-402), none of the vitiligo patient sera was positive for 
reactivity to the deletion protein encoded therein (Table 3.6). 
Longitudinal serum samples taken at 8,3,12 and 5 months after the initial tested 
sample from patients V2. V4, V6 and V9, respectively, were analysed for reactivity 
to the panel of MCHRI deletion derivatives. The sera displayed a pattern of 
reactivity with the radio-labelled ligands identical to the initial serum sample 
obtained from the patient (data not shown). 
SDS-PAGE and autoradiography indicated that major protein bands equating to 
the size of the radio-labelled ligands were immunoprecipitated by MCHRI antibody- 
positive vitiligo patient sera and that the sera did not react with any other proteins. 
The results obtained for three MCHRI antibody-positive vitiligo patient sera with 
five of the receptor deletion derivatives and full-length MCHRI are illustrated in 
Figure 3.4. As determined by SDS-PAGE and autoradiography, normal control sera 
and MCHRI antibody-negative vitiligo patient sera did not immunoprecipitate any 
of the radio-labelled ligands (data not shown). 
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Figure 3.4 SDS-PAGE and autoradiography of radio-labelled proteins 
following immunoprecipitation with vitiligo patient sera. In vitro translated radio- 
labelled proteins were used in radio-binding assays with MCHRI antibody-positive 
vitiligo patient as detailed in Section 3.2.4 prior to analysis by SDS-PAGE. MCHRI 
proteins encoded by: pcMCHRI (lane 1) and pMCHRI-378 (lane 2) 
immunoprecipitated by vitiligo patient serum (VI); pMCHR I -338 (lane 4) and 
pMCHRI-298 (lane 3) immunoprecipitated by vitiligo patient serum (V2); 
pMCHRI-258 (lane 5) and pMCHRI-218 (lane 6) immunoprecipitated by vitiligo 
patient serum (V3). Protein molecular weight markers are shown on the right-hand 
side of the gel. 
102 
3.3.3 Analysis of the antibody binding sites on MCHRI 
The results of the radio-binding assays indicate the existence of multiple antibody 
binding sites on MCHR1: between amino acids 1-138 located at the N-terminal of 
the receptor, and between amino acids 139-298 found towards the centre of the 
MCHRI molecule (Table 3.7). No epitopes were identified between amino acid 
residues 299-402. Of the sera examined, seven of nine (78%) reacted with the 
epitope domain comprising amino acids 1-138. Five of the nine (56%) sera 
recognised the epitope region containing amino acids 139-298 and within this 
domain two sera were reactive towards an epitope between amino acids 259-298. 
More than one epitope was recognised by three of nine (33%) sera. No clear 
correlation between epitope recognition and the presence of antibodies that inhibited 
MCH binding to MCHRIwas evident (Table 3.7). 
3.3.4 Computer prediction of putative antigenic regions within MCHR1 
Computer prediction analysis revealed several putative antigenic regions within 
MCHRI including amino acids 1-75,110-115.165-175.190-205,245-250,275-300 
and 365-402 (Figure 3.5). The epitope domains identified on the receptor were found 
to overlap, at least in part, with the areas on the protein that were predicted to he 
highly antigenic. Amino acid homologies between the identified epitope domains 
and either microbial or viral polypeptides were not demonstrated. 
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Table 3.7 Epitope regions on MCHR1 that are recognised by vitiligo sera. 
Vitiligo 
patient sera 
MCH binding- 
inhibition 
reactivity' 
Reactivity of sera with MCHR1 
epitope domains2 
1-138 139-298 
V1 + + + 
V2 + + - V3 + + + 
V4 + + + 
Vs ND - +3 
V6 + - +3 
V7 + + - V8 ND + - V9 ND + - 
'MCH binding-inhibition reactivity of antibodies taken from Kemp et al. (2002): + 
positive for MCH binding-inhibition reactivity; -, negative for MCH binding- 
inhibition reactivity; ND, not determined. 
2Reactivities with epitope regions are indicated as: +, reactivity with the specified 
epitope region; -, unreactive with the specified epitope region. 
3Sera VS and V6 recognize an epitope between 259 and 298. 
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Figure 3.5 Antigenicity profile of the deduced amino acid sequence of MCHR1. 
Local antigenicity values, calculated as previously detailed (Parker et al. 1986), are 
plotted against the amino acid residues of MCHRI. The y-axis from 0-100 reflects 
increasing antigenicity. 
105 
3.4 Discussion 
Recently, MCHRI has been identified as an autoantigen in patients with vitiligo 
(Kemp et al. 2002). Immunoreactivity against the receptor was demonstrated in 
16.4% of vitiligo patient sera, but not in the sera of either normal subjects or 
individuals with other autoimmune disorders, including systemic lupus 
erythematosus (Kemp et al. 2002). In this chapter, B cell epitopes on the receptor 
which are recognised by vitiligo sera containing MCHRI antibodies have been 
identified using radio-labelled MCHR1 deletion derivatives and radio-binding 
assays. The in vitro translation system is a useful procedure for producing both intact 
and modified [35S]methionine-labelled proteins, which can then be used for testing 
antibody reactivity in radio-binding assays (Wedlock et al. 1993; Daw et al. 1996; 
Volpato et al. 1998). Indeed, this method of epitope mapping has been successfully 
used to identify antibody-binding sites on the vitiligo autoantigens tyrosinase (Kemp 
et al. 1999a) and Pmel17 (Kemp et al. 2001 b). 
Analysis of results obtained in radio-binding assays with receptor deletion 
derivatives suggested the existence of multiple antibody binding sites on MCHR1, 
including regions between amino acids . 1-138 and 139-298. These domains 
overlapped with areas on the receptor that were predicted to be highly antigenic. As 
autoimmune responses may be triggered by an infection with a pathogenic agent 
(Wucherpfennig 2001), homologies of the identified epitope regions with either 
microbial or viral polypeptides were searched for. Potentially cross-reacting epitopes 
were not demonstrated, however, and, therefore, no evidence for molecular mimicry 
in causing the humoral immune response to MCHR1 was apparent. 
Mapping of B cell epitopes can provide an understanding of the association of an 
autoantigen with a particular autoimmune disease. For example, in myasthenia gravis 
autoantibodies are directed to an epitope in the acetylcholine-binding site in the 
acetylcholine receptor (Hoedemaekers et al. 1997). No clear correlation, however, 
between epitope recognition and the presence of antibodies that inhibited MCH 
binding to MCHR1 (Kemp et al. 2002) was found. Although epitope 139-298 
contains an aspartic acid residue reported to be involved in the binding of MCH to its 
receptor (Macdonald et al. 2000), antibodies from two patients (V2 and V7) that 
inhibited hormone interaction with MCHR1 did not appear to recognise this epitope 
domain, at least in the context of the radio-binding assays used in this study. 
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Our findings indicate that the humoral response to MCHR1 in vitiligo is 
heterogeneous in nature with several patients exhibiting autoantibodies to more than 
one MCHR1 epitope. Similarly, autoantibodies in autoimmune thyroid disorders and 
type 1 diabetes have been reported to react against multiple epitopes on thyroid 
peroxidase (Zanelli et al. 1992) and tyrosine phosphatase-like IA-2 autoantigen 
(Lampasona et al. 1996), respectively. This has been explained by the intramolecular 
spreading of an autoimmune response from a single or few epitope(s) to multiple 
epitopes during the progression of the disease. For example, in type 1 diabetes, a 
temporal spreading of the autoantibody response has been described from 
immunodominant epitopes in an early preclinical phase to lesser immunogenic 
domains at the manifestation of disease (Naserke et al. 1998). We did not find 
evidence of epitope spreading in longitudinal serum samples, however, taken from 
four of the patients included in this study. Possibly, these four sequential patients 
may have been studied too late in the disease to see an indication of epitope 
spreading (Naserke et al. 1998). 
The use of human sera in the mapping of MCHR1 epitopes can be problematic 
because sera contain multiple antibody species against the autoantigen. It is difficult, 
therefore, to examine the reactivity of a specific MCHR1 autoantibody in isolation 
and it is not possible to discriminate between a single MCHR1 antibody targeted at 
an epitope and a set of closely related MCHR1 antibodies directed at the same 
epitope. To gain information on the array of autoantibodies present in a particular 
serum and the epitope specificity of a particular autoantibody usually requires the 
production of human monoclonal antibodies from the patient. Indeed, monoclonal 
antibodies isolated from individuals with insulin-dependent diabetes mellitus have 
been successfully employed in identifying the antibody binding sites on glutamic 
acid decarboxylase, an autoantigen in this disease (Syren et al. 1996). Although the 
monoclonal antibody approach can allow the precise characterization of epitopes 
recognized by a specific antibody, there are drawbacks. For example, it is difficult to 
know the relative frequencies of the different monoclonal antibodies in the patient 
under investigation. Despite this, the isolation of monoclonal antibodies from vitiligo 
patients would allow a more complete and detailed analysis of the epitopes 
recognized by MCHRI autoantibodies. 
Although only a limited number of MCHR1 epitopes were identified, it is 
possible that more autoreactive epitopes could be present on the receptor. The 
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methodology used here for epitope mapping, employing recombinant proteins 
produced from deletion mutants generated by PCR amplification, is useful to detect 
linear/continuous epitopes but is not effective for the identification of 
conformational/discontinuous antigenic domains (Petterson 1992). In Graves' 
disease, for example, it is well documented that the autoantibodies to the thyrotropin 
receptor, which are responsible for disease activity, recognize a number of different 
conformational epitopes (Morgenthaler et al. 1999). Autoantibody epitopes on 
MCHR1 dependent upon the conformation of the receptor were not, therefore 
characterised, in this study. In so far as short linear sequences may contribute to 
conformational epitopes, it may be possible to identify at least part of some 
conformational epitopes using the methodology applied in this study. Nevertheless, 
it would be of interest to apply phage-display technology (Table 3.1; Scott 1992; 
Williams et al. 2001) to mapping epitopes on MCHRI. Phage-display is more suited 
to the study of conformational epitopes since expressed proteins are able to fold into 
their correct three-dimensional structures in the periplasmic space of the bacterial 
host, and can maintain a native arrangement once displayed on the surface of a phage 
particle (Wilson and Finlay 1998). The identification of conformational epitopes on 
MCHRI by phage-display technology is the subject of Chapter 4. 
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4B Cell Epitope Mapping of the Melanin-Concentrating 
Hormone Receptor 1 using Phage-display Technology 
4.1 Introduction 
Traditional methods of epitope mapping are to use deletion mutants of the antigen or 
to work at the peptide level by screening small synthetic peptides derived from the 
antigen. Indeed, autoantibody epitopes on autoantigens in vitiligo have been 
identified in this and previous studies by the use of deletion derivatives (Kemp et al. 
1999a; Kemp et al. 2001b; Gottumukkala et al. 2003). However, these methods have 
proved labour intensive, expensive and require the antigen to be cloned and 
expressed (Petterson 1992). In addition, the traditional methods of epitope mapping 
can only detect linear epitopes and short sequences that may constitute part of the 
conformational epitopes. A recent development in the identification of epitopes is 
that of phage-display technology (Williams et al. 2001). 
4.1.1 Phage-display technology 
Filamentous phage, so called because of their narrow rod-shaped appearance (Figure 
4.1), comprise three families of bacterial viruses that depend on the F-pilus for 
infection of their E. coli host (Wilson and Finlay 1998). Each phage particle consists 
of a single-stranded DNA genome packaged in a tube made up of 2700 copies of a 
major coat protein, pVIII, closed at the ends by four or five copies of each of four 
species of minor coat proteins, including pIII (Wilson and Finlay 1998). The 
discovery that insertion of foreign DNA fragments into the filamentous phage gene 
gIII results in the display of the encoded foreign polypeptide as a fusion protein with 
the minor coat protein pIII on the phage surface (Smith 1985), led to the 
development of phage-display technology. Libraries of phage-displayed fusion 
proteins can be screened for peptides based on their binding properties, with the 
advantage that the selected peptide sequences are physically linked to the genetic 
material that encodes them. 
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pVII, pIX 
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Figure 4.1 The filamentous phage. A schematic representation of the structure of a 
filamentous phage particle reproduced from (Wilson and Finlay 1998). A single- 
stranded circular genome is surrounded by -2700 copies of the major coat protein 
pVIII, and 4 or 5 copies of each of four types of minor coat proteins, including pI1I. 
Part of the coat sheath, formed by copies of the major coat protein, is not shown in 
order to reveal the phage genome. 
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7nm 
The technique has become a powerful tool for studying protein-ligand interactions 
and has been applied to the study of receptor-ligand (Bass et al. 1990), enzyme- 
substrate (Redl et al. 1999), transcription factor-ligand (Butteroni et al. 2000), and 
antibody-antigen (Barbas 1993) interactions. Previous immunological applications of 
phage-display include the immunoscreening of phage libraries displaying antibody 
fragments to identify antibodies that interact with a specific antigen (Barbas 1993). 
More recently, immunoscreening of proteins expressed on phage from cDNA 
libraries has been utilised to identify novel autoantigens (Kemp et al. 2002). 
Furthermore, phage-display technology has been used to map B cell epitopes on 
autoantigens by using antibodies to screen libraries displaying random peptide 
sequences generated from a selected antigen (Table 4.1). Phage-display provides for 
the possibility of detecting conformational epitopes: larger peptides can be displayed 
that may adopt structural conformations, which are important for the binding of some 
antibodies. In addition, an advantage of this method is the large library size that can 
be generated ensuring that each clone in the library is well represented and can be 
rapidly screened. 
4.1.2 Aim 
The aim of this part of the study was to identify B cell epitopes on MCHRI using 
phage-display technology. Initially, this involved the construction of a phage-display 
MCHRI cDNA fragment library in the vector pComb3 (Figure 4.2). In this library, 
peptides encoded by the MCHR1 cDNA fragments were expressed as fusions with 
coat protein pIII and subsequently exposed on the surface of phage particles (Figure 
4.3). The phage-display library was then immunoscreened with IgG samples purified 
from vitiligo patients in order to identify immunoreactive peptides that are 
recognised by MCHR1 autoantibodies (Figure 4.4). 
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Table 4.1 Examples of B cell epitope mapping of autoantigens using phage- 
display technology. 
Autoantigen 
Glutamic acid 
decarboxylase 
Glutamic acid 
decarboxylase 
Tyrosinase 
phosphatase-like 
protein IA- 
2/ICA512bdc 
Tyrosinase 
phosphatase-like 
protein IA-2 
Smith autoantigen 
Gliadin 
Disease Reference 
Autoimmune polyendocrine Al-Bukhari et al. 
syndrome type II and Stiff-man 2002 
syndrome 
Type 1 diabetes mellitus Myers et al. 2000 
Type I diabetes mellitus 
Type I diabetes mellitus 
Systemic lupus erythematosus 
Celiac disease 
Farilla et al. 2002 
Dromey et at 2004 
del Rincon et al. 2000 1 
Osman et al. 2000 
Pyruvate Primary biliary cirrhosis Rowley et al. 2000 
dehydrogenase 
complex E2 
Platelet autoantigen Autoimmune thrombocytopenic Gevorkian et al. 1998 
purpura 
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V 
gill 
lacZ 
petB 
AmpicillinR 
Figure 4.2 A map of the pComb3 vector. MCHRI cDNA fragments were 
generated by digestion of PCR amplified MCHRI cDNA. The cDNA fragments 
were cloned into the EcoRV restriction site of pComb3. 
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library 
C Isolation of recombinant No Identification of MCHRI 
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ISOLATIO 
of phage 
INFECTION of E. colt and 
GROWTH of enriched 
phage-display library 
6 
ROUNDS OF 
ENRICHMENT 
REPEATED 
SEVERAL TIMES 
Phage 
2 
Biotinylated IgG Pu 
bound to 
streptavidin-coated 
\ 
magnetic beads l 
ELUTION 
of specific phage 
displaying IgG- 
binding peptides 
5 
WASHING 
AFFINITY to remove non- 
SELECTION of specific, 
phage displaying IgG- unbound phage binding MCHRI 
peptide on their 
surface 
4 
3 
Figure 4.4 Enrichment of phage displaying MCHR1 peptides on their surface. 
1. Phage expressing immunoreactive cDNA-encoded products. 2. Biotinylated IgGs 
are attached to streptavidin-coated magnetic beads. 3. Biotinylated IgGs are then 
used to capture phage expressing immunoreactive cDNA-encoded products. 
4. Non-specific unbound phage are removed by washing. 5. Phage displaying 
peptides that bind specifically to IgG molecules are eluted with glycine-HCI. 6. The 
eluted phage are super-infected into E. coif to enrich specific-bound phage. 7. The 
phage are isolated either for use further rounds of panning or for identification of 
MCHRI cDNA inserts by DNA sequencing. (Adapted from Crameri and Suter 
1993). 
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4.2 Materials and Methods 
4.2.1 Patients and controls 
Immunoglobulin G from three vitiligo patients (V2, V3 and V7; Table 2.1), that 
were previously shown to contain MCHR1 antibodies (Kemp et al. 2002), were 
analysed in these experiments. Immunoglobulin G from one healthy individual 
(female; age: 32 years) with no history of either vitiligo or autoimmune disorders 
was used as a control. 
4.2.2 Isolation of IgG from sera 
Immunoglobulin G was isolated from the patient and control serum samples by 
protein G Sepharose 4 Fast Flow affinity column chromatography (Amersham 
Pharmacia Biotech). Serum (1-2 ml) was passed through a protein G sepharose 
column with 0.01 M phosphate buffer (pH 7.0). The elution of bound IgG was with 
0.1 M glycine-HC1(pH 2.7) was monitored by UV absorption at 280 nm with a 2138 
UVlcord S (LKB Wallac, Turku, Finland). Eluted IgG was neutralised with IM 
Tris-HCL (pH 9.0). The fractions containing IgG were pooled and dialysed against 
PBS at 4°C overnight. After dialysis, the eluted IgG fractions were concentrated 
using an Amicon Concentrator (Amicon Inc., Beverley, MA, USA). The 
concentrated IgG was filter-sterilised with a Millex® Filter Unit (Millipore UK, 
Watford, UK) and the final IgG concentration measured by spectrophotometry at 280 
nm with a Unicam 8625 UV/VIS spectrometer (Unicam, Cambridge, UK). All IgG 
samples were stored at -20°C until required and were at a concentration of 1-5 
mg/ml. 
4.2.3 Anti-MCHR1 antibody 
Rabbit polyclonal anti-human MCHR1 antibody C1ICB (Hervieu et al. 2000) was 
used as a positive control in biopanning experiments and was provided by Professor 
G. Hervieu (Neurology and Gastro-Intestinal Centre for Drug Discovery, 
GlaxoSmithKline Beecham, Harlow, UK). The CIICB antibody was raised against 
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the C-terminal intracellular tail of the receptor between amino acid residues 387-402 
with sequence SNAQTADEERTESKGT. 
4.2.4 Construction of a phage-display MCHR1 cDNA fragment library 
4.2.4.1 Preparation of MCHR1 cDNA fragments 
Initially, MCHR1 cDNA was prepared by PCR amplification of pcMCHR1 (Kemp 
et al. 2002) using the following primers (Invitrogen): 
Forward primer: 5' TTGAATTCGCCGCCATGTTGTGTCCTTCCAAG 3' 
Reverse primer: 5' AATCTAGACGCCTATCAGGTGCCTTTGCTTTC 3' 
Samples (50 ng) of pcMCHR1 plasmid DNA were subjected to 38 cycles of PCR 
amplification in a DNA Thermal Cycler using the following conditions: denaturation 
at 94°C for 1 minute, annealing at 55°C for 1 minute, extension at 72°C for 2 
minutes and 72°C for 10 minutes to terminate the reaction. The composition of each 
50-µl PCR amplification reaction was as previously described (Section 2.15). 
Random 100-300 base pair fragments of MCHR1 cDNA were then prepared by 
digestion with DNAseI (Promega) in a reaction containing: 1 µg of MCHRI cDNA, 
5 µl of lOx digestion buffer (500 mM Tris HCI, pH 7.6; 100 mM MnC12; 1 mg/ml 
BSA; Promega) and 1.5 µl of DNAseI (diluted 1: 65 from the stock enzyme in 50 
mM Tris HCI, pH 8.0). The reaction was left at room temperature for 1 hour and 
then terminated by the addition of EDTA (pH 8.0) to a final concentration of 50 mM. 
The DNA fragments were cleaned by phenol-chloroform extraction. Firstly, the 
DNAseI digestion reaction was made up to 200 µl in TE buffer and then mixed with 
200 µl of phenol: chloroform (1: 1 v/v). Following centrifugation for 10 minutes at 
10,000 g, the top layer was removed and transferred to a fresh tube. An equal volume 
of 100% ethanol was added and the precipitated DNA pelleted by centrifugation at 
10,000 g for 20 minutes. The DNA pellet was washed in 70% (v/v) ethanol and then 
air-dried before resuspension in 100 µl of TE buffer. 
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The ends of the DNA fragments were repaired to allow subsequent cloning into 
the blunt-end EcoRV restriction site of pComb3. The end-filling reaction contained: 
20 µl of DNA fragments, 3 pI of 10 mM dNTPs, 5 µl of 25 mM MgC12 and 1.5 µl of 
T4 polymerase (Promega). The reaction was left at room temperature for 15 minutes 
prior to the addition 1 µl of Klenow fragments (Promega) and incubated at room 
temperature for a further 15 minutes. The DNA fragments were loaded onto a 0.8% 
(w/v) agarose gel (Section 2.11) and, following electrophoresis, DNA fragments of 
100-300 base pairs were excised from the gel and purified using a Wizard PCR Prep 
DNA Purification Kit (Section 2.12). 
4.2.4.2 Vector preparation 
Vector pComb3 (Figure 4.2) was digested with EcoRV in a 20-µl reaction 
containing: I µg of pComb3 DNA, 2 µl of 1 Ox restriction buffer (Promega) and 1 µl 
of EcoRV (Promega). The reaction was incubated at 37°C for 2 hours. Two units 
alkaline phosphatase (Promega) and 10 µl of alkaline phosphatase buffer (Promega) 
were then added and the reaction left at 37°C for a further 30 minutes. The DNA was 
loaded onto a 1% (w/v) agarose gel (Section 2.11) and, following electrophoresis, 
the vector fragment was excised from the gel and purified using a Wizard PCR Prep 
DNA Purification Kit (Section 2.12). 
4.2.4.3 Ligation of MCHR1 cDNA fragments into pComb3 
A ligation reaction was set up containing EcoRV-digested pComb3 and MCHR1 
cDNA fragments. The ratio of insert: vector (10: 1) was much higher than in a 
standard ligation reaction (Section 2.13), as ligations using blunt-ended DNA are 
less efficient than those using DNA with protruding ends. The ligation reaction 
contained: 2 µl of EcoRV-digested pComb3,20 gl of MCHR1 cDNA fragments, 2 µl 
of l Ox ligase buffer and 1 µl of T4 DNA ligase. The reaction was incubated at 16°C 
overnight. The ligated DNA was cleaned by phenol-chloroform extraction as 
described in Section 4.2.4.1 and finally resuspended in 20 µl of sterile water. 
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4.2.4.4 Preparation of the phage-display library 
The total ligation reaction was electroporated into E. coli XL-1 Blue cells as detailed 
earlier (Section 2.14.2). A 10-µ1 aliquot of the electroporated culture was plated onto 
a LB agar plate containing 10 pg/ml tetracycline and 100 µg/ml ampicillin, which 
was incubated at 37°C overnight. The colonies obtained after incubation were used 
to assess the total number of transformants obtained from electroporation of the 
ligation reaction. In addition, individual transformants were picked, added to 10 ml 
of LB medium containing 10 µg/ml tetracycline and 100 pg/ml ampicillin and grown 
overnight with shaking at 37°C. Subsequently, phagemid DNA was prepared from 
each culture using a Wizard Minipreps DNA Purification System (Section 2.8). Each 
phagemid DNA sample was then analysed by PCR amplification (Section 4.2.9) in 
order to assess the frequency of recombinants in the initial library, and by DNA 
sequencing (Section 4.2.7) in order to identify the MCHRI cDNA fragments. 
The remainder of the electroporated cells were added to 10 ml of LB, containing 
10 µg/ml tetracycline and 100 µg/ml ampicillin, and grown at 37°C. When turbid, 
1x101' plaque-forming units of VCS-M13 helper phage (Stratagene) were added to 
the culture, which was then left at room temperature for 15 minutes. The culture was 
then transferred to 100 ml of LB containing 10 gg/ml tetracycline, 100 gg/ml 
ampicillin and 10 µg/ml kanamycin, and grown overnight with shaking at 37°C. 
The 100 ml culture was centrifuged at 2000 g for 15 minutes to remove all 
bacterial cells. Phage particles were precipitated from the supernatant with 15 ml of 
40% polyethylene glycol 4000 and 15 ml of 5M NaCl (PEG/NaCI). Following 
overnight incubation at 4°C, the phage were harvested by centrifugation at 2000 g for 
30 minutes and the pellet resuspended in 1-2 ml of PBS before storage at -20°C. 
The phage titre was determined by infecting 2 ml of log-phase E. coli XL-1 Blue 
with an aliquot of the phage-display library, incubating at room temperature for 30 
minutes and then plating out samples of the culture onto LB agar containing 
10 pg/ml tetracycline and 100 gg/ml ampicillin. A titre of 1x10" colony-forming 
units /ml was estimated. 
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4.2.5 Immunoscreening of the phage-display library 
4.2.5.1 Biotinylation of IgG 
Biotinylation of IgG was performed using EZ-LinkTM Sulfo-NHS-LC-LC-Biotin 
(Pierce, Rockford, IL, USA), according to the manufacturer's protocol. Briefly, a1 
mg/ml solution of Sulfo-NHS-LC-LC-Biotin was made up immediately prior to 
setting up the biotinylation reaction, which comprised 2 mg of IgG sample in 1 ml of 
PBS and 75 µl of the Sulfo-NHS-LC-LC-Biotin solution. The reaction was mixed 
gently and allowed to proceed for 2 hours on ice, after which time any unreacted 
biotin was removed by extensive dialysis against fresh PBS. All IgG samples were 
stored at 4°C until required and were at a concentration of 2 mg/ml. 
4.2.5.2 Paramagnetic bead preparation 
Dynabeads® M-280 Streptavidin (Dynal Biotech, Oslo, Norway) beads were used to 
immobilise biotinylated IgGs during the isolation, of phage particles that displayed 
IgG-binding peptides. For each experiment, a 20-gi (10 mg/ml) sample of beads was 
washed extensively with 500-µ1 aliquots of PBS containing Tween 20 at 0.05% 
(v/v). A Dynal Magnetic Particle Concentrator (Dynal Biotech) was used to separate 
the beads after each wash and the beads were finally resuspended in 235 µl of sterile 
water. 
4.2.5.3 Isolation of phage displaying IgG-binding peptides 
A 15-gl aliquot of either biotinylated rabbit anti-MCHRI antibody, biotinylated IgG 
from a vitiligo patient (n=3) or biotinylated IgG from a healthy control (n=1) was 
incubated with 235 µl of prepared Dynabeads® on a rotating wheel at 4°C for 30 
minutes. To block any non-specific binding to the beads later in the procedure, 300 
µ1 of 2% (w/v) dried milk powder in PBS were added to the bead-IgG suspension 
and incubation continued for 1 hour at 4°C. After blocking, the bead-IgG complexes 
were separated from the blocking buffer using a Dynal Magnetic Particle 
Concentrator, washed twice with PBS/0.05% Tween 20 and finally resuspended in 
150 µl of PBS/0.05% Tween 20. A 100-µ1 sample of the phage-display library was 
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then added to the bead-IgG suspension, which was then incubated overnight at 4°C 
to allow the interaction of antibody-bead complexes with peptides diplayed on the 
surface of the phage particles. 
The bead-IgG complexes were washed extensively with PBS/0.05% Tween 20 
and resuspended to remove any unbound phage. Bound phage were eluted from the 
bead-IgG complexes with 150 µl of 100 mM HC1 (adjusted to pH 2.2 with solid 
glycine), and the beads then magnetically separated from the supernatant that 
contained the phage particles. Neutralisation of the supernatant was accomplished by 
the addition of 9 µl of 2M Tris-HCL (pH 8.0). The eluted phage were then used to 
infect 2 ml of exponentially growing E. coli XL-1 Blue cells at room temperature for 
15 minutes. Aliquots of the infected cells were then plated onto LB agar containing 
10 gg/ml tetracycline and 100 µg/ml ampicillin and the plates incubated overnight at 
37°C. This allowed the assessment of the number of eluted phage following each 
round of biopanning. 
To generate a phage-display library for the next round of selection, the infected E. 
coli XLI-Blue culture was made up to 10 ml with LB medium and incubated for 1 
hour with shaking at 37°C before superinfection with of 1x1011 plaque-forming units 
of VCS-M13 helper phage. Following incubation at room temperature for 30 
minutes, the cells were transferred to 100 ml LB medium containing 10 µg/ml 
tetracycline, 100 µg/ml ampicillin and 10 gg/ml kanamycin and grown overnight 
with shaking at 37°C. Phage were prepared from the infected culture as described 
above (Section 4.2.4.4) and then stored at -20°C. This first round library, enriched in 
phage particles displaying IgG-binding peptides, was used in a second round of 
biopanning in the same way as the original library. In all, five rounds of biopanning 
were undertaken. 
In the final round of biopanning, individual colony-forming units, isolated by 
plating out the culture infected with eluted phage, were picked and grown overnight 
with shaking at 37°C in 10 ml of LB medium containing 10 µg/ml tetracycline and 
100 gg/ml ampicillin. Subsequently, phagemid DNA was prepared from each culture 
using a Wizard Minipreps DNA Purification System (Section 2.8) and each 
phagemid DNA sample was analysed by DNA sequencing (Section 4.2.7) in order to 
identify any immunoreactive MCHR1 peptides that had been enriched during the 
biopanning procedure. 
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4.2.6 Analysis of recombinant pComb3 phagemid by PCR amplification 
Phagemid DNA (50 ng) was subjected to 38 cycles of PCR amplification in a 
standard reaction as described previously (Section 2.15) with primers (Invitrogen): 
Forward primer PetCombl: 5' GGCTCGAGGTCGACGGTATCGATAAG 3' 
Reverse primer PetComb2: 5' GGCTCGAGGCCACCACTAGTGGATCC 3' 
The forward and reverse primers. anneal to pComb3 (Figure 4.2) upstream and 
downstream, respectively, of the EcoRV restriction site thereby amplifying any 
cloned DNA fragments. The following reaction conditions were used: 94°C, 1 
minute; 55°C, 1 minute; 72°C, 2 minutes; 72°C for 10 minutes. An aliquot of each 
PCR amplification product was analysed by electrophoresis in a 0.8% (w/v) agarose 
gel (Section 2.11) to confirm the presence of a fragment of MCHR1 cDNA. 
4.2.7 DNA sequencing of pComb3 phagemid 
Automated DNA sequencing of phagemid DNA was performed as detailed in 
Section 2.17.2. The sequencing primer (Invitrogen), 5' 
GGTGGCGGCCGCAAATTC 3', annealed to pComb3 (Figure 4.2) upstream of 
pe1B. The insert DNA sequences were compared with the full-length MCHR1 cDNA 
sequence using the BLAST network service of the National Centre for 
Biotechnology Information. 
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4.3 Results 
4.3.1 Construction of the MCHR1 cDNA phage-display library 
The size of the MCHR1 cDNA fragment library was Ix 106 independent clones. In 
order to determine the frequency of recombinant phagemid in the library, ten 
individual colony-forming units obtained after electroporation of the library ligation 
reaction into E. coli XL1-Blue were picked and grown. Phagemid DNA was 
prepared from each cultured transformant and analysed by PCR amplification with 
primers PetcombI and Petcomb2. This indicated that 15/15 (100%) of phagemids in 
the MCHR1 cDNA fragment library contained a DNA insert (Figure 4.5). The 
inserts ranged from 100-500 base pairs. Ten phagemid were also sequenced to 
determine if the library contained random MCHR1 cDNA fragments (Table 4.2). 
The results indicated that the library inserts were varied in their sequence. Following 
amplification with helper phage, an initial phage-display library with a titre of 1x 
1011 colony-forming units/ml was produced. 
4.3.2 Screening of the phage-display MCHRI cDNA fragment library with 
anti-human MCHR1 antibody C11CB 
The phage-display MCHR1 cDNA fragment library was screened for 
immunoreactive peptides with rabbit polyclonal anti-human MCHRI antibody 
C 11 CB. Five rounds of enrichment were carried out. A significant increase in the 
number of phage eluted was observed by the third round of biopanning (Table 4.3). 
Phagemid DNA from ten bacterial clones isolated from the final round of biopanning 
was analysed by DNA sequencing in order to identify if particular MCHR1 peptides 
had been selected during the enrichment process. Table 4.4 summarises the peptide 
sequences from the ten phagemid. The results demonstrated that specific MCHR1 
peptides were indeed enriched by biopanning of the phage-display library with 
C11CB antibody. Seven of the ten MCHRI peptide sequences included the amino 
acid region (residues 387-402), or part there of, that is recognised by C11CB. All the 
peptide sequences were in-frame with both the Pe1B leader sequence and the gill 
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500 bp-* 
100 bp--* 
*-- 500 bp 
f- 100 hp 
Figure 4.5 PCR amplification of the DNA inserts from 15 phagemid from the 
initial MCHR1 cDNA fragment library. PCR amplification products show a size 
distribution of between 100-500 base-pairs. Individual phapemid (lanes 2-16); non- 
recombinant pComb3 vector (lane 17); negative control containing no DNA (lane 
18); 100 base-pair ladder (lanes I and 19). 
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Table 4.3 Enrichment of phage by biopanning of the phage-display MCHR1 
cDNA fragment library with anti-MCHR1 antibody C11CB. 
Biopanning round Amount of infected bacteria plated out 
onto selective LB1 agar 
Total number of 
phage eluted 
1 Al 10µl 
Round 1 11 129 04 
Round 2 73 TMTC2 1.46x10 
Round 3 783 TMTC 1.56x10 
Round 4 831 TMTC 1.67x10 
Round 5 905 TMTC 1.81x106 
1LB, Luria Bertani. 
2TMTC, Too many to count. 
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protein product which would result in the expression of the peptides as fusion 
proteins on the surface of phage. 
4.3.3 Screening of the phage-display MCHR1 cDNA fragment library with 
IgG from vitiligo patients and a healthy control 
The phage-display MCHR1 cDNA fragment library was screened for 
immunoreactive IgG from three vitiligo patients (V2, V3 and V7) and one control. 
Five rounds of enrichment were carried out for each IgG sample. In experiments 
with two of the vitiligo patient IgGs (V2 and V3), a moderate level increase in the 
number of eluted phage was observed, by the final round of biopanning (Table 4.5) 
suggesting that some enrichment had occurred. In experiments with the remaining 
vitiligo patient (V7) and control IgGs, no increase in the number of eluted phage was 
observed by the final round of biopanning (Table 4.5), suggesting that no significant 
enrichment had taken place. 
Phagemid DNA from twenty bacterial clones isolated from the final round of 
biopanning with IgG from three vitiligo patients and one control was analysed by 
DNA sequencing in order to identify if particular MCHR1 peptides had been 
selected during the enrichment process. The results demonstrated that biopanning of 
IgG from one vitiligo patient (V2) had enriched MCHRI peptides containing a 
consensus sequence of MCHR1 amino acid residues 49-82 in 11/20 of the phagemid 
analysed (Table 4.6). The remaining nine clones contained MCHR1 cDNA 
fragments that could not be expressed as fusion proteins as they were not in the 
correct reading frame with respect to the PelB leader sequence and the gill protein 
product. Biopanning with IgG from a second vitiligo patient (V3) enriched phage 
expressing MCHRI peptides containing a consensus of amino acid residues 156-194 
(Table 4.7). This was found in 9/20 of the phagemid sequenced. Again, the 
remaining eleven clones contained MCHR1 cDNA fragments that could not be 
expressed as fusion proteins as they were not in the correct reading frame with 
respect to the Pe1B leader sequence and the gill protein product. Immunoglobulin G 
from the third vitiligo patient (V7) and the control did not enrich any particular 
MCHRI peptide sequences and the majority of the phagemid carried MCHR1 cDNA 
fragment inserts that would not be expressed as fusion proteins. 
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Table 4.5 Enrichment of phage by biopanning of the phage-display MCHR1 
cDNA fragment library with vitiligo patient and control IgG. 
Biopanning 
round 
Total number of phage eluted 
Patient V2 Patient V3 Patient V7 Control 
Round 1 2.72x104 1.96x 104 3.02x104 1.24x104 
Round 2 04 3.18x10 1.56x10 04 
Round 3 3.46x10 04 04 04 
Round 4 4.70x10 04 04 1.90XI04 
Round 5 1.12x10 1.22x10 OX104 04 
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4.4 Discussion 
In this study, a phage-display MCHR1 cDNA fragment library was screened with an 
anti-MCHR1 antibody CI1CB and with vitiligo patient IgGs in order to map B cell 
epitopes on MCHR1. On biopanning of the library with C 11 CB antibody, which is 
raised against amino acid residues 387-402 of the receptor and served as an 
experimental positive control, high levels of enrichment were observed. Sequence 
analysis of ten phagemid from bacterial clones isolated following the final round of 
biopanning revealed that seven of them contained an amino acid consensus sequence 
of residues 380-397. This consensus contained the target amino acid sequence, or 
part thereof, for CII CB. This initial control experiment demonstrated that the library 
could be successfully screened with a specific antibody. 
Biopanning of the phage-display library with IgG from three vitiligo patients that 
were positive for MCHR1 autoantibody reactivity, resulted in a moderate level of 
enrichment in 2/3 cases. For one patient (V2), sequence analysis of twenty phagemid 
from bacterial clones isolated following the final round of biopanning revealed that 
eleven of them contained an amino acid consensus sequence of residues 49-82. This 
epitope was located within the autoantigenic domain (amino acid residues 1-138; 
Table 3.7) that had been previously determined for this vitiligo patient 
(Gottumukkala et al. 2003). Biopanning with IgG from a second vitiligo patient (V3) 
enriched by the final round' phage expressing MCHR1 peptides containing a 
consensus of amino acid residues 156-194 and this was found in 9/20 of the 
phagemid sequenced. This epitope was located within one of the autoantigenic 
domains (amino acid residues 139-298; Table 3.7) that had been previously 
determined for this vitiligo patient (Gottumukkala et al. 2003). In contrast to the 
screening of these two vitiligo patients, IgG from the third vitiligo patient (V7), 
which had previously been shown to react with MCHR1 epitope domain 1-138 
(Table 3.7; Gottumukkala et al. 2003), and the control did not enrich any particular 
MCHRI peptide sequences. 
The presence of significant numbers of peptide sequences in the . final round of 
biopanning with patient IgGs, which were not in the correct reading frame for 
expression, is probably due to the low titres of MCHR1 autoantibodies in vitiligo 
patients compared with the titre of the anti-MCHR1 CI 1CB antibody. So, although 
enrichment takes place with patient IgGs, it is at a lower level and the selected phage 
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probably do not completely dominate the binding of non-specific phage that is 
inherent in this technique. 
Each of the consensus sequences identified may represent a linear epitope that is 
recognised by patient MCHR1 autoantibodies. Conversely, the consensus sequences 
could have been selected due to them being part of a conformational epitope as the 
biopanning method is carried out in liquid phase and might therefore facilitate 
folding of the peptide. To differentiate, Western blot analysis could be applied to the 
expressed peptides, which would identify linear epitopes due to the denatured state 
of the protein in SDS-polyacrylamide gels. 
Phage-display technology has been used previously to identify linear and 
conformational autoantigenic epitopes in several autoimmune conditions. For 
example, a random peptide phage-display library was used to identify discontinuous 
epitopes in autoantigens that are recognised by anti-platelet autoantibodies in 
patients with autoimmune thrombocytopenic purpura (Gevorkian et al. 1998). 
Similarly, four prominent epitopes in a-type gliadin and one prominent and 
repetitive epitope in y-type gliadin have been demonstrated in patients with celiac 
disease, an autoimmune disorder caused by the indigestion of gluten (Osman et al. 
2000). In addition, the major conformational epitope for the pyruvate dehydrogenase 
complex E2 in primary biliary cirrhosis patients has been predicted by comparing 
epitopes derived by phage-display screening with the known nuclear magnetic 
resonance structure of the lipoyl domain (Rowley et al. 2000) and phage-display 
technology has been used to identify conformational epitopes on tyrosinase 
phosphatase-like IA-2/ICA512bdc autoantigens in type 1 diabetes (Farilla et al. 
2002; Dromey et al. 2004). Autoantibodies to 65 kDa glutamic acid decarboxylase 
(GAD65) are produced in many patients with autoimmune polyendocrine syndrome 
type II, stiff-man syndrome and type 1 diabetes mellitus (Myers et al. 2000; Al- 
Bukhari et al. 2002). The major linear epitopes of GAD65, which are recognised by 
patient autoantibodies, occur in the N-terminal and C-terminal regions of the protein 
and these epitopes have been mapped using random peptide phage-display libraries 
(Al-Bukhari et al. 2002). 
The examples given above indicate the usefulness of phage-display as a method 
of mapping autoantigenic epitopes in various autoimmune disorders. From this 
study, the phage-display MCHRI cDNA fragment library proved a useful tool in 
mapping the epitopes recognised by MCHR1 autoantibodies in vitiligo patients. This 
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method enabled the more precise identification of epitopes that were located within 
larger autoantigenic domains determined previously using deletion derivatives of 
MCHR1 (Chapter 3; Gottumukkala et al. 2003). 
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5 Functional Blocking of the Melanin-Concentrating 
Hormone Receptor 1 by Vitiligo Patient Autoantibodies 
5.1 Introduction 
5.1.1 Receptor autoantibodies in autoimmune disease 
In several autoimmune disorders, including autoimmune thyroid disease, myasthenia 
gravis, Addison's disease and pernicious anaemia, autoantibodies have been 
demonstrated to affect the functioning of cell receptors. TSHR is one of the major 
target autoantigens in autoimmune thyroid disease. TSHR autoantibodies are 
functionally heterogeneous: they include both thyroid-stimulating autoantibodies 
(TSAb) and thyroid-blocking autoantibodies (TBAb). Thyroid-stimulating 
autoantibodies activate TSHR and elicit hyperthyroidism in Graves' disease by 
mimicking the ability of TSH to bind to TSHR. Antibody binding to the receptor is 
more prolonged thereby inducing a chronic overproduction of thyroid hormone 
(Zakarija and McKenzie 1987; McGregor 1990; Nagayama and Rapoport 1992; 
Weetman and McGregor 1994; Song et al. 1996; Watanabe et al. 1997; Akamizu 
2001). In contrast, receptor occupancy by non-stimulatory TBAb prevents TSH 
action and may result in 'atropic thyroiditis, which is often accompanied by 
hypothyroidism (Arikawa et al. 1985; -McKenzie and Zakarija 1992; Kosugi et al. 
1993). 
In myasthenia gravis, autoantibodies directed against the acetylcholine receptor 
block the acetylcholine-binding site and provoke accelerated receptor degradation 
(Hara et al. 1993; Eymard and Chillet 1997; Hoedemaekers et al. 1997; Ferrero et al. 
1997; Fabien et al. 2001). 
Pernicious anaemia is characterised by cobalamine (Vitamin B 12) deficiency, 
autoimmune gastritis and anti-intrinsic factor autoantibodies that block the 
cobalamine-binding site of intrinsic factor, a gastric protein that is required for the 
assimilation of Vitamin B 12 (Wahlstedt 1990; Gueant et al. 1997). In addition, it has 
been demonstrated that serum immunoglobulin in patients with pernicious anaemia 
can block the gastrin-stimulation of acid secretion and it has been suggested that this 
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blocking activity is mediated by competition with gastrin for the surface receptors on 
parietal cells (de Aizpurua et al. 1985; Burman et aL 1989). 
In Addison's disease, patient IgGs can block the in vitro action of ACTH on 
adrenal growth and cortisol production by binding to its receptor (Wulffraat et al. 
1989). In contrast, subsequent studies did not demonstrate the blocking actions of 
IgGs from Addison's disease patients on ACTH receptor (Wardle et al. 1993). 
5.1.2 Intracellular calcium signalling 
The calcium ion is an important intracellular messenger, controlling a diverse range 
of cellular processes, such as gene transcription, muscle contraction, cell growth, cell 
survival and cell proliferation (Clapham 1995; Berridge et al. 1998). In most cells, 
calcium has its major signalling function when it is elevated in the cytosolic 
compartment. The calcium concentration inside cells is regulated by the interplay of 
several processes, which can be divided into calcium `on' and calcium 'off' 
mechanisms depending on whether they serve to increase or decrease cytosolic 
calcium, respectively (Bootman and Lipp 2001). The calcium `on' mechanisms 
include channels located at the plasma membrane (PM) which regulate the 
inexhaustible supply of calcium from the extracellular space, and channels on the 
endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR) which release the 
finite intracellular calcium stores. A more diverse set of `off mechanisms is 
employed by cells to remove calcium from the cytoplasm. These include calcium 
ATPases on the PM and ER/SR, in addition to exchangers that utilize gradients of 
other ions to provide the energy to transport calcium out of the cell (Bootman and 
Lipp 2001). 
When cells are at rest, the balance lies in favour of the `off mechanisms, thus 
yielding an intracellular calcium concentration of approximately 0.1 µM. However, 
when cells are stimulated by various means such as hormones the `on' mechanisms 
are activated and the cytosolic calcium concentration increases to levels of 1 µM or 
more. The binding of hormones, such as TSH and MCH, to their specific receptors 
on the PM leads to the activation of phospholipase C which catalyses the hydrolysis 
of phospholipids to produce the intracellular messenger IP3. Although derived from a 
lipid, IP3 is water-soluble and diffuses into the cell interior where it can encounter 
IP3 receptors on the ER/SR. The binding of IP3 changes the conformation of IP3 
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receptors such that an integral channel is opened, thus allowing the calcium stored at 
high concentrations in the ER/SR to enter the cytoplasm (Bootman and Lipp 2001). 
It has been reported that melanocyte growth, differentiation, dendricity and 
pigmentation have all been linked to the induction of the 
IP3/diacylglycerol/phospholipase C cascade that yields increased levels of 
intracellular calcium (Yaar and Gilchrest 1991). Since MCH can stimulate the 
release of intracellular calcium on binding to MCHRI, this receptor might have a 
role in regulating melanocyte function. Indeed, a recent study demonstrated that 
stimulation of cultured human melanocytes with MCH reduced a-MSH-induced 
increases in cyclic AMP production (Hoogduijn et al. 2002) suggesting that MCH 
can down regulate the actions of a-MSH, a well-known stimulator of melanogenesis, 
via MCHRI expressed on pigment cells (Hoogduijn et al. 2002). Recently, it has 
been reported that binding of MCH to MCHRI can be inhibited significantly by 
vitiligo patient IgG: the mean percentage of inhibition (± SD) of MCH binding was 
45% (± 4%) and 16% (± 14%), respectively, for vitiligo patient and control groups 
(p=0.001; Kemp et al. 2002). We were, therefore, interested in studying the effects 
that vitiligo patient MCHR1 autoantibodies might have upon the functioning of the 
receptor. As MCHRI is exposed on the cell surface, it could be accessible to 
autoantibodies that might adversely affect receptor function as in other autoimmune 
disorders (Section 5.1.1). This might disrupt normal pigment cell behaviour resulting 
in vitiligo. 
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5.1.3 Aim 
The present study aimed to examine the effects of MCHR1 autoantibodies from 
vitiligo patients on the functioning of the receptor by using fluorimetry to measure 
changes in intracellular calcium levels in response to MCH-stimulation in a CHO-K1 
cell line expressing MCHR1. Various in vitro studies have shown that CHO-K1 cells 
and human embryonic kidney (HEK)-293 cells expressing MCHR1 respond to MCH 
resulting in an increase in intracellular calcium levels, the inhibition of forskolin- 
stimulated cyclic AMP production, an increase in IP3 production and the activation 
of mitogen-activated protein kinase (Chambers et al. 1999; Lembo et al. 1999; Saito 
et al. 1999; Shimomura et al. 1999; Hawes et al. 2000; Verlaet et al. 2002). Initially, 
a CHO-K1 stable cell line expressing MCHR1 was established by transfection of 
CHO-K1 cells with pcMCHRI and then characterised by: flow cytometry with a 
rabbit polyclonal anti-human MCHR1 antibody, measuring changes in intracellular 
calcium levels in response to MCH-stimulation by fluorimetry and analysis of 
changes in forskolin-stimulated cyclic AMP levels in response to MCH-stimulation 
using a cyclic AMP immunoassay. The MCHRI-expressing cell line (CHO- 
MCHR1) was then used to investigate the effect of MCHR1 autoantibodies on 
receptor function. 
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5.2 Materials and Methods 
5.2.1 Transfection of CHO-KI cells with pcMCHR1 
A stable CHO-K1 cell line expressing MCHRI was isolated by transfection of CHO- 
K1 cells with pcMCHRI. A liposome-mediated transfection technique was 
employed using Tfx-50 reagent (Promega) prepared according to the manufacturer's 
instructions. Approximately 2x106 of CHO-K1 cells in 10 ml of CHO-K1 culture 
medium (Section 2.20) were plated in 10-cm dishes and the cells incubated at 37°C 
in a 5% CO2 incubator until 80% confluent. For each 10-cm dish, 6 ml of Nutrient 
Mixture F-12 (Ham) medium containing 2 mM L-glutamine was pre-warmed to 
37°C in a 5% CO2 incubator and then added to a sterile tube along with 20 gg of 
plasmid pcMCHRI. After mixing, 60 µl of Tfx-50 reagent was added, vortexed, and 
incubated at room temperature for 10-15 minutes. Subsequently, the medium was 
removed from the plated CHO-K1 cells and 6 ml of the Tfx-50 reagent /DNA mix 
was added to each dish before incubation at 37°C in a 5% CO2 incubator for 1 hour. 
Cells were overlaid with 10 ml of CHO-K1 culture medium, pre-warmed to 37°C in 
a 5% CO2 incubator, and incubated for a further 48 hours. To select transfected cells 
at the end of the incubation period, the cultures were re-plated in 10-cm dish at 1: 20, 
1: 200, and 1: 500 dilutions, in CHO-K1 culture medium containing 1 mg/ml 
geneticin sulphate. The cells were incubated at 37°C in a 5% CO2 incubator for 
approximately 2 weeks, with a change of culture media every 3-4 days. When 
complete cell death had occurred in any untransfected cells, the small islands of 
transfected cells remaining were removed from the dish, transferred to wells on a 
24-well plate and grown in CHO-K1 culture media containing geneticin sulphate at 
1 mg/ml. Each geneticin-resistant cell line was then analysed for expression of 
MCHR1 by flow cytometry. 
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5.2.2 Flow cytometry 
Flow cytometry was used to detect MCHR1 expression in pcMCHR1-transfected 
CHO-K1 cells. Forty-eight geneticin-resistant CHO-K1 cell lines were grown to 
confluence in T75 tissue culture flasks in CHO-K1 culture medium containing 
geneticin sulphate at I mg/ml. Subsequently, the cells were washed once with PBS 
and detached from the tissue culture flask using Cell Dissociation Solution (Sigma). 
After centrifugation at 1000 g for 5 minutes, cells were resuspended in PBS and 
100-µ1 samples aliquoted into LP4 tubes (Becton Dickinson Labware, Oxford, UK). 
One hundred microlitres of Reagent A of a CALTAG Fix and Perm® Cell 
Permeabilization Solution Kit (Caltag Laboratories, Burlingame, CA, USA) were 
added to the cells which were then incubated at room temperature for 20 minutes. 
Following incubation, the cells were washed with 2 ml of PBS containing 5% FBS 
and then centrifuged at 2000 g for 5 minutes. Expression of MCHR1 was detected 
using C11CB, a rabbit polyclonal anti-human MCHR1 antibody (Section 4.2.3). 
Three microlitres of a 1: 10 dilution of C11CB stock antiserum were added to the 
cells along with 50 µl of Reagent B of a CALTAG Fix and Perm® Cell 
Permeabilization Solution Kit (Caltag Laboratories) and the cells then incubated at 
4°C for 30 minutes. Cells were washed again with 2 ml PBS/5% FBS and then 
centrifuged at 2000 g for 5 minutes. Cells were resupended in 50 µl of Reagent B of 
a CALTAG Fix and Perm® Cell Permeabilization Solution Kit along with I µl of 
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG (Sigma) prior to 
incubation at 4°C for 30 minutes in the dark. After a final wash with 2 ml PBS/5% 
FBS, cells were analysed using a FACScan fluorescence activated cell sorter running 
CELLQuest acquisition and analysis software (Becton Dickinson, Oxford, UK). 
Overall, each cell line was analysed in duplicate in two separate experiments along 
with untransfected CHO-K1 cells. 
140 
5.2.3 Measurement of intracellular calcium levels by fluorimetry 
The changes in intracellular calcium levels in untransfected CHO-K1 cells and 
pcMCHR1-transfected CHO-K1 cells when stimulated with MCH were measured 
using the fluorescent dye FURA-2/AM (Merck Biosciences, Nottingham, UK). 
FURA-2/AM is able to transverse the lipid bilayer of cells and, once inside, esterases 
react with the dye to produce the active derivative FURA-2 that is not longer 
membrane-permeable. The active dye FURA-2 is then able to bind intracellular 
calcium that can then be measured by fluorimetry (Metcalfe et al. 1998). 
Initially, cells were plated out on glass coverslips in 6-well plates at 5.0x105 cells 
per well in 2.5 ml of CHO-K1 culture medium and incubated at 37°C in a 5% CO2 
incubator for two days. Geneticin sulphate was included in the medium for culturing 
CHO-MCHR1 cells at 1 mg/ml. Subsequently, intracellular calcium was measured 
using a Kontron SFM 25 fluorimeter (Kontron Instruments Ltd, Watford, UK) as 
previously described (Metcalfe et al. 1998). Monolayers of cells (used at around 
80% confluence by eye) were incubated with 4 pM FURA-2/AM for 30 minutes at 
37°C in a 5% CO2 incubator. The coverslips were then rinsed twice in balanced salt 
solution (BSS; 135 mM NaCl; 4.5 mM KCI; 1.5 mM CaC12; 0.5 mM MgC12; 5.6 mM 
glucose; 10 mM HEPES; pH 7.4) to remove any excess dye. The coverslips were 
placed across the diagonal of a 1-cm quartz cuvette being supported on a plastic 
bridge within the cuvette that allowed a small magnetic stirrer to be used to give a 
continuous mixing of the cuvette contents. 
To ensure that the cells were loaded with FURA-2/AM, they were excited at 335 
nm and emissions recorded between the wavelengths of 400 nm and 600 nm (Figure 
5.1). The emission scan peaked at around 490 nm, indicating that the cells had taken 
up the dye and were fluorescing at this wavelength. Changes in intracellular calcium 
levels were detected by measuring changes in relative fluorescence intensity versus 
time by exciting cells at 335 nm and collecting emissions at 490 nm. Once a stable 
baseline of fluorescence was obtained by adding BSS to the cells, acute bolus 
additions of MCH (Alpha Diagnostics, San Antonio, TX, USA) were made at 
different concentrations ranging from 10-12 M to 10'7 M along with an adenosine 
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Figure 5.1 Emission scan for FURA-2/AM-loaded CHO-KI cells. Cells cultured 
on glass coverslips were loaded with FURA-2/AM for 30 minutes and excess dye 
removed by washing with BSS. Cells were excited at 335 nm and emissions 
recorded between the wavelengths of 400 nm and 600 nm. Emissions are in arbitrary 
units of relative fluorescence intensity (y-axis). The emission scan peaks at 490 nm, 
indicating that cells have taken up the dye and are fluorescing at this wavelength. 
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derivative N6-(L-2-phenylisopropyl adenosine) (PIA) at 0.1 M (Sigma). In all cases, 
additions represented no more than 1-2% of the cuvette contents (3 ml). 
In all, eight pcMCHRI-transfected cell lines that were shown to express the 
receptor by flow cytometry were analysed for changes in intracellular calcium levels 
when stimulated with MCH. Each cell line was tested in duplicate in at least two 
experiments with untransfected CHO-K1 cells as a control. 
5.2.4 Measurement of cyclic AMP levels 
Eight pcMCHRI-transfected cell lines that were shown to express the receptor by 
flow cytometry were analysed for changes in forskolin-stimulated cyclic AMP levels 
in response to MCH-stimulation. Each cell line was tested in duplicate in three 
experiments with untransfected CHO-K1 cells as a control. Initially, cells were 
plated out in 24-well plates at 5x104 cells per well in 1 ml of CHO-K1 culture 
medium containing geneticin sulphate at 1 mg/ml and incubated at 37°C in a 5% CO2 
incubator for two days. Subsequently, the cells were washed once with PBS and 
incubated for 20 minutes at 37°C in 1 ml of cyclic AMP buffer comprising Hanks 
balanced salt solution (HBSS; 1.26 mM CaCl2; 5.53 mM KC1; 0.44 mM KH2P04; 
0.5 mM MgCi2; 0.41 mM MgS04 7H20; 4 mM NaHCO3; 0.30 mM NaH2P04; 5.6 
mM glucose; 222 mM sucrose; 20 mM HEPES; pH 7.2), 0.1 % bovine serum 
albumin (Sigma) and 1 mM 3-isobutyl-l-methyl xanthine (Sigma). At the end of the 
incubation period, the cells were treated with either 20 µM forskolin (Sigma) alone 
or 20 µM forskolin in combination with a series of concentrations of MCH (10"10 to 
10"7 M) and then incubated for 60 minutes at 37°C in "a 5% CO2 incubator. Finally, 
100 µl of supernatant were taken from each well and cyclic AMP levels measured 
using a cyclic AMP Immunoassay Kit (R &D Systems, Abingdon, UK) according to 
the manufacturer's instructions. 
One hundred microlitres of supernatant were diluted in 300 µl of assay buffer 
ED2 prior to running the assay. Standard dilutions (200,50,12.5,3.12 and 0.78 
pmoles/ml) of cyclic AMP were also made in ED2 assay buffer from the cyclic AMP 
standard stock (2000 pmoles/ml) provided with the kit. All reagents and samples 
were kept at room temperature before use. Each sample and standard was assayed in 
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duplicate. To a 96-well microtitre plate coated with a goat anti-rabbit polyclonal 
antibody, 100 µl of cyclic AMP standard dilutions (200,50,12.5,3.12 and 0.78 
pmoles/ml) and of diluted test sample were added. Fifty microlitres of cyclic AMP- 
conjugated to alkaline phosphatase were added to each well followed by 50 µl of 
rabbit polyclonal anti-cyclic AMP antibody. The 96-well plate was covered with an 
adhesive strip and incubated at room temperature for 2 hours on a horizontal 
microtitre plate shaker set at 500 rpm. At the end of the incubation, each well was 
decanted and washed three times with 200 µl of wash buffer. Two hundred 
microlitres of p-nitrophenyl phosphate substrate were applied to all wells and the 
plate incubated for one hour at room temperature on the bench without shaking. Fifty 
microlitres of stop solution were added to each well and the optical density of each 
well was measured immediately using a Labsystems Integrated EIA Management 
System (Labsystems, Basingstoke, UK) set to 405 nm. 
5.2.5 Patients and controls 
Immunoglobulin G samples from nine vitiligo patients (V1-V9; Table 2.1), that were 
previously shown to contain MCHRI autoantibodies in a radiobinding assay (Kemp 
et al. 2002), were analysed in this study. In addition, IgG from nine vitiligo patients 
(V10-V18; Table 2.1), which were previously shown not to contain MCHR1 
autoantibodies (Kemp et al. 2002), were analysed. In addition, IgG samples from 
ten SLE patients (1 male, 9 females; mean age: 45 years with range 21-55 years) and 
from 20 healthy individuals (9 males, 11 females; mean age: 32 years with range 24- 
48 years) with no history of either vitiligo or autoimmune disorders were analysed. 
5.2.6 Isolation of IgG from sera 
Immunoglobulin G was isolated from the serum samples by protein G Sepharose 4 
Fast Flow affinity column chromatography as described in Section 4.2.2. 
5.2.7 Cell culture 
Untransfected CHO-K1 cells and CHO-MCHR1 cells were grown in CHO-K1 
culture media as described in Section 2.20. The CHO-MCHR1 cells were grown in 
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culture media containing 1 mg/ml of geneticin sulphate. Initially, cells were plated 
out on glass coverslips in 6-well plates at 5.0x105 cells per well in 2.5 ml of CHO- 
K1 culture medium and incubated at 37°C in a 5% CO2 incubator for two days. Cells 
were then pre-incubated with either patient or control IgG as described below. 
5.2.8 Effect of different concentrations of vitiligo patient and control IgG on 
the functioning of MCHRI 
In order to study the effect of vitiligo patient autoantibodies on the functioning of the 
MCHR1, preliminary experiments were carried out to determine the minimum 
concentration of vitiligo patient IgG that can block the functioning of MCHRI. 
Initially, untransfected CHO-K1 cells and CHO-MCHRI cells were pre-incubated 
with different concentrations of IgG (10,50,100,150 and 300 µg/ml) from either 
vitiligo patients (n=4) or controls (n=4) for 30 minutes at 37°C in a 5% CO2 
incubator. Vitiligo patient IgGs used in the preliminary experiments contained 
MCHRI autoantibodies (Kemp et al. 2002). Intracellular calcium levels were 
measured in response to MCH (1012 to 10-7 M) and PIA (0.1 M) additions using 
fluorimetry as described in Section 5.2.3. Each IgG sample at each concentration 
was tested in duplicate in at least two separate experiments with untransfected CHO- 
KI cells as a control. 
5.2.9 Effect of vitiligo patient, SLE patient and control IgG on the functioning 
of MCHR1 
Once the minimum concentration of IgG (150 pg/ml) that could block the 
functioning of MCHRI was determined, further experiments were carried out to 
examine the effects of vitiligo patient IgG on the functioning of MCHRI. CHO- 
MCHRI cells were pre-incubated with 150 µg/ml of purified IgG from either vitiligo 
patients (n=18), SLE patients (n=10) or controls (n=20) for 30 minutes at 37°C in a 
5% CO2 incubator. Intracellular calcium levels were measured in response to MCH 
(1012 to 10-7 M) and PIA (0.1 M) addition using fluorimetry as described in Section 
5.2.3. Each sample was tested in duplicate in at least two separate experiments. 
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5.2.10 Statistical analysis 
The frequency of MCHR1 function-blocking autoantibodies was compared between 
vitiligo patients and controls using 2x2 contingency tables and chi-squared tests. 
Yates' correction was applied and p values <0.05 (two-tailed) were regarded as 
significant. 
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5.3 Results 
5.3.1 Transfection of CHO-K1 cells with pcMCHR1 
Plasmid pcMCHRI was transfected into CHO-K1 cells as described in Section 5.2.1. 
Transfected cells were selected by growth in culture media containing geneticin at 
1 mg/ml. Forty-eight geneticin-resistant cell lines were isolated and analysed by flow 
cytometry following staining with a rabbit polyclonal anti-human MCHR1 antibody 
C11CB, in order to confirm the expression of MCHR1. Receptor expression was 
also assessed by measuring changes in intracellular calcium levels following 
stimulation with MCH using fluorimetry and by measuring changes in forskolin- 
stimulated cyclic AMP levels in response to MCH-stimulation using a cyclic AMP 
immunoassay. 
53.2 Flow cytometry analysis 
Both untransfected CHO-K1 cells and 48 geneticin-resistant pcMCHRI-transfected 
cell lines were grown to confluence in T75. tissue culture flasks. The cells were 
permeabilized and receptor expression assessed by staining with rabbit polyclonal 
anti-human MCHR1 antibody C11CB and subsequently analysing the stained cells 
by flow cytometry as explained in Section 5.2.2. Each cell line was tested in 
duplicate in two separate experiments along untransfected CHO-K1 cells. The results 
revealed that 8/48 geneticin-resistant pcMCHRI-transfected CHO-K1 cell lines 
exhibited a higher level of MCHR1 expression compared to untransfected CHO-K1 
cells (Figure 5.2). Transfected cells did not show any expression of MCHRI if 
stained without permeabilization (data not shown) suggesting that antibody C1ICB 
recognises an intracellular epitope only present in MCHR1-expressing cells. 
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Figure -5.2 Flow cytometry analysis of CHO-KI cells transfected with 
pcMCHRI. Assessment of MCHRI expression was carried out by staining 
pcMCHRI-transfected cell lines and untransfected CHO-KI cells with rabbit 
polyclonal anti-human MCHRI antibody Cl ICB (primary antibody) and then with 
FITC-conjugated anti-rabbit IgG (secondary antibody). Subsequently, the stained 
cells were analysed by flow cytometry as described in Section 5.2.2. Results are 
shown for one transfected cell line and untransfected CHO-K I cells. The increasing 
fluorescence intensity (x-axis) indicates that the geneticin-resistant pcMCHRI- 
transfected CHO-KI cell line (green) stained with primary and secondary antibody 
exhibits a higher level of MCHRI expression compared to genetic in-resistant 
pcMCHRI-transfected CHO-KI cell line (blue) stained with secondary antibody 
alone and untransfected CHO-KI cells (red) stained with primary and secondary 
antibody. 
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5.3.3 Measurement of intracellular calcium in untransfected CHO-K1 cells 
and pcMCHR1-transfected CHO-K1 cells 
Changes in intracellular calcium levels in response to MCH additions were measured 
in untransfected CHO-KI cells and eight pcMCHRI-transfected CHO-KI cell lines 
using fluorimetry. Each cell line was tested in duplicate in at least two experiments 
and untransfected CHO-K1 cells were used as a control. All cells were exposed to 
BSS in order to determine the `noise' level of each experiment. Once the baseline 
was formed with BSS, the cells were exposed either to MCH (10"12 to 10'7 M), PIA 
(0.1 M) or MCH (10.12 to 10"7 M) in combination with PIA (0.1 M) and intracellular 
calcium levels measured. 
In all cells, the addition of MCH alone did not cause release of intracellular 
calcium, as there was no increase in relative fluorescence intensity (Figure 5.3 a and 
b). Intracellular calcium responses were only ever observed when cells were co- 
stimulated with MCH in combination with PIA, a pharmacological adenosine agonist 
that inhibits intracellular elevation of cyclic AMP (Figure 5.3 b). The agonist PIA 
alone did not elevate intracellular calcium levels (Figure 5.3 a and b). Increases in 
intracellular calcium levels were typically observed within the first 10 seconds of 
MCH and PIA addition to the transfected cells and responses returned to the original 
baseline level approximately 30 to 60 seconds thereafter (Figure 5.3 b). Changes in 
intracellular calcium responses were observed in pcMCHRI-transfected CHO-K1 
cells in response to MCH addition at different concentrations ranging from 10"12 to 
10"7 M along with PIA addition at 0.1 M concentration as indicated by an increase of 
relative fluorescence intensity (Figure 5.3 b). In contrast, changes in intracellular 
calcium levels were not observed in untransfected CHO-KI cells in response to the 
addition of MCH and PIA, as there was no increase of relative fluorescence intensity 
(Figure 5.3 a). These results clearly indicate that pcMCHRI-transfected CHO-KI 
cells express the receptor. 
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5.3.4 Measurement of cyclic AMP levels 
To assess the functional activity of MCHR1, the effect of stimulation by MCH on 
forskolin-stimulated cyclic AMP levels in both untransfected and pcMCHRI- 
transfected CHO-K1 cells was analysed. Eight pcMCHRI-transfected CHO-K1 cell 
lines were examined with each cell line being tested in duplicate in three 
experiments with untransfected CHO-K1 cells as a control. Both untransfected 
CHO-K1 cells and pcMCHR1-transfected CHO-K1 cells were incubated with either 
20 pM forskolin or 20 µM forskolin in combination with MCH at different 
concentrations (10'10 to 10"7 M). Cyclic AMP levels were then measured using a 
cyclic AMP Immunoassay Kit as described in Section 5.2.4. Forskolin directly 
activated adenylate cyclase to produce an increase in cyclic AMP in pcMCHRI- 
transfected CHO-KI cells (Figure 5.4). Co-incubation of pcMCHRI-transfected 
CHO-K1 cells with forskolin and MCH inhibited forskolin-stimulated cyclic AMP 
production in a concentration-dependent manner (Figure 5.4). A maximum inhibition 
of cyclic AMP production was observed at 10"7 M MCH (Figure 5.4). In contrast, 
untransfected CHO-K1 cells did not show any inhibition of cyclic AMP levels when 
the cells were co-incubated with forskolin (20 µM) and MCH at different 
concentrations (10-10 to 10"7 M) (Figure 5.5). 
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Figure 5.4 Effect of MCH on forskolin-stimulated cyclic AMP levels in 
pcMCHR1-transfected CHO-K1 cells. Forskolin was used as a positive control at 
a concentration of 20 pM. The cells were incubated with either forskolin alone or 
forskolin in combination with MCH at different concentrations (10"10 to 10'7 M). 
Forskolin directly activated adenylate cyclase to produce an increase in cyclic AMP 
in pcMCHRI-transfected CHO-K1 cells. Co-incubation of pcMCHR1-transfected 
CHO-K1 cells with forskolin and MCH inhibited forskolin-stimulated cyclic AMP 
production in a concentration-dependent manner. A maximum inhibition of cyclic 
AMP production was observed at 10"7 M MCH. The results show the mean values (± 
SE) of duplicate samples in one experiment for one pcMCHR1-transfected CHO-KI 
cells. 
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Figure 5.5 Effect of MCH on forskolin-stimulated cyclic AMP levels in 
untransfected CHO-K1 cells. Forskolin was used as a positive control at a 
concentration of 20 µM. The cells were incubated with either forskolin alone or 
forskolin in combination with MCH at different concentrations (10.10 to 10'7 M). 
Forskolin directly activated adenylate cyclase to produce an increase in cyclic AMP 
in untransfected CHO-KI cells. Co-incubation of untransfected CHO-K1 cells with 
forskolin and MCH did not inhibit forskolin-stimulated cyclic AMP production. The 
results show the mean values (± SE) of duplicate samples in one experiment for one 
untransfected CHO-K1 cells. 
154 
Cells without Forskoln Fotskolin (20 µM) Forskoln (20 µ! U Forskoln (20 µM) Forskoln (20 µM) 
forskolinand (20ph1) +NICH(1010h'I) +MCH(le ND +MCH(104NO +MCH(10'M) 
MCH 
5.3.5 Effect of different concentrations of vitiligo patient and control IgG on 
the functioning of MCHR1 
Preliminary experiments were carried out to determine the minimum concentration 
of vitiligo patient IgG that blocked the functioning of MCHR1. For this, both 
untransfected CHO-K1 cells and CHO-MCHR1 cells were pre-incubated with either 
control IgG (n=4) or vitiligo patient IgG (n=4) at different concentrations. Changes 
in intracellular calcium levels in response to MCH and PIA addition were then 
measured using fluorimetry. Each IgG sample at each concentration was tested in 
duplicate in at least two separate experiments with untransfected CHO-K1 cells as a 
control. 
None of the untransfected CHO-K1 cells pre-incubated with different 
concentrations of either control or vitiligo patient IgG released any intracellular 
calcium in response to MCH and PIA addition, as there was no increase in relative 
fluorescence intensity (Figures 5.6 and 5.7). In contrast, when CHO-MCHRI cells 
were pre-incubated with different concentrations of control IgG, there was a release 
of intracellular calcium in response to MCH and PIA addition, as there was an 
increase of relative fluorescence intensity (Figure 5.8). 
Pre-incubation of CHO-MCHRI cells with vitiligo patient IgG at 10,50 and 100 
µg/m1 resulted in the release of intracellular calcium in response to MCH and PIA 
addition, as there was an increase of relative fluorescence intensity (Figure 5.9 a to 
c). In contrast, CHO-MCHRI cells did not release any intracellular calcium in 
response to MCH and PIA addition when the cells were pre-incubated with vitiligo 
patient IgG at concentration of 150 and 300 µg/ml, as there was no increase of 
relative fluorescence intensity (Figure 5.9 d and e). These results indicated that pre- 
incubation of CHO-MCHRI cells with vitiligo patient IgG at concentrations of 150 
and 300 µg/ml blocked the functioning of MCHR1. 
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Figure 5.6 Effect of different concentrations of control IgG on untransfected 
CHO-KI cells. Measurement of intracellular calcium levels in response to MCH in 
untransfected CHO-K1 cells pre-incubated with different concentrations of control 
IgG at (a) 10 pg/ml (b) 50 gg/ml (c) 100 µg/ml (d) 150 pg/ml (e) 300 pg/ml. The 
results are shown for one control IgG sample. Each concentration of IgG was tested 
in duplicate in at least two experiments. There was no release of intracellular 
calcium in untransfected CHO-K1 cells pre-incubated with different concentrations 
of IgG (10,50,100,150 and 300 pg/ml) in response to MCH (1012 to 10 M) and 
PIA (0.1 M) additions, as there was no increase in relative fluorescence intensity. 
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Figure 5.7 Effect of different concentrations of vitiligo patient IgG on 
untransfected CHO-KI cells. Measurement of intracellular calcium levels in 
response to MCH in untransfected CHO-K1 cells pre-incubated with different 
concentrations of vitiligo patient IgG at (a) 10 pg/ml (b) 50 µg/ml (c) 100 gg/ml (d) 
150 pg/ml (e) 300 µg/ml. The results shown are for one vitiligo patient IgG sample. 
Each concentration of IgG was tested in duplicate in at least two experiments. There 
was no release of intracellular calcium in untransfected CHO-K1 cells pre-incubated 
with different concentrations of IgG (10,50,100,150 and 300 µg/ml) in response to 
MCH (1012 to 10-7 M) and PIA (0.1 M) additions as there was no increase in relative 
fluorescence intensity. 
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Figure 5.8 Effect of different concentrations of control IgG on the functioning of 
MCHR1 in CHO-MCHR1 cells. Measurement of intracellular calcium levels in 
response to MCH in CHO-MCHRI cells pre-incubated with different concentratiöns 
of control IgG at (a) 10 µg/ml (b) 50 µg/ml (c) 100 µg/ml (d) 150 µg/ml (e) 300 
pg/ml. The results shown are for one control IgG sample. Each concentration of IgG 
was tested in duplicate in at least two experiments. There was a release of 
intracellular calcium in CHO-MCHR1 cells pre-incubated with different 
concentrations of IgG (10,50,100,150 and 300 µg/ml) in response to MCH (1012 to 
10-7 M) and PIA (0.1 M) additions as indicated by the increase in relative 
fluorescence intensity. 
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Figure 5.9 Effect of different concentrations of vitiligo patient IgG on the 
functioning of MCHR1 in CHO-MCHR1 cells. Measurement of intracellular 
calcium levels in response to MCH in CHO-MCHR1 cells pre-incubated with 
different concentrations of vitiligo patient IgG at (a) 10 µg/ml (b) 50 µg/ml (c) 100 
pg/ml (d) 150 pg/ml (e) 300 pg/ml. The results shown are for one vitiligo patient 
IgG sample. Each concentration of IgG was tested in duplicate in at least two 
experiments. There was a release of intracellular calcium in CHO-MCHR1 cells pre- 
incubated with different concentrations of IgG (10,50 and 100 µg/ml) in response to 
MCH (1012 to 10-7 M) and PIA (0.1 M) additions as indicated by the increase in 
relative fluorescence intensity. There was no release of intracellular calcium in 
CHO-MCHRI cells pre-incubated with different concentrations of IgG (150 and 300 
pg/ml) in response to MCH (1012 to 10-7 M) and PIA (0.1 M) additions, as there was 
no increase in relative fluorescence intensity. 
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5.3.6 Effect of vitiligo patient and control IgG on the functioning of MCHR1 
Once the minimum concentration of IgG required to block the functioning of 
MCHR1 was determined as 150 µg/ml, IgG samples from eighteen vitiligo patients 
and twenty healthy controls were tested for their ability to block the functioning of 
MCHR1. CHO-MCHRI cells were pre-incubated with IgG at 150 gg/ml and 
changes in intracellular calcium levels in response to MCH and PIA additions were 
measured by fluorimetry. Each IgG sample was tested in duplicate in at least two 
experiments. 
Of twenty control IgG samples analysed, none blocked the release of intracellular 
calcium in response to MCH and PIA additions, as there was an increase of relative 
fluorescence intensity (Figure 5.10; Table 5.1). Of eighteen vitiligo patient IgG 
samples tested, eight had no effect upon the release of intracellular calcium in 
response to MCH and PIA additions, as there was an increase in relative 
fluorescence intensity (Figure 5.11; Table 5.2). In contrast, 10/18 vitiligo patient IgG 
samples blocked the release of intracellular calcium in response to MCH and PIA 
additions, as there was no increase in relative fluorescence intensity (Table 5.2; 
Figure 5.12). These results indicated that 10/18 (56%) of the vitiligo patient IgG 
samples tested were able to block the functioning of MCHR1. Seven (VI to V4 and 
V10 to V12) of the vitiligo patient IgGs that blocked MCHR1 function were able to 
do so at a concentration of 150 gg/ml (Table 5.2), and three vitiligo patient IgGs (V5 
to V7) blocked MCHR1 function only at a concentration of 300 gg/ml (Table 5.2). 
Among the nine vitiligo patients that contained MCHR1 binding autoantibodies as 
measured in a radiobinding assay (Kemp et al. 2002), seven (VI to V7; Table 5.2) 
contained MCHR1 autoantibodies that blocked receptor function. In addition, of nine 
patients that were previously shown not to contain MCHR1 binding autoantibodies 
(Kemp et al. 2002), three (V 10 to V12; Table 5.2) were demonstrated to have 
MCHR1 function blocking autoantibodies. 
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Figure 5.10 Effect of control IgG on the functioning of MCHR1 in CHO- 
MCHR1 cells. Measurement of intracellular calcium levels in response to MCH in 
CHO-MCHR1 cells pre-incubated with control IgG at 150 µg/ml. The results shown 
are for one control IgG sample. Each IgG sample was tested in duplicate in at least 
two experiments. Results (a) and (b) represent one control IgG sample in duplicate. 
Results (c) and (d) represent the same sample in duplicate in a separate experiment. 
There was a release of intracellular calcium in CHO-MCHR1 cells pre-incubated 
with control IgG in response to MCH (1012to 10-7 M) and PIA (0.1 M) additions, as 
indicated by the increase in relative fluorescence intensity. 
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Table 5.1 Effect of control IgG on the functioning of MCHR1. 
Sample 
Concentration 
of IgG used 
(µg/ml) 
Number of 
times sample 
tested 
Number of 
times 
intracellular 
calcium 
released after 
pre-incubation 
with IG 
IgG blocking 
MCHR1 
function 
CI 150 4 4 No 
C2 150 4 3 No 
C3 150 4 3 No 
C4 150 4 4 No 
C5 150 .4 4 No 
C6 150 4 4 No 
C7 150 4 3 No 
C8 150 4 3 No 
C9 150 4 3 No 
CIO 150 4 3 No 
Cll 150 4 3 No 
C12 150 4 3 No 
C13 150 4 4 No 
C14 150 4 4 No 
C15 150 4 4 No 
C16 150 4 4 No 
C17 150 4 4 No 
C18 150 4 4 No 
C19 150 4 4 No 
C20 150 4 4 No 
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Figure 5.11 Effect of vitiligo patient IgG on the functioning of MCHRI in CHO- 
MCHR1 cells. Measurement of intracellular calcium levels in response to MCH in 
CHO-MCHRI cells pre-incubated with vitiligo patient IgG at 150 µg/ml. The results 
shown are for one vitiligo patient IgG sample. Each IgG sample was tested in 
duplicate in at least two experiments. Results (a) and (b) represent one vitiligo IgG 
sample in duplicate. Results (c) and (d) represent the same sample in duplicate in a 
separate experiment. There was a release of intracellular calcium in CHO-MCHRI 
cells pre-incubated with vitiligo patient IgG in response to MCH (1012 to 10 
7 M) 
and PIA (0.1 M), additions as indicated by increase in relative fluorescence intensity. 
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Table 5.2 Effect of vitiligo IgG on the functioning of MCHR1. 
IgG 
Sample' 
Concentration 
of IgG used 
(µg/ml) 
Number of 
times sample 
tested 
Number of 
times 
intracellular 
calcium 
released after 
pre-incubaion 
with IG 
IgG blocking 
MCHRI 
function 
V1 150 4 0 Yes 
V2 150 4 0 Yes 
V3 150 4 1 Yes 
V4 150 4 0 Yes 
V52 150 4 3 No 
300 4 0 Yes 
V62 150 4 3 No 
300 4 1 Yes 
V72 150 4 2 Yes/No 
300 4 0 Yes 
V8 150 4 4 No 
V9 150 4 4 No 
V10 150 4 0 Yes 
Vii 150 4 0 Yes 
V12 150 4 0 Yes 
V13 150 4 3 No 
V14 150 4 4 No 
V15 150 4 4 No 
V16 150 4 3 No 
V17 150 4 4 No 
V18 150 4 4 No 
'IgG from vitiligo patients containing MCHRI autoantibodies (V1 to V9); IgG from 
vitiligo patients negative for autoantibody reactivity to MCHR1 (V10 to V18). 
2Vitiligo patient IgG samples that blocked MCHR1 function only at an IgG 
concentration of 300 pg/ml. 
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Figure 5.12 Effect of vitiligo patient IgG on the functioning of MCHR1 in CHO- 
MCHR1 cells. Measurement of intracellular calcium levels in response to MCH in 
CHO-MCHRI cells pre-incubated with vitiligo patient IgG at 150 µg/ml. The results 
shown are for one vitiligo patient IgG sample. Each IgG sample was tested in 
duplicate in at least two experiments. Results (a) and (b) represent one vitiligo IgG 
sample in duplicate. Results (c) and (d) represent the same sample in duplicate in a 
separate experiment. There was no release of intracellular calcium in CHO-MCHR1 
cells pre-incubated with vitiligo patient IgG in response to MCH (1012 to 10 
7 M) 
and PIA (0.1 M) additions as there was no increase in relative fluorescence intensity. 
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5.3.7 Effect of SLE patient IgG on the functioning of MCHR1 
Systemic lupus erythematosus patient IgG samples were used as controls. These 
individuals generally display a wide variety of autoantibody reactivity. Ten SLE 
patient IgG samples were tested for MCHR1 function blocking reactivity. Each 
sample was tested in duplicate in at least two separate experiments (Table 5.3). 
CHO-MCHR1 cells were pre-incubated with SLE patients IgG at 150 µg/ml. 
Changes in intracellular calcium levels in response to MCH and PIA additions were 
then measured using fluorimetry. None of SLE patients IgG samples tested were 
able to block the release of intracellular calcium in response to MCH and PIA 
additions, as there was an increase in relative fluorescence intensity (Figure 5.13). 
These results demonstrate that SLE IgG do not block the functioning of MCHR1 and 
show that MCHR1 function blocking autoantibodies are specific to patients with 
vitiligo. 
5.3.8 Comparison of the frequency of MCHR1 function blocking 
autoantibodies in patient and control groups 
Overall, MCHR1 function blocking IgGs were found at a significantly increased 
frequency in the vitiligo patients compared with healthy controls (p=0.0004; Table 
5.4). Comparison of healthy controls with vitiligo patient IgG samples containing 
MCHRI autoantibodies indicated that there was a significantly increased frequency 
of MCHR1 function blocking IgGs in the vitiligo patient group (p<0.0001; Table 
5.4). Similarly, when comparing healthy controls and vitiligo patient IgG samples 
not containing MCHRI autoantibodies, a significant increase in the frequency of 
function blocking IgGs was noted in the vitiligo patient cohort (p=0.0387; Table 
5.4). In contrast, there was no apparent difference in the frequency of MCHR1 
function blocking autoantibodies in SLE patients compared with controls (Table 
5.4). 
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Table 5.3 Effect of SLE IgG on the functioning of MCHR1. 
Number of 
Concentration Number of times IgG blocking 
Sample of IgG used times sample intracellular MCHR1 
(µg/ml) tested calcium function 
released after 
pre-incubation 
with IG 
S1 150 4 4 No 
S2 150 4 4 No 
S3 150 4 4 No 
S4 150 4 4 No 
S5 150 4 4 No 
S6 150 4 4 No 
S7 150 4 4 No 
S8 150 4 3 No 
S9 150 4 3 No 
S 10 150 4 3 No 
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Figure 5.13 Effect of SLE patient IgG on the functioning of MCHR1 in CHO- 
MCHR1 cells. Measurement of intracellular calcium levels in response to MCH in 
CHO-MCHR1 cells pre-incubated with SLE patient IgG at 150 gg/ml. The results 
shown are for one SLE patient IgG sample. Each IgG sample was tested in duplicate 
in at least two experiments. Results (a) and (b) represent one SLE IgG sample in 
duplicate. Results (c) and (d) represent the same sample in duplicate in a separate 
experiment. There was a release of intracellular calcium in CHO-MCHRI cells pre- 
incubated with SLE patient IgG in response to MCH (1012 to 10-7 M) and PIA (0.1 
M) additions as there was an increase in relative fluorescence intensity. 
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Table 5.4 Summary of results of the effects of IgG on the functioning of 
MCHR1. 
IgG samples Number of 
samples tested 
Number of samples 
blocking MCHRI 
function 
p value3 
Total vitiligo 18 10 0.0004 
Vitiligol 9 7 <0.0001 
Vitiligo2 9 3 0.0387 
Controls 20 0 - 
SLE 10 0 - 
'IgG samples from vitiligo patients containing MCHRI autoantibodies (Kemp et al. 
2002). 
2IgG samples from vitiligo patients that do not contain MCHR1 autoantibodies 
(Kemp et at 2002). 
3The frequency of MCHR1 function-blocking autoantibodies was compared between 
patient and control groups using 2x2 contingency tables and chi-squared tests. 
Yates' correction was applied and p values <0.05 (two-tailed) were regarded as 
significant. 
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5.4 Discussion 
In the current study, initially a stable CHO-K1 cell line has been established that 
expresses functional MCHRI. The results of flow cytometry analysis clearly showed 
the expression of MCHR1 in pcMCHRI-transfected CHO-K1 cells. To verify if the 
receptor was functional, the effects of MCH on forskolin-stimulated cyclic AMP 
production and calcium signalling pathways were analysed. 
Intracellular calcium levels were increased in pcMCHRI-transfected CHO-K1 
cells following the addition of MCH at different concentrations (10.12 to 10"7 M) and 
PIA (0.1 M). In contrast, the untransfected cells did not release any intracellular 
calcium in response to MCH and PIA additions. Although previous in vitro studies 
demonstrated the release of intracellular calcium by MCH addition alone in MCHR1 
transfected cells (Saito et al. 1999; Chambers et al. 1999; Hawes et al. 2000; 
Hoogduijn et al. 2002; Verlaet et al. 2002), in the current study, the transfected cells 
only responded to MCH in combination with PIA, a very specific adenosine agonist 
that inhibits the activation of adenylate cyclase and elevation of cyclic AMP. These 
findings essentially confirm the co-operativity first reported by Yanagita et al. 
(1996) for adenosine and TSH in studies on individual human thyroid cells. Later, 
Metcalfe et al. (1998) followed the same approach in CHO-K1 cells expressing the 
TSHR and demonstrated a calcium response to TSH when using PIA to inhibit the 
TSH-stimulated elevation of cyclic AMP. In their study, the majority of cells gave a 
small increase in calcium in response to TSH alone, and this was greatly enhanced 
by prior addition of PIA illustrating mutual co-operativity in the behaviour of these 
agonists. Recently, a similar method was used to measure intracellular calcium levels 
in human keratinocytes in response to a-MSH, MSH 11-13 KPV and ACTH (Elliott 
et al. 2004). Keratinocytes only responded and released intracellular calcium 
following the addition of PIA along with the peptide. 
As previously reported (Chambers et al. 1999; Lembo et al. 1999; Saito et al. 
1999; Shimomura et al. 1999; Hawes et al. 2000; Verlaet et al. 2002), forskolin- 
stimulated cyclic AMP production was decreased in MCHR1-expressing cells, in 
response to MCH. This is in contrast to the effects of a-MSH that acts via the 
MC-1R to increase the production of cyclic AMP and subsequently melanogenesis 
(Hunt et al. 1994). The down-regulation of the cyclic AMP pathway by MCH in 
transfected cells is, therefore, antagonistic to the actions of a-MSH on 
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melanogenesis. In this respect, MCH resembles the agouti protein that acts as an 
inhibitor of melanogenesis in rodents by blocking the action of a-MSH (Lu et al. 
1994; Graham et al. 1997). The MCH could function in a similar way to regulate 
melanogenesis in human melanocytes, but this has yet to be determined. 
Taken together, the 'functional studies indicate that the pcMCHRI-transfected 
CHO-K1 cells express the receptor. The stable cell line was used for further studies 
to investigate whether the MCHRI antibodies in vitiligo patients have any effects 
upon the functioning of the receptor. 
Vitiligo patient IgGs that blocked the functioning of MCHRI were detected in 
56% (10/18) of the vitiligo patient IgGs tested. Overall, when comparing healthy 
controls and vitiligo patients, MCHRI function blocking IgGs were found at a 
significantly increased frequency in the vitiligo patient group (p=0.0004). 
Comparison of healthy controls and vitiligo patients containing MCHR1 
autoantibodies (Kemp et al. 2002), indicated that there was a significantly increased 
frequency of receptor function blocking IgGs in the vitiligo patient group 
(p<0.0001). Similarly, the comparison of healthy controls and vitiligo patients that 
did not to contain MCHR1 autoantibodies (Kemp et al. 2002), demonstrated that 
there was a significantly increased frequency of function blocking IgGs in the 
vitiligo patient group (p=0.0387). 
Among the nine vitiligo patients that contained MCHRI binding autoantibodies 
as measured in a radio-binding assay (Kemp et al. 2002), seven contained MCHR1 
autoantibodies that blocked receptor function. In the two patients that only contained 
receptor-binding autoantibodies, it is probable that the MCHRI autoantibodies bind 
at a site on the receptor that has no effect upon its functionality. In addition, of nine 
patients that were previously shown not to contain MCHRI binding autoantibodies 
(Kemp et al. 2002), three were demonstrated to have MCHRI function blocking 
autoantibodies. The existence of antibodies that appear to inhibit receptor function 
but do not bind MCHR1 could be due to a number of reasons. It may be that the in 
vitro-translated protein used in the radio-binding assay (Kemp et al. 2002) fails to 
bind these antibodies due to incorrect folding of the molecule, the absence of a 
correct pattern of glycosylation or may simply reflect differential detection 
sensitivity in the two assays. This is not unprecedented, as similar findings have been 
documented for TSAb. In one study, one third of Graves' disease sera positive in a 
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TSH binding inhibiting immunoglobulin assay (TBII) failed to bind to in vitro- 
translated TSH receptor (Morgenthaler et al. 1999). 
None of the control IgG samples or SLE patient IgGs analysed was able to block 
the function of MCHR1, indicating that MCHR1 function blocking autoantibodies 
are specific to patients with vitiligo and are not present in patients with another 
autoimmune disease. 
Similar to our finding that MCHRI autoantibodies in vitiligo patients can block 
the function of MCHR1, non-stimulatory TBAb can prevent TSH action resulting in 
hypothyroidism (Arikawa et al. 1985; McKenzie and Zakarija 1992; Kosugi et al. 
1993). In Addison's disease, patient IgGs can block the in vitro action of ACTH on 
adrenal growth and cortisol production by binding to its receptor (Wulffraat et al. 
1989). Furthermore, autoantibodies in myasthenia gravis patients directed against the 
acetylcholine receptor block the acetylcholine-binding site and provoke accelerated 
receptor degradation (Hara et al. 1993; Eymard and Chillet 1997; Hoedemaekers et 
al. 1997; Ferrero et al. 1997; Fabien et al. 2001). In addition, it has been 
demonstrated that serum immunoglobulin in patients with pernicious anaemia can 
block the gastrin-stimulation of acid secretion and it has been suggested that this 
blocking activity is mediated by competition with gastrin for the surface receptors on 
parietal cells (de Aizpurua et al. 1985; Burman et al. 1989). 
Here, we have shown that MCHRI autoantibodies in vitiligo patients can have a 
blocking effect upon the functioning of the receptor. However, the effect of MCHR1 
autoantibodies on the behaviour of melanocytes has yet to be determined and the 
relevance of MCHRI autoantibodies to the aetiology of vitiligo needs to be further 
investigated. 
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6 An Investigation into the Immunological Functions of 
Melanin-Concentrating Hormone Receptor 1 
Autoantibodies 
6.1 Introduction 
Although the exact role of anti-melanocyte autoantibodies in the pathogenesis of 
vitiligo has not been determined, possible mechanisms by which they can destroy 
pigment cells have been investigated including complement activation and ADCC. 
The complement system has been described in Section 1.4.4.2 and examples of 
autoimmune disorders in which complement can have a pathogenic role have been 
discussed previously (Section 1.4.4.2). Complement-fixing autoantibodies that bind 
to melanocytes have been reported in patients with mucocutaneous candidiasis, 
multiple endocrine insufficiencies, alopecia areata and vitiligo (Hertz et al. 1977). 
However, these autoantibodies were not found in patients with isolated vitiligo 
(Howanitz et al. 1981). Deposition of complement component C3 can occur in the 
basement membrane of vitiliginous skin (Uda et al. 1984) and the sera of vitiligo 
patients can cause direct cytotoxic damage of cultured melanocytes by complement 
fixation (Norris et al. 1988b). In addition, a reduced expression of the membrane 
regulators of complement activation in both lesional and perilesional keratinocytes 
and melanocytes has been reported, possibly indicating an increased vulnerability of 
these cells to autologous complement attack (van den Wijngaard et al. 2002). The 
mechanism of ADCC and examples of autoimmune disorders in which this can play 
a pathogenic role are discussed in Section 1.4.4.3. With respect to vitiligo, there is 
evidence that the sera of patients with the disease can induce cultured human 
melanocytes to detach from their cell matrix and can cause direct cytotoxic damage 
by ADCC (Norris et al. 1988b). 
6.2 Aim 
The aim of the current study was to examine the immunological reactivities of 
autoantibodies to MCHRI using a stable CHO-KI cell line expressing the receptor. 
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The ability of MCHR1 autoantibodies to fix complement and mediate ADCC were 
assessed by flow cytometry and in chromium-release assays, respectively. 
6.3 Materials and Methods 
6.3.1 Patients and controls 
In the complement-fixation assay, sera from the following subjects were analysed: 
nine vitiligo patients (V1-V9; Table 2.1), that were previously shown to contain 
MCHRI autoantibodies in a radio-binding assay (Kemp et al. 2002), nine vitiligo 
patients (V10-V18; Table 2.1), that were previously shown not to contain MCHR1 
autoantibodies (Kemp et al. 2002) and eighteen healthy controls (7 males, 11 
females; mean age: 34 years with range 24-48 years) with no history of either vitiligo 
or autoimmune disorders. In the ADCC assay, sera from nine vitiligo patients (V1- 
V9; Table 2.1), that were previously shown to contain MCHR1 autoantibodies 
(Kemp et al. 2002), and three vitiligo patients (V10-V12; Table 2.1), that were 
previously shown not to contain MCHRI autoantibodies (Kemp et al. 2002) were 
analysed. Eleven healthy controls (4 males, 7 females; mean age: 36 years with 
range 24-48 years) with no history of either vitiligo or autoimmune disorders were 
also investigated. 
6.3.2 Specific antisera 
Rabbit polyclonal anti-CHO-K1 antibody was kindly provided by Professor B. P. 
Morgan (Department of Biochemistry and Immunology, University of Wales 
College of Medicine, Cardiff, UK) and was used as a positive control in the 
complement-fixation assay. 
6.3.3 Complement-fixation 
Untransfected CHO-K1 cells and the CHO-MCHR1 cell line were grown to 
confluence in T75 tissue culture flasks in CHO-KI culture medium (Section 2.20). 
Geneticin sulphate was included in the medium for culturing CHO-MCHRI cell line 
at 1 mg/ml. Subsequently, the cells were washed once with PBS and detached from 
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the tissue culture flask using Cell Dissociation Solution. After centrifugation at 1000 
g for 5 minutes, cells were resuspended in 1 ml of PBS and 100-µ1 samples were 
aliquoted into LP4 tubes. Cells were then incubated with either 5 µl of anti-CHO-K1 
antibody (positive control), 10 µl of control sera (n=18) or 10 µl of vitiligo patient 
sera (n=18) at 4°C for 30 minutes. Before use, serum samples were heat-inactivated 
by incubation at 56°C for 30 minutes. Cells were washed twice with 2 ml of PBS and 
then incubated with 50 pl of human complement C7-deficient serum (Sigma), which 
had been diluted 1: 5 in veronal-buffered saline (Sigma), for 15 minutes at 37°C in a 
5% CO2 incubator. Cells were then washed twice with 2 ml of PBS and resuspended 
in 50 µl of PBS with 1 µl goat anti-human C3 antibody (ICN Biomedicals Inc, 
Aurora, OH, USA) for 30 minutes at 4°C. At the end of the incubation period, the 
cells were washed twice with 2 ml of PBS and resuspended in 50 µ1 of PBS with 1 µl 
of FITC-conjugated rabbit anti-goat IgG antibody (Sigma) for 30 minutes at 4°C. 
Following the final wash with 2 ml of PBS, cells were analysed for C3 deposition 
using a FACScan fluorescence activated cell sorter running CELLQuest acquisition 
and analysis software. Overall, each serum sample was tested in duplicate in two 
separate experiments with untransfected CHO-K1 cells and the CHO-MCHR1 cell 
line. In total, eighteen vitiligo patient sera and eighteen control sera were tested. 
6.3.4 Purification of peripheral blood mononuclear cells 
Ten millilitres of blood from a normal human donor were collected over heparin. 
The blood was layered over 6 ml of Lymphoprep (Nycomed Pharma AS, Oslo, 
Norway) and centrifuged at 2800 rpm for 20 minutes. Peripheral blood mononuclear 
cells (PBMC) present at the interface were collected and washed twice with PBS by 
centrifugation at 2000 rpm for 5 minutes. The pellet of PBMC was resuspended in 2 
ml of CHO-K1 cell culture medium (Section 2.20) and the cells counted in a 
haemocytometer before making any finäl adjustments to obtain the required 
concentration of cells. 
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6.3.5 Antibody-dependent cell-mediated cytotoxicity 
The CHO-MCHR1 cell line were grown to confluence in T75 tissue culture flasks in 
CHO-K1 culture medium (Section 2.20) containing geneticin sulphate at 1 mg/ml. 
Subsequently, the cells were washed once with PBS and detached from the tissue 
culture flask after incubation for 5 minutes at 37°C in a 5% C02 incubator with 
trypsin/EDTA. After centrifugation at 1000 g for 5 minutes, cells were resuspended 
in PBS at a concentration of 106 cells/ml. The cells were then labelled with 7.4 MBq 
of chromium-51 (51Cr; Amersham Pharmacia Biotech) by incubation at 37°C for 2 
hours in a 5% CO2 incubator. 51Cr labelled cells were washed twice with PBS and 
diluted to 105 cells/ml in CHO-K1 cell culture medium (Section 2.20). Fifty 
microlitres (5000 cells) of cells were then added to each well of a round-bottomed 
96-well microtitre plate (Nalge Nunc International). To the wells, either 100 µ1 of 
CHO-K1 cell culture medium, 100 Al of control sera (n=l1) or 100 µl of vitiligo 
patient sera (n=12) were added in triplicate and the plate incubated for 1 hour at 
37°C in a 5% C02 incubator. Sera were heat-inactivated by incubation at 56°C for 30 
minutes and diluted at 1: 10 in CHO-KI cell culture medium before use. Overall, 
each serum sample was tested in triplicate in at least two separate experiments. 
The plate was then centrifuged at 1000 g for 5 minutes and the supernatant 
removed from each well. A 150-µl aliquot of PBMC (Section 7.3.4) suspension 
containing 4x105 cells/ml was added in to each well. The same normal donor was 
used in all experiments to ensure consistency. The plate was incubated for 4 hours at 
37°C in a 5% CO2 incubator after which it was centrifuged at 1000 g for 5 minutes. 
One hundred and fifty microlitres of the supernatant were removed and the release of 
51Cr was counted in an LKB 1470 Rackgamma liquid scintillation analyser (Wallac 
UK). Spontaneous chromium-release was estimated from incubation of cells with 
CHO-K1 cell culture medium alone. Maximum chromium-release was estimated 
from incubation of cells with 100% Triton X-100. Percentage lysis by each serum 
sample was expressed as: 
Sample 51Cr release value - Spontaneous 
51Cr release value 
% Lysis =X 100 
Maximum S'Cr release value - Spontaneous 
S? Cr release value 
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Percentage lysis values above the set arbitary level of 20% are considered as a 
positive indication of ADCC in this assay (Metcalfe et al. 1997). Differences in the 
percentage lysis as' a measure of ADCC activity in control and vitiligo patient 
samples were analysed using the Student's t test and p values less than 0.05 (two- 
tailed) were regarded as significant. 
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6.4 Results 
6.4.1 Complement-fixation by MCHR1 autoantibodies in vitiligo patients 
The complement-fixing activity of MCHRI autoantibodies in vitiligo patients was 
tested on the CHO-MCHR1 cell line and untransfected CHO-K1 cells by flow 
cytometry. Both the CHO-MCHRI cell line and untransfected CHO-K1 cells were 
incubated with the serum sample to be tested before the addition of human serum 
containing all complement factors except C7. If MCHR1 autoantibodies fix 
complement, a higher intensity of C3 deposits would be detected by flow cytometry 
on the CHO-MCHRI cell line compared to untransfected CHO-K1 cells. In this 
method, cell lysis is prevented by the use of serum deficient in terminal complement 
factor C7. 
In total, eighteen vitiligo patient sera and eighteen control sera were analysed, 
along with a positive control anti-CHO-K1 antibody. Each sample was tested in 
duplicate at least in two separate experiments. When untransfected CHO-K1 cells 
and the CHO-MCHR1 cell line were incubated with polyclonal anti-CHO-KI 
antibody, C3 deposition was detected on both cell types, as there was an increase in 
fluorescence intensity (Figures 6.1). This positive control indicated that complement- 
fixation could be detected by the method used here. In contrast, when untransfected 
CHO-KI cells and the CHO-MCHR1 cell line were incubated with vitiligo patient 
sera, C3 deposition could not be detected, as there was no increase in fluorescence 
intensity (Figure 6.2). Similarly, C3 deposition on untransfected CHO-K1 cells and 
on the CHO-MCHRI cell line could not be detected with the control sera tested, as 
again there was no increase in fluorescence intensity (Figure 6.3). 
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Figure 6.1 Complement-fixation on untransfected CHO-K1 cells and the CHO- 
MCHR1 cell line by rabbit anti-CHO-KI antibody using flow cytometry. 
Untransfected CHO-KI cells and the CHO-MCHRI cell line were initially incubated 
without and with rabbit anti-CHO-KI antibody (primary antibody) and then with 
human C7-deficient serum. Cells were then incubated with goat anti-human C3 
antibody (secondary antibody) and were finally stained with FITC-conjugated rabbit 
anti-goat IgG antibody (tertiary antibody). The deposition of C3 was analysed by 
flow cytometry as described in Section 6.3.3 and the results are shown for 
untransfected CHO-KI cells (a) and one CHO-MCHRI cell line (b). The increasing 
fluorescence intensity (x-axis) indicates C3 deposition on untransfected CHO-KI 
cells and a CHO-MCHRI cell line incubated with rabbit anti-CHO-KI antibody 
(green). In contrast, no increase of fluorescence intensity (blue and red) and hence no 
C3 deposition is apparent on untransfected CHO-KI cells and the CHO-MOHR I cell 
line without incubation with anti-CHO-KI antibody (red) and with only secondary 
and tertiary antibody (blue). 
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Figure 6.2 Detection of complement C3 deposition on CHO-K1 cells and the 
CHO-MCHR1 cell line incubated with vitiligo patient sera. Both untransfected 
CHO-KI cells and the CHO-MCHRI cell line were incubated with vitiligo patient 
sera (primary antibody) and then with human C7-deficient serum. Cells were then 
incubated with goat anti-human C3 antibody (secondary antibody) and were finally 
stained with FI"IC-conjugated rabbit anti-goat IgG antibody (tertiary antibody'). The 
deposition of 0 was analysed by flow cytometry as described in Section 6.3.3 and 
the results are shoNNn in duplicate (a and b) for one vitiligo patient serum sample. 
There was no complement C3 deposition on either untransfected CHO-KI cells 
(blue) or the CHO-MCHRI cell line (green), as there was no increase of 
fluorescence intensity on the x-axis. No staining was done with secondary antibody 
alone. 
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Figure 6.3 Detection of complement C3 deposition on CHO-K1 and the CHO- 
MCHR1 cell line incubated with control sera. Both untransfected CHO-KI cells 
and the C'HO-MCHRI cell line were incubated with control sera (primary antibody) 
and then with human C'7-deficient serum. Cells were then incubated with goat anti- 
human 0 antibody (secondary antibody) and were finally stained with FITC- 
conjugated rabbit anti-goat loG antibody (tertiary antibody). The deposition of C3 
was analysed b\ flow cytometry as described in Section 6.3.3 and the results are 
shown in duplicate (a and b) for one control serum sample. There was no 
complement C3 deposition on either untransfected CHO-K I cells (blue) or the CHO- 
MCHRl cell line (green). as there was no increase of fluorescence intensity on the x- 
axis. No staining N% as done '%ith secondary antibody alone. 
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6.4.2 Antibody-dependent cell-mediated cytotoxicity by MCHRI 
autoantibodies in vitiligo patients 
Antibody-dependent cell-mediated cytotoxicity activity of MCHR1 autoantibodies in 
vitiligo patients was tested in 51Cr-release assays with the CHO-MCHR1 cell line. 
Initially, both control and vitiligo patient sera were incubated with 51Cr-labelled 
CHO-MCHR1 cell line. After washing to remove any unbound antibody, the labelled 
cells were incubated with PBMC. These act as effector cells causing lysis and 51Cr- 
release on interaction with any MCHR1 antibody that might be bound to the labelled 
cells via MCHR1. Spontaneous 51Cr-release and maximum 51Cr-release were 
estimated in each experiment. In total, eleven control sera and twelve vitiligo patient 
sera (nine with and three without MCHR1 autoantibodies, as previously found in a 
radio-binding assay; Kemp et al. 2002), were tested in triplicate in two separate 
experiments. 
The results indicated that the mean percentage lysis initiated by the control serum 
samples was 7.37% with a range of 2.04-12.12% (Table 6.1). None of the control 
sera was, therefore, considered positive for ADCC. Equally, none of the vitiligo 
patient sera tested contained positive ADCC activity against 51Cr-labelled CHO- 
MCHRI cell line as all percentage lysis values were below the arbitary set level of 
20% (Table 6.2). The mean percentage lysis in this patient group was 6.28% with a 
range of 3.79-11.4% (Table 6.2). No significant difference was evident between the 
mean percentage lysis values of the control sera and those of the vitiligo patient sera 
(p=0.295). 
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Table 6.1 Percentage lysis values of control sera in the ADCC assay. 
Control sample 
number 
Percentage lysis 
values 
Mean percentage lysis 
value' 
Ci 5.30 5.36 
5.42 
C2 2.10 2.04 
1.98 
C3 6.92 6.52 
6.12 
C4 10.87 10.52 
10.17 
C5 6.8 7.40 
8.0 
C6 9.27 8.96 
8.67 
C7 6.49 6.88 
7.27 
C8 8.04 7.80 
7.56 
C9 11.88 12.12 
12.36 
C10 5.86 5.84 
5.82 
Cli 7.84 7.68 
7.56 
'The percentage lysis value shown for each control serum sample is the mean of the 
percentage lysis values from two separate experiments. 
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Table 6.2 Percentage lysis values of vitiligo patient sera in the ADCC assay. 
Vitiligo sample number' Percentage lysis 
values 
Mean Percentage lysis 
value2 
vi 7.21 7.16 
7.11 
V2 4.02 3.79 
3.56 
V3 6.55 6.76 
6.97 
V4 6.51 6.52 
6.53 
VS 6.02 6.04 
6.06 
V6 9.03 8.76 
8.49 
V7 4.09 4.12 
4.15 
V8 6.56 5.96 
5.36 
V9 6.24 6.28 
6.32 
V10 11.01 11.40 
11.79 
V11 4.19 4.16 
4.13 
V12 4.87 4.52 
4.17 
'Vitiligo patient sera containing MCHR1 autoantibodies (V1 to V9); vitiligo patient 
sera negative for autoantibody reactivity to MCHR1 (V 10 to V 12). 
2The percentage lysis value shown for each vitiligo patient serum sample is the mean 
of the percentage lysis values from two separate experiments. 
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6.5 Discussion 
Although the exact role of anti-melanocyte autoantibodies in the pathogenesis of 
vitiligo has not been determined, possible mechanisms by which they can destroy 
pigment cells have been investigated including complement activation and ADCC. 
Complement-fixing autoantibodies that bind to melanocytes have been reported in 
patients with mucocutaneous candidiasis, multiple endocrine insufficiencies, 
alopecia areata and vitiligo (Hertz et al. 1977). However, these autoantibodies were 
not found in patients with isolated vitiligo (Howanitz et al. 1981). Deposition of 
complement component C3 can occur in the basement membrane of vitiliginous skin 
(Uda et al. 1984) and the sera of vitiligo patients can cause direct cytotoxic damage 
of cultured melanocytes by complement-fixation (Norris et al. 1988b). In addition, a 
reduced expression of the membrane regulators of complement activation in both 
lesional and perilesional keratinocytes and melanocytes has been reported, possibly 
indicating an increased vulnerability of these cells to autologous complement attack 
(van den Wijngaard et al. 2002). 
In contrast to these studies, MCHR1 autoantibodies from vitiligo patients did not 
appear to fix complement as there was no deposition of complement C3 on the CHO- 
MCHR1 cell line following incubation with vitiligo patient sera. This difference 
could be related to the different assays used between studies. In order to assess the 
reliability of our complement-fixation assay, both untransfected CHO-K1 cells and 
the CHO-MCHR1 cell line were initially incubated with rabbit anti-CHO-K1 
antibody as a positive control and then with human complement with C7-deficient 
serum. Finally, C3 deposition was analysed by flow cytometry. These control 
experiments clearly showed the deposition of C3 on the cells and confirmed that the 
assay was working. However, it is possible that low expression of MCHRI on the 
surface of the CHO-MCHR1 cell line and/or low levels of MCHRI autoantibodies in 
vitiligo patient sera might mean that any complement-fixing activity of 
autoantibodies to the receptor remains undetected in the assay system used. 
With respect to ADCC, there is evidence that the sera of patients with vitiligo can 
induce cultured human melanocytes to detach from their cell matrix and can cause 
direct cytotoxic damage to pigment cells by ADCC (Norris et al. 1988b). However, 
in contrast to the aforementioned study, we were unable to detect any ADCC activity 
in vitiligo patient sera. Again, the difference between this and the previous study 
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may be related to the different methodologies used to measure ADCC. Here, the 
most popular method for assessing ADCC, that is the labelling of target cells with 
radioisotope chromium-51 (Brunner et al. 1968),, which binds to cytoplasmic 
proteins that are subsequently released during cell lysis, was employed. This method 
has been successfully used to analyse the ADCC activity of thyroid peroxidase 
autoantibodies in several autoimmune thyroid diseases (Bogner et al. 1984; Rodien 
et al. 1992; Bogner et al. 1995; Metcalfe et al. 1997). Again, it is possible that low 
expression of MCHR1 on the surface of CHO-MCHR1 cells and/or low levels of 
MCHRI autoantibodies in vitiligo patient sera might mean that any ADCC activity 
of receptor autoantibodies remains undetected in our experiments. 
Taken together, the immunological studies indicate that MCHR1 autoantibodies 
from vitiligo patients do not fix complement and do not mediate ADCC, at least in 
the assay systems used here with the CHO-MCHR1 cell line. However, the effects of 
MCHR1 autoantibodies on melanocytes through complement-fixation and ADCC 
activity have yet to be determined. 
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7 General Discussion 
7.1 Discussion of results 
Several hypotheses have been proposed to explain the destruction of cutaneous 
melanocytes in vitiligo. Persuasive observational and experimental evidence 
suggests that autoimmune mechanisms play a role in the development of the disease 
including aberrant humoral immune reactivites (Section 1.3.6). However, only a few 
autoantigens have been identified as targets of autoantibodies in vitiligo patients 
(Section 1.5.2.2). Characterisation of autoantigens in vitiligo may be beneficial in the 
advancement of more appropriate therapies and diagnostic tools and, perhaps, in 
determining the aetiology of the disease. 
Recently, MCHRI has been identified as a novel autoantigen in 16.5% of vitiligo 
patients (Kemp et al. 2002). In the present work, the autoantibodies that recognise 
MCHRI were characterised. Briefly, the aims of the study were (i) to identify B cell 
epitopes on the MCHRI using recombinant protein and phage-display technology 
(ii) to isolate a stable CHO-K1 cell line expressing MCHRI (iii) to examine the 
effects of MCHRI autoantibodies on the functioning of the receptor using the CHO- 
MCHR1 cell line (iv) to investigate complement-fixation and ADCC with respect to 
MCHRI autoantibodies again using the CHO-MCHRI cell line. 
The mapping of B cell autoepitopes can provide an understanding of the 
association of an autoantigen with a particular autoimmune disease and may give an 
insight into the mechanisms involved in the initiation and pathogenesis of the 
disease. Few studies have been carried out to identify B cell epitopes on vitiligo 
autoantigens (Kemp et al. 1999a; Kemp et al. 2001b). In this study, molecular 
analysis of the B cell epitopes on MCHRI was performed using recombinant 
proteins in radio-binding assays (Chapter 3) and phage-display technology (Chapter 
4). In radio-binding assays, multiple regions of MCHRI were found to be targets for 
vitiligo patient MCHR1 autoantibodies, including regions between amino acids 1- 
138 and 139-298. These domains overlapped with areas on the receptor that were 
predicted to be highly antigenic. 
It has been speculated that the autoimmune responses may arise from cross- 
reactivity between self-proteins and those of infecting micro-organisms 
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(Wucherpfennig 2001). However, no similarity was apparent between the amino acid 
sequences of the identified epitope regions and those of microbial proteins. The 
current study results indicated that the humoral response to MCHRI in vitiligo is 
heterogeneous in nature as several patients exhibiting autoantibodies to more than 
one MCHRI epitope. Similarly, autoantibodies in autoimmune thyroid disorders and 
type 1 diabetes mellitus have been reported to react against multiple epitopes on 
thyroid peroxidase (Zanelli et al. 1992) and tyrosine phosphatase-like IA-2 
autoantigen (Lampasona et al. 1996), respectively. This has been explained by the 
intramolecular spreading of an autoimmune response from a single or few epitope(s) 
to multiple epitopes during the progression of the disease. In type 1 diabetes 
mellitus, a temporal spreading of the autoantibody response has been described from 
immunodominant epitopes in an early preclinical phase to lesser immunogenic 
domains at the manifestation of disease (Naserke et al. 1998). In contrast, in the 
current study we did not find any evidence of epitope spreading in longitudinal 
serum samples, however, taken from four patients. Possibly, these four sequential 
patients may have been studied too late in the disease to see an indication of epitope 
spreading (Naserke et al. 1998). 
In addition, biopanning using IgG from vitiligo patients to screen a phage-display 
MCHRI cDNA fragment library, identified epitopes located within the larger 
autoepitope domains between amino acids 49-82 and 156-194 (Chapter 4). Each of 
the consensus sequences identified may represent a linear epitope that is recognised 
by patient MCHRI autoantibodies. Conversely, the consensus sequences could have 
been selected due to them being part of a conformational epitope as the biopanning 
method is carried out in liquid phase and might therefore facilitate folding of the 
peptide. However, it was not determined here if the recognised MCHRI epitopes 
were linear or conformational. Phage-display technology has been successfully used 
previously to identify linear and conformational autoantigenic epitopes in several 
autoimmune diseases such as autoimmune thrombocytopenic purpura (Gevorkian et 
al. 1998), celiac disease (Osman et al. 2000), primary biliary cirrhosis (Rowley et al. 
2000), type 1 diabetes mellitus (Myers et al. 2000; Farilla et al. 2002; Dromey et al. 
2004), autoimmune polyendocrine syndrome type II and stiff-man syndrome (Al- 
Bukhari et al. 2002). To differentiate the epitopes on the MCHR1, Western blot 
analysis could be applied to the expressed peptides, which would identify linear 
epitopes due to the denatured state of the protein in SDS-polyacrylamide gels. 
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A stable CHO-K1 cell line expressing the MCHRI (Chapter 5) was isolated for 
studying the effects of MCHR1 autoantibodies on the functioning of the receptor. 
Flow cytometry clearly showed the expression of MCHRI in transfected CHO-K1 
cells and the cell line responded to MCH with a reduction in forskolin-stimulated 
cyclic AMP levels and increases in intracellular calcium, both characteristic of 
MCHR1 function. 
Subsequently, CHO-K1 cells expressing MCHR1 were used to investigate 
whether or not MCHR1 autoantibodies in vitiligo patients have any effects upon the 
functioning of the receptor (Chapter 5). In these experiments, CHO-MCHR1 cells 
were pre-incubated with vitiligo patient IgG and then any subsequent release in 
intracellular calcium in response to MCH measured by fluorimetry. Of the vitiligo 
patient IgG samples tested, 56% (10/18) were able to block the receptor function. In 
contrast, none of the control IgG or SLE IgG samples tested was able to block the 
functioning of MCHR1. Among the eighteen vitiligo IgGs analysed, nine were from 
patients previously shown to contain MCHRI autoantibodies in radio-binding assays 
(Kemp et al. 2002). The remaining nine IgG samples were from patients shown in 
the same study not to contain MCHR1 autoantibodies. Of the nine vitiligo patient 
IgG samples that contained MCHRI binding autoantibodies, seven contained 
MCHR1 autoantibodies that blocked receptor function. In the two patients that only 
contained receptor-binding autoantibodies, it is probable that the MCHRI 
autoantibodies bind at a site on the receptor that has no effect upon its functionality. 
In addition, of nine patients that were previously shown not to contain MCHR1 
binding autoantibodies, three were demonstrated to have MCHRI function blocking 
autoantibodies. The existence of autoantibodies that appear to inhibit receptor 
function but do not bind MCHRI could be due to a number of reasons. It may be that 
the in vitro-translated protein used in the radio-binding assay (Kemp et al. 2002) 
fails to bind these antibodies due to incorrect folding of the molecule or the absence 
of an normal pattern of glycosylation, or it may simply reflect differential detection 
sensitivity in the two assays. Similar to our current findings in that MCHR1 
autoantibodies in vitiligo patients can block the function of MCHR1, non- 
stimulatory TBAb can prevent TSH action resulting in hypothyroidism (Arikawa et 
al. 1985; McKenzie and Zakarija 1992; Kosugi et al. 1993). In Addison's disease, 
patient IgGs can block the in vitro action of ACTH on adrenal growth and cortisol 
production by binding to its receptor (Wulffraat et al. 1989). Furthermore, 
197 
autoantibodies in myasthenia gravis patients directed against the acetylcholine 
receptor block the acetylcholine-binding site and provoke accelerated receptor 
degradation (Hara et al. 1993; Eymard and Chillet 1997; Hoedemaekers et al. 1997; 
Ferrero et al. 1997; Fabien et al. 2001). In addition, it has been demonstrated that 
serum immunoglobulin in patients with pernicious anaemia can block the gastrin- 
stimulation of acid secretion and it has been suggested that this blocking activity is 
mediated by competition with gastrin for the surface receptors on parietal cells (de 
Aizpurua et al. 1985; Burman et al. 1989). Although MCHR1 autoantibodies in 
some vitiligo patients were found to have a blocking effect upon the functioning of 
the receptor, the effect of MCHRI autoantibodies on the behaviour of melanocytes 
has yet to be determined. Equally, the relevance of MCHRI autoantibodies to the 
aetiology of vitiligo needs to be further investigated. 
Finally, MCHR1-expressing cells were used to investigate complement-fixation 
activity and ADCC with respect to MCHRI autoantibodies (Chapter 6). The 
complement-fixing capability of MCHRI-specific autoantibodies was measured by 
the incubation of heat-inactivated vitiligo patient sera with MCHR1-expressing cells, 
followed by the addition of serum containing all complement factors except C7. The 
level of deposition of C3 on the cells was subsequently measured by flow cytometry. 
In this in vitro study model, deposition of C3 on MCHR1-expressing cells by vitiligo 
patient MCHRI-specific autoantibodies was not detected. In contrast, previous 
studies have reported the deposition of C3 in the basement membrane of vitiliginous 
skin (Uda et al. 1984) and the detection of anti-melanocyte antibodies from vitiligo 
patients that display complement-fixation and damage pigment cells (Norris et al. 
1988b). For ADCC experiments, MCHR1-expressing cells were radiolabelled with 
51Cr and then incubated with either heat-inactivated vitiligo patient sera or control 
sera to allow binding of any MCHR1 autoantibodies to the receptor. After the 
addition of effector cells, the percentage of cell lysis was determined by measuring 
the amount of 51Cr released. No difference in the percentage lysis was found between 
the vitiligo and control serum samples tested. In contrast, previous research has 
demonstrated that vitiligo patient sera are able to cause direct cytotoxicity to 
melanocytes by ADCC (Norris et al. 1988b). The contrasting results obtained here to 
those in previous reports, with respect to complement-fixation and ADCC, could be 
due to differences in the techniques used or that MCHRI-specific autoantibodies do 
not mediate complement-fixation and ADCC. Alternatively, the expression levels of 
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MCHRI on the isolated cell line may not be sufficient to detect MCHR1-specific 
autoantibodies or low MCHR1-specific autoantibody titres in the patients tested may 
preclude the detection of complement-fixation and ADCC. 
7.2 Future studies 
The radio-binding assay originally used to detect MCHRI autoantibodies (Kemp et 
al. 2002) would not necessarily identify autoantibodies that react with 
conformational epitopes on the receptor. This is an important area for further study 
as it is well-documented that autoantibodies to TSHR that are responsible for disease 
activity in Graves' disease recognise several conformational epitopes (Morgenthaler 
et al. 1999). To address this, work is currently in progress to isolate a cell line 
expressing high levels of MCHRI that can be used in flow cytometry to screen 
vitiligo patient sera for autoantibodies that bind to native receptor. 
The isolation of purified receptor would be useful for a number of studies. This 
would probably be achieved by the expression of histidine-tagged MCHRI in either 
a mammalian or insect cell expression system. The MCHR1 protein could 
subsequently be used for: 
(i) Development of an ELISA format for routinely detecting autoantibodies in 
vitiligo patients. 
(ii) Detection of T cell reactivity to the receptor in vitiligo patients. 
(iii) Preparation of a MCHR1 affinity column that could be used to purify 
MCHR1 autoantibodies from vitiligo patient sera. The effects of purified 
receptor autoantibodies on the growth and pigmentation of melanocytes 
could then be studied. 
(iv) Development of an animal model of vitiligo by inoculation of mice with 
MCHRI protein. As well as studying any immune responses to the antigen, 
it would be interesting to investigate any effects on pigmentation. 
(v) Biopanning of antibody libraries prepared from vitiligo patients in order to 
isolate MCHR1 Fabs that could be used in the fine-mapping of MCHR1 
epitopes. These would also allow the gene usage of MCHR1 autoantibodies 
to be determined. 
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7.3 Conclusion 
This thesis has concentrated on characterising MCHR1 autoantibody reactivity in 
vitiligo patients. However, the relationship between MCHR1 autoantibodies, and 
indeed all vitiligo autoantibodies, and the pathogenesis of the disease has yet to be 
established. The possibility that MCHR1 autoantibodies play no part in vitiligo 
aetiology but rather indicate the presence of autoreactive anti-MCHR1 T 
lymphocytes that are cytotoxic to pigment cells, should be investigated. Even if they 
prove not to be directly pathogenic, MCHR1 autoantibodies may serve as useful 
markers of cellular disruption in the epidermis of vitiligo patients so further 
characterisation of them will continue. 
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